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ABSTRACT 
Remodeling of the Extracellular Matrix Components of the Mitral Valve Due to 
Alterations in the Mechanical and Chemical Environments of the Tissue 
by 
Janet Christine Elliott Barzilla 
This body of research explored mitral valve remodeling due to changes in 
the mechanical and chemical environments of the tissue in order to better predict 
patient response to medical device and drug therapies. This work was novel 
both in its characterization of the mitral valve and in the consideration of the 
impacts of the biological environment on the multilayered valve structure. Left 
ventricular dilation due to congestive heart failure (CHF) changes the mechanical 
forces experienced by the mitral valve. Collagen, cellular, glycosaminoglycan, 
and proteoglycan compositions of valve tissues were therefore compared 
between CHF patients treated with and without the left ventricular assist device 
(LVAD). Mechanical properties of these tissues were also tested to assess 
effects of matrix changes on valve function. Since mechanical stimulation was 
determined to be required to maintain valve structure and function, a novel 
splashing bioreactor was then designed to maintain the valve mechanical 
environment in vitro in preparation for studies altering the chemical environment 
of the tissue. After validation, this bioreactor was used to study initial changes to 
valve structure after two weeks of organ culture with media containing the 
serotonin receptor agonists serotonin and norfenfluramine (fen-phen) as well as 
a receptor antagonist. In the mechanical stimulation study, CHF valve tissue 
exhibited fibrotic remodeling compared to normal tissue, impeding normal mitral 
valve function. LVAD treatment, while it tended to restore functionality of the 
mitral valve chordae, encouraged compensatory remodeling that did not improve 
leaflet structure or mechanical behavior. Conversely, the gentle stretching 
provided by bioreactor was deemed sufficient to maintain matrix composition 
after two weeks of culture. Serotonin and norfenfluramine exposure appeared to 
upregulate different proteoglycans within the mitral valve structure, and exposure 
to a serotonin receptor antagonist had varying levels in success in blocking these 
drug effects. The results from these studies showed that changes to the 
mechanical (CHF and LVAD) and chemical (serotonin and norfenfluramine) 
environments altered mitral valve tissue structure and function. These effects of 
device use and drug therapies should be considered when assessing treatment 
for pathologies, such as CHF and obesity, which may not appear to directly 
impact the mitral valve. 
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Chapter 1. Introduction 
The overall goal of this research project was to explore the mechanisms 
behind remodeling of the extracellular matrix (ECM) of the mitral valve. Two 
categories of potential stimuli were studied: mechanical and chemical. For the 
purposes of this research, mechanical stimulation of the valve was represented 
by changes in the forces imparted upon the tissue due to dilation of the left 
ventricle with congestive heart failure (CHF) as well as any reversal of this 
dilation after left ventricular assist device (LVAD) implantation. Chemical 
stimulation of the valve was represented by changes to the milieu due to the 
introduction of the serotonergic agents serotonin and fen-phen. Both types of 
stimuli have been noted clinically to induce changes to the valve structure that 
impede normal valve function. 
To fully comprehend the consequences of altering the mechanical or 
chemical environment of mitral valve tissue, investigation of the early 
mechanisms of these diseases is required. Understanding these disease 
mechanisms can give researchers the tools needed to treat valve disease early 
or even to prevent it altogether. If LVAD use is determined to cause pathological 
changes to the valve tissue, changes should be made in the device protocol. For 
example, the physician could recommend that the device be turned off 
periodically or that the mitral valve be replaced prior to device implantation. If a 
concern exists that a new pharmaceutical may cause serotonergic valve disease, 
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the specific receptor activity of the drug can be altered, or the receptor itself can 
be blocked. 
Dilation of the left ventricle caused by CHF instigates pathological 
changes to the myocardium as well as to aortic and mitral valve tissue. While the 
LVAD improves left ventricular function and occasionally reverses CHF effects on 
the cardiac muscle, its use can also lead to pathological remodeling of the aortic 
valve. Although the effects of LVAD use on the aortic valve have been well-
characterized, its impact on the mitral valve has not been studied. If the LVAD is 
to be used as a destination therapy for CHF, as opposed to a bridge to heart 
transplantation, the goal should be to restore tissue structure and function of both 
the cardiac and the valve tissue. Otherwise, a workaround for these patients 
should be developed. The unknown LVAD influence on mitral valve remodeling 
led to the first specific aim of this project: 
Aim 1: Determine how LVAD treatment, when compared to current 
oral medical management therapies, affects the ECM composition 
and the resulting material behavior of the mitral valve of CHF 
patients. 
The study of tissue damage in CHF patients involved the use of human 
valve tissue exposed to CHF conditions and LVAD treatment in vivo. When 
attempting to induce valve damage to study the early mechanism of disease-
induced remodeling, however, an in vitro system was desired. The first specific 
2 
aim assumed that pathological changes to valve tissue were due to changes in 
the mechanical environment. Since a further goal of this project was to study the 
effects of changes of the chemical environment of the mitral valve, a bioreactor 
was designed to mimic the mechanical forces imparted upon the valve in its 
biological environment to ensure that observed structural changes were due to 
the chemical stimulus. The bioreactor design and validation studies were the 
subject of the second specific aim: 
Aim 2: Develop an inexpensive, easily reproducible bioreactor to 
maintain the mechanical environment of the mitral valve while 
investigating the impact of an altered chemical environment on the 
tissue. 
The formation of superficial plaques on patients taking Fen-Phen and 
other serotonergic drugs has been extensively documented in the past decade. 
These plaques are similar in composition to those observed in patients with 
carcinoid syndrome, which leads to an excess of serotonin in the circulatory 
system. Knowledge of the early mechanism of this plaque formation, as well as 
confirming the specific receptor activated, can assist in the treatment for these 
patients and provide researchers with information needed to prevent the release 
of similar drugs to the public in the future. The study of the activity of these 
serotonin receptor agonists formed the final specific aim: 
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Aim 3: Determine receptor effects and early remodeling of mitral 
valve ECM composition due to the introduction of two serotonin 
receptor agonists, serotonin and norfenfluramine. 
The completion of these three specific aims gave a complete picture of 
remodeling of the mitral valve ECM due to changes in the mechanical and 
chemical environments of the tissue. This structural remodeling had 
consequences to the normal function of the valve. A thorough understanding of 
structural and functional changes to the mitral valve tissue will lead to improved 
treatment of afflicted patients. 
The next two chapters in this document focus present the current state of 
the literature. Since this project focused on ECM remodeling, the second chapter 
will begin with an overview of the different ECM components and turnover 
mediators and their contribution to the anatomy of the normal mitral valve. The 
background will then review the known impacts of CHF and LVAD treatment on 
the structures of the myocardium and left heart valves. The pathologies and 
proposed mechanisms of serotonergic valve disease will also be presented. In 
preparation for the design and validation of the splashing bioreactor in the later 
chapters of this work, current bioreactor designs used in the organ culture and 
tissue engineering of heart valves will also be discussed. Chapter three is a 
review article previously published in the American Journal of Geriatric 
Cardiology1. This article discusses the tissue engineering of heart valves in the 
elderly, a population that is frequently affected by CHF as well as valvulopathy. 
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The use of donor hearts is uncommon in the elderly; therefore, characterizing the 
effects of the LVAD on the diseased heart is of particular importance in this 
population. The splashing bioreactor designed and used in Aims 2 and 3 could 
also be applied to tissue engineering of the valve, and a selection of the 
bioreactors currently used in this application is also discussed in chapter three. 
Chapters four, five, and six each discuss one of the three specific aims 
that comprise this research project. Chapter four will describe the remodeling of 
the mitral valve to its pathological CHF state and any recovery of the tissue 
structure due to LVAD treatment (Aim 1). Chapter five will discuss the design, 
construction, and validation of the splashing bioreactor (Aim 2). The use of this 
bioreactor to expose the mitral valve to serotonergic drugs will be contained in 
chapter six (Aim 3). The final chapter of this work will review the results obtained 
for each aim, discuss the significance of this body of research to the current 
literature, and indicate possible future directions for this work. 
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Chapter 2. Background 
This chapter will review the literature pertaining to heart valve pathology 
and subsequent extracellular matrix (ECM) remodeling. The major ECM 
components and turnover mediators will be discussed first, as will their role in 
normal heart valve tissue structure. The anatomy of the normal mitral valve will 
be presented in order to give the reader a basis of comparison to the abnormal 
valves examined throughout this research project. The relationship between 
normal valve structure and function, i.e. the valve mechanical properties, will also 
be discussed. Next, the review will introduce the heart pathologies to be studied 
in this report, congestive heart failure and serotonergic valve disease, and their 
known effects on the heart and valves. After examining these pathological valve 
environments, current heart valve bioreactor models influencing the design of the 
splashing bioreactor in Chapter 5 will be presented. This chapter concludes with 
a brief synopsis of the unresolved questions in the literature that this body of 
research has examined in greater detail in Chapters 4 through 6. 
2.1. Extracellular Matrix Components 
The ECM is made of three major components: collagen, elastin, and 
proteoglycans/glycosaminoglycans (PGs/GAGs). A main function of ECM is to 
provide structure and the material properties to a tissue. The ECM also acts as 
the cell environment and plays a role in signal transduction to the cell. Finally, 
the ECM sequesters biological molecules; for example, the core protein of the 
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PG decorin will bind and sequester transforming growth factor-p (TGF- p), 
inhibiting its effect. All of these classes of ECM components, which are 
described below in greater detail, are found in heart valves. 
2.1.1. Collagen 
Collagen is the protein that provides mechanical integrity and strength to 
tissue and is the main load-carrying component of soft tissues. Multiple types of 
collagen exist; fibrillar types I, III, and V are of greatest interest in studying the 
heart valves2. The basic molecular structures of these three types, described 
below, are the same. 
Figure 2.1: Collagen triple helix. Common amino acids in the a-chain are noted3. 
The primary structure of collagen is a peptide string of amino acid triplets 
with the form glycine-X-Y, where X and Y are frequently either proline or 
hydroxy proline (Figure 2.1). Each a-chain contains a sequence of about 300 
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triplets in addition to shorter terminal domains. All collagens are immediately 
modified after synthesis by hydroxylation of the proline and lysine residues into 
hydroxyproline and hydroxylysine. Hydroxyproline, which is found only in 
collagen and elastin, is often used as an indicator of the amount of collagen in 
tissue4,5. 
The secondary structure is a tight, right-handed a-helix with a regular 
residue spacing of 0.286 nm and angular separation of 108°. This structure 
satisfies the geometric constraints placed on the a-helix by the large ring group 
on the proline residues and the small hydrogen side group of the glycine 
residues4 (Figure 2.1). 
The tertiary structure is a triple helix comprised of three individual a-
helices coiled around each other. Collagen type I is a heterotrimer of two a11 
chains and one a2l chain. Collagen type III is a homotrimer of a1 III, and collagen 
type V is a heterotrimer of crt V, a2V, and a3V4. The triple helix is a chemically 
stable structural unit, also called procollagen, that is both stiff and flexible. The 
procollagen molecule is about 1.5 nm wide and 300 nm long, with a pitch of 10.4 
nm4. The terminal domains are cleaved after secretion into the extracellular 
space to form tropocollagen, also called collagen. These collagen molecules are 
arranged in a quarter-staggered assembly to form fibrils, which bundle to form 
collagen fibers. 
A number of molecules assist collagen fibrillogenesis and can be used as 
an indication of collagen turnover within the tissue. Heat shock protein 47 
(HSP47) is a molecular chaperone that appears to prevent denaturation of 
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unstable regions (areas lacking hydroxyproline) of the collagen triple helix while 
in the cell. Prolyl-4-hydroxylase (P4H) also has a role in collagen production, but 
shows a higher affinity for non-helical intermediates6. Lysyl oxidase (LOX) 
catalyses the cross-links in collagen and elastin fibers; studies with knockout 
mice have indicated that a deficiency of LOX leads to thinner elastic fibers and 
loosely-packed collagen7. 
Normal mitral valves contain 74% type I, 24% type III, and 2% type V 
collagen. Types I and III are often found in association with each other, and type 
V is found in the pericellular space2. Previous studies have found that certain 
types of diseased valves (i.e., myxomatous, or floppy valve, disease) contain 
increased concentrations of all three types of collagen, but in different 
proportions. For example, the ratio of collagen type I to collagen type III is higher 
in a normal valve than in a myxomatous valve2; it is presumed that type III 
collagen production increases as a result of the body's repair processes. 
Additionally, the type V collagen increase may signal an increase in the DNA 
content, and therefore cell number, of the valves2. 
2.1.2. Glycosaminoglycans 
Four classes of GAGs exist: hyaluronan (HA); chondroitin sulfate 
(CS)/dermatan sulfate (DS); heparin/heparan sulfate (HS); and keratan sulfate 
(KS)8. GAGs are unbranched polysaccharides of varying length made of 
repeating disaccharide units, usually an amino sugar and uronic acid (Figure 
2.2). GAGs are frequently associated with PGs and play a role in tissue 
compressibility. Negatively charged sulfate and carboxyl groups create a highly 
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anionic domain for the GAG disaccharide. Cations are then attracted to the 
GAG, and the system becomes osmotically unbalanced. Water is then drawn 
toward the molecule to restore osmotic equilibrium, resulting in a highly hydrated 
domain. 
repeating disaeeharid* 
t ! 1 
glucuronic acid W-acetylglucosamine 
Figure 2.2: Basic repeating disaccharide structure of GAG. The glucuronic acid and N-
acetyl-glucosamine are characteristic of HA\ 
The differences between the four types of GAGs lay in the two 
disaccharide components. Glucuronic acid (Figure 2.2) and iduronic acid, the 
two types of uronic acid found in the GAG disaccharide, vary by a rotation of the 
carboxyl group (highlighted in Figure 2.2). Most GAGs also contain either N-
acetyl-glucosamine or A/-acetyl-galactosamine as the amino sugar. HA, the only 
GAG that is not part of a PG (Section 2.1.3), consists of glucuronic acid and N-
acetyl-glucosamine. HA is often found in the synovial fluid and loose connective 
tissues and plays a role in introducing water into the ECM. CS and DS are very 
similar in structure, with both GAGs containing A/-acetyl-galactosamine as the 
amino sugar. Their difference lies in the uronic acid epimer present; CS contains 
glucuronic acid, while DS contains iduronic acid. CS is found in cartilage and 
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some connective tissue8,10'11 and, along with HA, contributes to the 
compressibility of a tissue11. DS, on the other hand, has a general distribution 
within the animal tissues. Heparin and HS both contain glucosamine, but heparin 
usually contains iduronic acid while HS contains glucuronic acid. Heparin is 
found in the granules of mast cells, and HS is present within the PGs on many 
different cell surfaces. KS is made of repeating units of galactose and A/-acetyl-
glucosamine; galactose replaces the uronic acid present in the other GAG 
classes. Two types of KS exist: type I is present in the cornea, and type II is 
found in loose connective tissue8,10,11. Common alterations to the GAGs include 
the introduction of sulfate groups at the 4 and 6 carbon of the amino sugar, as in 
C4SorC6S11. 
The primary GAGs of interest in the mitral valve are HA and CS/DS. 
CS/DS are affiliated with the structural PGs in the ECM that are abundant either 
in areas experiencing tension and compression. A previous study documenting 
levels of GAGs and PGs in normal mitral valves has shown that compressive 
regions of the valve tend to contain high levels of HA and water as well as a high 
ratio of C6S to C4S. Regions exposed to tensile force have a high overall 
concentration of DS and a high ratio of 4-sulfated CS/DS to 6-sulfated CS/DS12. 
Changes in GAG concentrations can indicate valve matrix remodeling. 
2.1.3. Proteoglycans 
PGs are comprised of at least one GAG covalently linked to a core protein 
(Figure 2.3). Although some PGs are present at cell surfaces, PGs are also 
abundant in the ECM and can interact with collagen and elastin to direct the 
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matrix structure. The negatively-charged GAGs within the PGs allow the ECM to 
absorb water and resist compression on the tissue, as described in Section 2.1.2. 
Since the GAG polysaccharide chains tend to be long (30-250 disaccharides13), 
the PGs can also act as a barrier to the flow of molecules within the matrix. 
Additionally, PGs occupy a large portion of the ECM relative to collagen and 
elastin, allowing the PG to act as space fillers11. 
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Figure 2.3: Schematics of the proteoglycans aggrecan and versican. Versican, a large 
chondroitin sulfate proteoglycan, is commonly found in the mitral valve. 
HABR=hyaluronan-binding region, GAG=glycosaminoglycan attachment region, 
EGF=epidermal growth factor repeat, LEC=Type C lectin, C=complementary protein14. 
The main PGs of interest in the mitral valve are the CS/DS PGs versican, 
decorin, and biglycan. Versican is a large CS PG10 that is predominantly found in 
regions of compression of the mitral valve. Versican can also aggregate with HA 
to act as a lubricant within the tissue and to prevent certain receptor-ligand 
interactions within the ECM10,12. The tensile regions of the mitral valve 
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predominantly contain the small leucine-rich PGs (SLRPs) biglycan and decorin. 
Decorin is known to regulate collagen fibrillogenesis in vitro10, and it is abundant 
in tissues containing type I collagen. Decorin, therefore, likely provides strength 
to load-bearing tissues. Biglycan is not generally found in association with 
decorin, but it is also known to play roles in collagen fibril diameter and tissue 
strength12. The ability of versican to bind water makes this PG a compressive 
load bearing element, while the close associations of biglycan and decorin with 
collagen make these PGs indirectly responsible for bearing tensile loads within 
tissues. 
2.1.4. Elastin 
Elastic fibers in adult tissue are comprised of elastin with a sparse 
covering of microfibrils15. Elastin, the predominant protein in the fiber, provides 
extensibility and gives tissue the ability to recover after placement of a load15'16. 
Tropoelastin, the soluble form of elastin secreted by a cell, is made mostly of the 
hydrophobic amino acids. Glycine and proline, respectively, comprise about 1/3 
and 1/9 of these residues. Each tropoelastin molecule contains approximately 40 
lysine residues that form covalent cross-links between the monomers15. 
Microfibrils are made mostly of the proteins fibrillin and microfibril-associated 
glycoprotein. Microfibrils act as a scaffold to align tropoelastin, and the structure 
can be cross-linked by LOX 15,16. Previous studies have also documented a co-
localization between versican and elastin fibers17,18. 
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2.1.5. ECM Turnover Mediators 
2.1.5.1. Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) influence many cellular activities by 
their ability to degrade ECM proteins when activated. MMPs can influence 
normal and pathologic biologic processes such as wound repair and cancer 
development19. More than 25 MMPs have been characterized thus far; the 
primary MMPs of interest in the current research are MMP1, MMP2, MMP9, and 
MMP13. 
Each individual MMP will degrade multiple ECM proteins; the proteins of 
interest to this project are listed below. MMP1, also called collagenase-1, digests 
collagen types I and III. MMP2, or gelatinase A, digests collagen types I, III, and 
V in addition to decorin, elastin, and fibrillin. MMP9, or gelatinase B, digests 
collagen type V, decorin, elastin, and fibrillin. MMP13, also called collagenase-3, 
digests collagen types I and III. 
The basic MMP structure includes a "pre" domain, a "pro" domain, and a 
catalytic domain. The "pre" domain, an N-terminal signal sequence, is generally 
removed prior to secretion. The propeptide "pro" domain keeps the enzyme 
inactive until removed. The catalytic domain contains the zinc-binding region of 
the enzyme19. Most MMPs are therefore initially secreted as zymogens and can 
be activated via cleavage by serine proteases or other MMPs. MMP9, for 
example, can be activated by MMP3, MMP10, and MMP1320. 
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2.1.5.2. Tissue Inhibitors of Metalloproteinases 
As the name suggests, tissue inhibitors of metalloproteinases (TIMPs) 
bind to and inhibit the activity of the different MMPs. At least four TIMPs are 
known; TIMP1 and TIMP2 are of primary interest in this project. MMP1, MMP2, 
MMP9, and MMP13 are all inhibited by TIMP1 and TIMP220'21. 
2.2. Valve Anatomy 
The heart contains four valves to direct forward blood flow and prevent 
reverse flow through the heart and circulatory system. The two valves of the left 
heart, the mitral and aortic, are the focus of this project, because the pathological 
conditions examined herein are usually presented by the left heart valves. 
2.2.1. Mitral Valve 
The mitral valve is located between the left atrium and the left ventricle 
(Figure 2.4). 
Figure 2.4: Mitral valve location between the left atrium and left ventricle . 
15 
The mitral valve attaches to the heart wall at the top part of the valve, the 
annulus. When the valve closes, the free edges of the valve leaflets meet in 
coaptation. The valve opens to allow the blood to flow into the ventricle during 
diastole (relaxation) and closes prior to systole (contraction) to prevent blood 
from re-entering the atrium (Figure 2.5). A normal heart rate is about 72 
beats/min, and systole comprises about 40% of the cycle. The normal closed 
valve is able to withstand the high systolic pressure (100-150 mm Hg) of the left 
ventricle. Immediately after systole, the left ventricular pressure drops (<10 mm 
Hg), and the slightly greater left atrial pressure passively opens the mitral valve 
to increase left ventricular volume by approximately 60-70ml_23. 
Figure 2.5: Mitral valve in its closed (left) and open (right) positions. The closed valve on 
the left shows the anterior leaflet (upper) and the posterior leaflet (lower). The valve opens 
to allow blood flow into the left ventricle22. 
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The valve itself is divided into two major sections, the anterior and 
posterior leaflets (Figure 2.6). The anterior leaflet is positioned near the aorta, 
medial to the posterior leaflet. The posterior leaflet is attached to the posterior 
wall of the left ventricle and wraps around the anterior leaflet when the valve is 
closed. The chordae tendineae attach the underside of the valve leaflets to the 
papillary muscle of the ventricle and are separated into two categories: basal 
chordae, the large chordae that insert into the center of the leaflet; and the 
marginal chordae, the smaller chordae that insert into the free edge of the leaflet. 
Posterior Leaflet 
Anterior Leaflet 
Center 
Anterior Leaflet Free 
Maiginal Chordae 
Figure 2.6: Ventricular view of mitral valve excised from heart failure patient after 
transplant and cut open. The parts of the valve are labeled. 
The leaflet consists of three layers covered by vascular endothelial cells: 
the fibrosa, a thick collagenous layer on the ventricular side of the leaflet; the 
atrialis, a thin elastic layer on the atrial side of the leaflet; and the spongiosa, a 
middle layer rich in PGs and GAGs24 (Figure 2.7A). The atrialis and spongiosa 
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are less dense than the fibrosa and are sparsely populated by valvular interstitial 
cells, which display characteristics of both fibroblasts and smooth muscle cells25. 
These cells are supported in a PG "gel" containing the randomly aligned collagen 
and elastin of the atrialis as well as some of the dense collagen bundles of the 
fibrosa24. 
The total thickness of the anterior leaflet, especially the fibrosa, is greater 
than that of the posterior leaflet, indicating that the anterior leaflet is designed to 
support greater tensile loads24. The collagen fibers of the fibrosa prevent the 
prolapse of the leaflet into the atrium as the ventricle contracts2, while the elastic 
fibers of the atrialis allow the valve to recoil from its closed position as the valve 
opens. The atrialis and spongiosa are thicker at the leaflet free edge than the 
leaflet center in order to handle the compressive stresses present at coaptation, 
or leaflet closure. In the anterior leaflet, the ECM structure of the leaflet center 
and free edge are very different, more so than in the posterior leaflet. The center 
region (Figure 2.7B) is very collagenous, which supports the tensile forces 
imparted upon the tissue, while the PGs and GAGs found in high concentrations 
in the free edge (Figure 2.7B) allow the tissue to bear the compressive forces 
present during leaflet coaptation. The different components of the leaflet layers 
cause the tissue to act as a composite, so that the bending resistance of the 
structure is lower than an equal thickness of pure collagen representative of the 
fibrosa24. Unlike the leaflets, the chordae are rope-like structures of aligned 
collagen within a thin sheath of elastic fibers and endothelial cells26. This design 
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is well-suited to the primary function of the chordae which is to bear tensile forces 
upon valve closure. 
Annulus Free Edge 
Figure 2.7: (A) Movat pentachrome stain of the mitral valve showing the layered 
construction of the leaflet. (B) Drawing of whole mitral valve, cut open and laid flat, with 
leaflet regions and chordae defined. A=atrialis, S=spongiosa, F=fibrosa. 
The layered structure of the mitral valve supports the tissue bending as 
the valve opens and closes in addition to the tension applied to the leaflet center 
and the compression imparted upon the free edge. This tissue structure can 
change as the ECM is remodeled by the valve cells during a disease state. The 
mechanisms and result of tissue remodeling has yet to be completely 
characterized for the disease states highlighted in this project. Characterization 
of these ECM changes will help researchers find the causes of and improve 
treatments for mitral valve diseases. 
2.2.2. Aortic Valve 
At present, little research is available pertained to the effects of changes 
to the mechanical and chemical environments on the mitral valve. Structural and 
functional changes to the aortic valve in response to the same phenomenon, on 
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the other hand, have been well-characterized27"29. The location of the aortic 
valve in the left heart and the layered tissue structure make this valve a good 
indicator of possible remodeling that the mitral valve may undergo. 
The aortic valve is located at the exit of the left ventricle, just beneath the 
aorta (Figure 2.4). This valve prevents blood from leaving the ventricle until 
systole, when the chamber is emptied. The aortic valve contains three leaflets. 
The left semilunar (coronary) cusp corresponds to the location of the left 
coronary artery, inserted in the wall of the aorta above the cusp. The right 
semilunar (coronary) cusp corresponds to the location of the right coronary 
artery, and the posterior (noncoronary) semilunar cusp does not have an 
association with any of the smaller arteries that branch from the aorta. 
The microstructure of the aortic valve is similar to the mitral valve in that 
there are three distinct layers of tissue. The ventricularis, which lies below the 
inflow surface, contains collagen with radially aligned elastin fibers. The central 
layer of the valve leaflet is the spongiosa, which contains both GAGs and loosely 
arranged collagen. The fibrosa lies below the outflow surface and is comprised 
of densely packed, circumferentially aligned collagen30. 
Aortic valve mechanical properties and ECM composition in both normal 
and pathological conditions have been characterized to a greater extent than 
those of the mitral valve. Porcine aortic valves are widely used as, or in the 
manufacture of, bioprosthetic valve replacements, making them a common 
subject of study. This additional research available on the aortic valve is also 
due to the prevalence of cusp calcification and other valve diseases. 
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2.2.3. Valve Mechanics 
Valve tissue has been modeled using the quasi-linear viscoelasticity law, 
which relates changes in stress to step changes in strain to describe relaxation 
behavior of tissue31. As with traditional engineering materials such as steel, a 
stress-strain graph can be used to illustrate the role of the valve layers, 
specifically the collagen fiber structure, on the tissue mechanical behavior. 
Unlike steel, valve tissue exhibits different mechanical behavior depending on the 
magnitude of applied stress. In the region of lower strain, the slope of the stress-
strain curve is lower than in the region of higher strain. A transition point exists in 
this graph after which the slope increases by several magnitudes32. The 
mechanical properties of the lower strain "toe region" are influenced by both the 
collagen and elastic fibers in the tissue, as the crimped structure of the collagen 
has yet to extend and absorb the full impact of the load and the elastic fibers are 
therefore bearing the load (Figure 2.8). Mechanical properties of the higher 
strain, or elastic, region are mostly due to the loading of the uncrimped collagen 
fibers33. The slope of the stress-strain curve in this region is the tissue's Young's 
modulus (E). 
The valve tissue mechanical properties also depend upon the anatomical 
region of the valve and the orientation of the fibers. Collagen fibers in the mitral 
valve anterior leaflets are predominantly organized in the circumferential 
direction. Circumferential tissue samples therefore tend to have a greater 
Young's modulus (anterior leaflet: 4.26±0.740 - 7.44±0.990 MPa; posterior 
leaflet: 1.55±0.168 - 2.09±0.191 MPa)32, as applied forces are taken up by the 
21 
collagen. Tissue samples aligned in the radial direction tend to be less stiff 
(anterior leaflet: 1.53±0.183-1.99±0.0671 MPa; posterior leaflet: 1.17±0.106-
1.89±0.194 MPa)32, as the intrafibrillar matrix handles a greater portion of the 
load and the fibers must rotate to bear load. The collagen fibers of the mitral 
valve posterior leaflet are more askew; therefore, the tissue is not quite as stiff in 
the circumferential direction as the anterior leaflet. The entire valve can be 
compared to a composite, where the fibers handle stresses imposed along their 
main axes while the matrix is depended upon to handle the forces in other 
directions 32 
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Figure 2.8: Sample stress-strain curve for a circumferential section of the posterior leaflet. 
The toe region is encircled, and elastic region is indicated by a straight dashed line. The 
slope of the elastic region is known as the Young's modulus (E) of the tissue. 
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In general, chordal tissue has a shorter pre-transition region and a higher 
E (basal chordae: 21.0±2.89 - 22.1 ±1.95 MPa; marginal chordae: 39.8±6.20 -
40.1 ±4.67 MPa)32 in the post-transition region than the leaflets32. Chordae with 
smaller diameters are less extensible than those with greater diameters, due to 
greater collagen crimping within the larger chordae34,35. The straightening of the 
collagen fibers contributes more to the stress-strain characteristics of the 
chordae than the elastic fibers, since the elastic fibers are merely a sheath 
surrounding a collagen core26. 
Since the mitral valve tissue structure strongly influences the tissue 
function, it is assumed that any tissue remodeling can be assessed by changes 
to the ECM and by resulting changes to the mechanical properties. Changes to 
mitral valve mechanical properties are therefore examined in this project as a 
means of assessing impact of tissue remodeling. Conversely, changes in the 
valve ECM can explain changes in mechanical properties and tissue behavior. 
2.3. Heart Pathology 
A wide range of diseases exist that can affect the performance of the heart 
and its valves. This project will focus on two pathologies, congestive heart failure 
(CHF) and serotonergic valve disease, that can directly and indirectly damage 
the left heart valves. 
2.3.1. Congestive Heart Failure 
CHF often results from other types of heart disease, especially coronary 
heart disease or myocardial infarction. CHF-associated enlargement of the left 
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ventricle can lead to mitral valve regurgitation, causing some blood to leak back 
into the left atrium after the mitral valve has closed. Additionally, the possibility 
exists that the left ventricular assist device (LVAD) used to treat CHF may cause 
complications with the left heart valves. 
2.3.1.1. Disease Variations 
CHF causes chronic volume overloading of the left ventricle and is most 
commonly caused by cardiomyopathy. Four types of cardiomyopathy exist: 
dilated (DCM), hypertrophic, ischemic (ICM), and restrictive. 
DCM, the most common form of cardiomyopathy, can be caused by. , 
alcohol abuse, pregnancy, or myocarditis36,37. Most DCM cases are designated 
as idiopathic, meaning that there is no known cause. DCM is generally 
irreversible and is the underlying cause of approximately % of heart transplants 
performed since 198638. Heart muscle affected by DCM is weakened and cannot 
pump blood efficiently. Other body tissues try to compensate for DCM by 
retaining blood, and the body generates more blood as a result. The ventricular 
myocardium then dilates to allow collection of the extra fluid volume. The initial 
response is positive; the heart muscle stretches more, causing a stronger 
contraction. Unfortunately, the heart will also increase its pumping rate to force a 
greater volume of blood throughout the body. The muscle will eventually lose its 
ability to contract, and the body will retain fluid, causing edema36,37. Additionally, 
the plasma levels of angiotensin II, aldosterone, and arginine vasopressin are 
elevated; this altered blood chemistry is probably a compensatory mechanism to 
maintain the arterial blood pressure39. 
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The second most common form of cardiomyopathy, hypertrophic, is 
usually inherited. This disease causes a thickening of the heart muscle more 
extreme than the moderate thickening seen in athletes. The muscles in both 
ventricles become larger, blocking blood flow through the aortic valve or 
preventing the heart from filling with blood during diastole. Hypertrophic 
cardiomyopathy may also cause damage to the mitral valve, or the valve may 
adhere to the septum, preventing blood flow. Standard treatments include 
medication and lifestyle changes, especially a major reduction in athletic 
activity36'37. 
ICM is the weakening of heart muscle due to an ischemic event, such as 
the blockage of a coronary artery to prevent the entrance of oxygenated blood 
into the heart muscle. Treatment for ICM is similar to that for DCM, with 
emphasis on treatment for the underlying coronary heart disease. In cases of 
serious damage, transplant may be recommended36,37. 
Restrictive cardiomyopathy is rare in the United States. It is usually a 
result of another disease, such as excessive iron buildup in the body. The heart 
rhythm and pumping action are normal, but the stiffened walls of the heart 
chamber prevent complete filling. Blood flow is reduced, and excess blood is 
backed up into the circulation. While the original cause of restrictive 
cardiomyopathy can be treated, the muscle damage cannot be reversed. 
Medication can control the symptoms, but transplant is an option if damage is 
extensive36,37. 
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In most cases of CHF, the ventricular muscle becomes progressively 
weakened and overloaded as the body's original compensatory mechanisms fail 
to resolve the underlying cause of the disease. Remodeling of DCM hearts 
occurs, leading to upregulation of collagen types I and III in addition to 
associated turnover markers in the cardiac muscle40. As DCM progresses, the 
loading conditions upon the ventricular muscle change the directions of strains 
along the wall, causing the chamber to function more inefficiently41. 
As the heart muscle becomes more overloaded, the mitral valve tissue 
itself undergoes fibrotic remodeling42. An increase in DNA synthesis and 
collagen production has been noted in mitral valves, presumably an adaptation 
mechanism for excessive pressure43. Mitral valves from CHF patients have a 
greater concentration of DNA than normal, indicating an increase in the cell 
density within the valve tissues. These valves also contain less water but more 
collagen and GAGs; it is not known if the PGs or GAG classes are different from 
those present in the healthy valves. Changes to DNA, collagen, and GAG 
content are most pronounced in DCM patients, while changes in hydration are 
more apparent in ICM patients. CHF patients also have been observed to have 
moderate mitral regurgitation44, annular dilation, and thicker mitral valve leaflets. 
The fibrotic changes to the valve tissue indicate that the valve undergoes a 
dysfunctional remodeling process in response to the pathological changes to the 
left ventricular geometry during CHF42, although the altered blood chemistry may 
also play a role. 
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2.3.1.2. Treatment via Mechanical Assist 
The estimated prevalence of CHF in adults over age 20 in the United 
States was approximately 53 million in 2005. CHF was considered an underlying 
cause in 57,120 deaths in 200445. End-stage CHF is usually defined as New 
York Heart Association (NYHA) Class IV failure, characterized by a gross loss in 
cardiac myocyte function. Ambulatory patients with Class IV symptoms have a 
one-year mortality rate of 50%46. Short-term treatments for CHF include diet 
changes and medication, but these options can become exhausted quickly. At 
this point, the favored treatment option for DCM and ICM patients is a heart 
transplant; unfortunately, only 2500 donor hearts are available annually47. This 
major discrepancy between needed and available donor hearts makes the 
mechanical assist device an attractive treatment option. Other heart ailments, 
including myocardial infarction, myocarditis, and postcardiotomy shock, can also 
require use of a mechanical assist device47. 
The left ventricular assist device (LVAD) removes blood from the left 
ventricle and pumps it into the aorta, bypassing the aortic valve. LVAD 
mechanics differ between manufacturers, but some common characteristics are 
outlined below (Figure 2.9). An inflow cannula is inserted into the left ventricle, 
usually at the apex. The body of the pump, which is usually installed in the upper 
left quadrant of the chest, fills passively. In automatic mode, the blood is 
forcefully ejected into the aorta once the pump is approximately 90% full44'47. All 
LVADs have a percutaneous driveline leading to an external power source, which 
is often worn at the patient's waist44. 
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Figure 2.9: Novacor® Implantable LVAD. The device is connected between the left 
ventricular apex and the aorta to pump blood out of a weakened ventricle48. 
The first LVAD (Thermo Cardiosystems Inc, Woburn, MA) was implanted 
in 1966. The earliest LVADs did not differ greatly in function from those used 
today; however, the pneumatic console that powered these devices was so large 
that the patient was required to wheel it around with him. The LVAD therefore 
kept the patient alive, but did little to improve his physical strength or mental 
outlook since he could not fully return to his everyday activities. The first truly 
mobile LVAD was implanted in April 1996 (Baxter-Novacor, Oakland, CA). Final 
FDA approval to use the LVAD as a bridge-to-transplant was granted in 
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September 1998 . Three commercially available LVADs currently in use are the 
Novacor (Baxter-Novacor, Oakland, CA), the Heartmate 1000 implantable 
pneumatic (IP) pump, and the Heartmate vented-electric (V-E) pump (Thermo 
Cardiosystems Inc, Woburn, MA). The Heartmate 1000 IP device was approved 
by the FDA in 1994, and the other two devices were approved in 199844,49. 
The LVAD was designed for use as a bridge-to-transplant; in the United 
States, it is usually implanted into patients with NYHA Class IV CHF who have 
been approved for transplant, keeping the patient alive until a donor heart is 
available44'47. The LVAD has been successful in offloading the cardiac muscle, 
increasing myocyte contraction50 and decreasing myocyte diameter51'52, 
reducing CHF symptoms. Additionally, collagen deposition within the cardiac 
tissue has been found to decrease after LVAD use52'53. Ventricular function, as 
measured by left ventricular ejection fraction and end-diastolic diameter, was 
shown to improve after 30-60 days of LVAD treatment but declined after 90-120 
days52"54. The LVAD increases cardiac output, decreases cardiac workload, and 
maximizes subendocardial perfusion, allowing the myocardial tissue to recover 
both its geometry and its functionality47. 
Since the use of the LVAD encourages structural and functional recovery 
of the left ventricle, it has been suggested that the device can be used as an end 
treatment, also called destination therapy. The Randomized Evaluation of 
Mechanical Assistance for the Treatment of Congestive Heart Failure 
(REMATCH) studies were conducted from 1998 to 2001 to determine the 
feasibility of the use of the LVAD as a destination treatment44'47,55. These 
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studies have determined that the LVAD can alleviate CHF symptoms while 
stopping disease progression and improving survival rates55. Patients receiving 
LVAD therapy had a significantly lower mortality rate than patients receiving oral 
medical management therapy46,56'57 and reported a better quality of life46,57,58. 
Mortality among LVAD patients was often due to infection and device failure56"58; 
however, it was decided that the risks of the device were outweighed by the 
benefits57. 
If the LVAD is to be implanted permanently, major problems such as 
infection, post-operative bleeding, and thromboemboli formation must be 
considered44,49. An alternate treatment option is to implant the LVAD until the 
heart shows signs of recovery, after which the patient is weaned from the device. 
Timing of LVAD implantation for this treatment is critical; if the device is 
implanted too early, the patient is subjected to unnecessary surgery, but delaying 
implantation can lead to complications49, with lower survival rates for moribund 
patients. 
Although LVAD implantation has led to recovery of the ventricular tissue in 
most patients44,47,50'54,59, explantation of the device from a functionally 
recovered heart has often led to a recurrence of CHF symptoms38,49,59. An 
optimal level of muscle function recovery has been noted in LVAD patients, 
unique to each person, after which continued treatment causes a reversal of 
LVAD benefits and a loss of ventricular function. All patients who have suffered 
a recurrence of CHF symptoms after weaning had LVAD treatment continued 
after this optimal recovery point in an attempt to further stabilize the patient38. 
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Additionally, the time spent on the pump prior to this optimal recovery point was 
longer for the patients who were weaned unsuccessfully. Unfortunately, there 
was no difference between the two groups in duration, depth, type, or origin of 
heart disease prior to LVAD implantation, and investigators could not predict if 
later weaning would be successful prior to surgery38. 
2.3.1.3. Effect of Mechanical Assist on Heart Valves 
Since the LVAD pumps blood directly into the aorta, the aortic valve 
remains closed to blood flow after device implantation. If the patient has a 
mechanical valve, this valve is at risk for thrombosis, particularly on the aortic (as 
opposed to ventricular) side. This thrombus can propagate into the coronary 
arteries, causing myocardial infarction. Replacement of the mechanical valve 
with a tissue valve mitigates these risks. Additionally, severe insufficiency of the 
native aortic valve can cause a cycle of flow back through the pump and 
ventricle. Patients with this valve problem should have their native aortic valve 
replaced with a bioprosthetic tissue valve prior to use of the LVAD49. 
Fusion of the commisures, the connections between two leaflets 
comprised of loose fibrous tissue, has been noted between the aortic valve 
cusps27,29'60 (Figure 2.10) and was most common with the Heartmate VE LVAD. 
The fusion, which can lead to valve insufficiency, has also been noted to a lesser 
extent in valves of CHF patients who have not had LVAD therapy. This effect 
may be reduced by periodically decreasing the pump rate or stopping pump 
function to force the use of the inoperative valve27. No correlation was found 
between duration of LVAD use and the presence of either aortic valve thrombosis 
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or commissural fusion, and the overall effect of the LVAD on the ECM of the 
aortic valve remains a question29. 
Figure 2.10: Aortic valve of patient with LVAD support. The arrow indicates fusion between 
two of the valve cusps27. 
As noted above, mitral regurgitation is a common side effect of CHF. 
Although the movement of the mitral valve in an LVAD-assisted heart resembles 
a flutter motion, regurgitation is not an issue following unloading of the left 
ventricle with LVAD implantation. The changes in loading of the ventricular 
muscle that lead to mitral regurgitation in CHF are alleviated with the use of the 
LVAD. Additionally, although the replacement of mechanical aortic valve 
prostheses with tissue valves has been recommended prior to LVAD 
implantation, continued blood flow through the native mitral valve should make a 
similar replacement of the native mitral valve unnecessary49. 
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Many LVAD patients have suffered tricuspid valve regurgitation due to 
increased pulmonary artery pressure. As the patient remains on the LVAD, this 
initial high pressure can decrease. If the insufficiency does not recover, 
annuloplasty, a surgical technique used to reinforce the valve annulus after valve 
repair, can be performed49. An intermediate-length study (162 ± 29 days) has 
shown that, while the LVAD activity decreases left ventricular dimensions and 
mitral regurgitation, it increases right ventricle dimensions and tricuspid valve 
regurgitation61,62. These changes to the right heart likely stem from leftward 
septal shifting (Figure 2.4) with unloading of the left ventricle in addition to the 
volume loading of the right ventricle due to an increased venous return62. This 
change in function of the right heart can be difficult to quantify since the 
diminished left heart capability also increases afterload placed on the right 
heart61. 
In order for the LVAD to be an effective destination treatment, the heart 
and its valvular components must be able to function within a normal range after 
device removal. It is currently unknown whether the LVAD reverses the effects 
of CHF on the mitral valve, as it does with the left ventricular muscle, or if the 
LVAD has any adverse effects on the mitral valve that would cause poor 
functioning of the heart upon weaning. Any remodeling of the mitral valve due to 
LVAD placement should be identified before widespread use of the LVAD as a 
destination therapy in order to prevent any further health issues due to a 
regurgitant valve. 
33 
2.3.2. Valve Diseases - Serotonergic Valve Disease 
Serotonergic valve disease is characterized by the presence of a plaque 
on the valve surface that leaves the underlying valve microstructure intact. This 
superficial plaque is comprised of a collection of myofibroblasts within a matrix 
consisting mainly of collagen and GAGs63,64. Earlier reports of this disease 
indicated that the plaques contained no elastin fibers, but recent studies have 
shown that elastin is present in approximately 42% of the plaques, particularly 
within the chordae and even along the papillary muscles in advanced cases64. 
Elastin in these pathological valves is less commonly observed in the leaflets and 
valve cusps, and it is located deep within the tissue, in longitudinal layers 
separate from the normal atrialis layer64. Serotonergic valve disease has been 
associated with elevated serum serotonin levels, but the mechanism of the 
plaque formation is unknown. 
2.3.2.1. Serotonin Pathway 
Serotonin (5-hydroxytryptamine or 5HT) is a major neurotransmitter. 
Elevated blood serotonin levels are known to cause serotonergic valve disease, 
but the actual mechanism of the disease progression is still under investigation63" 
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. Seven different families of receptors for serotonin, 5HTi through 5HT7, have 
been identified66; the receptors of interest in serotonergic valve disease belong to 
the are 5HTi and 5HT2 families. Immunostaining has confirmed the presence of 
the 5HT1B in diseased valves but not in normal valves67. Reverse transcriptase-
polymerase chain reaction (RT-PCR) has identified the 5HT2A and 5HT2B 
receptors in sheep aortic valve interstitial cells (VICs)63'65. Further experiments 
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have suggested that the 5HT2B receptor is likely to be responsible for 
pathological changes to the valve tissue68. It is believed that the presence of 
serotonin stimulates the VICs to produce TGF-(31 through G-protein signal 
transduction via Src kinase and extracellular regulated kinase (ERK) 
phosphorylation63,69. The TGF- p expression leads to an increase in collagen 
and GAG production63 and possibly the matrix changes noted in serotonergic 
valve disease. Since the mechanism of the serotonin on the heart valve is still 
unknown, a bioreactor would be very useful in studying the activity of this altered 
blood chemistry on the valve tissue. 
2.3.2.2. Carcinoid Valve Disease 
The mechanism behind the creation of the plaque characteristic of 
carcinoid valve disease is unknown but is associated with high serum levels of 
serotonin. Carcinoid valve disease can affect all four heart valves, but the 
majority of non-drug related cases appear to affect the pulmonary and tricuspid 
valves in the right heart (Figure 2.4). These firm, pearly white plaques often 
appear on the arterial sides of the pulmonary and aortic valves or the ventricular 
sides of the tricuspid and mitral valves64 (Figure 2.11). The presence of these 
plaques on the tissue surface can lead to complications such as regurgitation 
and stenosis. The only current treatment for this condition is surgery. If left 
untreated, carcinoid valve disease can be fatal within one year64. 
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Figure 2.11: Gross pathologic specimens from a 20 year study on carcinoid valve disease 
conducted by the Mayo Clinic64. Plaques are indicated with arrows. All valves are from the 
same 58-year-old male patient. (A) Tricuspid leaflet with severe stenosis and regurgitation. 
(B) Whole pulmonary valve with severe regurgitation. (C) Whole mitral valve with severe 
regurgitation. (D) Two aortic valve cusps with moderate regurgitation. 
2.3.2.3. Fen-Phen Valvulopathy 
Fenfluramine-phentermine (fen-phen, Wyeth, Madison, NJ) is an anorectic 
drug cocktail voluntarily withdrawn from the market in September 1997 due to 
reports of carcinoid-like valve disease in patients. Symptoms of this fen-phen 
valvulopathy include plaques on the valve surface comprised of myofibroblasts in 
a myxoid matrix, with the underlying tissue structure left intact70 (Figure 2.12). 
These lesions are identical, grossly and histologically, to those characteristic of 
serotonergic valve disease. 
As with carcinoid valve disease, fen-phen valvulopathy was thought to be 
caused by elevated levels of serotonin in the blood. The racemic (equal amounts 
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of left- and right-handed stereoisomers of a chiral molecule) form of the 
fenfluramine component, dexfenfluramine, is metabolized to dexnorfenfluramine, 
which releases serotonin and activates the 5HT2 receptors71. Recent research, 
however, has noted that chronic fenfluramine exposure causes elevations in 
plasma serotonin far less than that required to initiate valve disease72. 
Figure 2.12: Valve sections showing difference between normal and fen-phen affected 
valves. Tissue stained with Verhoeff-van Gieson elastin. (A) Normal mitral valve with 
atrialis at top and fibrosa at bottom (magnification=40X). (B) Mitral valve with fen-phen 
plaque covering ventricular surface (10X). (C) Normal aortic valve with ventricularis below 
and fibrosa above (20X). (D) Aortic valve with fen-phen plaque on ventricular surface (40X). 
The underlying structure of both fen-phen affected valves are intact70. 
Unlike carcinoid valve disease, fen-phen valvulopathy tends to affect the 
valves of the left heart. This preferential effect has been hypothesized to be due 
to the role that the lungs play in clearing serotonin from the blood. When the 
lungs are functioning normally, as in patients with carcinoid valve disease, the 
serotonin is cleared from the blood in a single cycle. Previous studies have 
shown that the appetite suppressant chlorphentermine, chemically similar to 
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phentermine, compromises the lungs' ability to uptake and metabolize serotonin. 
When added to fenfluramine, the action of phentermine may allow higher 
concentrations of serotonin to reach the left heart71. 
2.3.2.4. Ecstasy 
The club drug 3,4-methylenedioxymethamphetamine (MDMA), or 
"Ecstasy," has been studied to determine similarities in activity to serotonin 
receptor agonists. It appears that MDMA can bind and activate the 5-HT2B 
receptor in a similar manner as the other serotonin receptor agonists. This 
receptor activation occurs at the same amount of chemical as is found in a 
standard recreational dose68. 
2.3.2.5. Pergolide 
With the exception of fenfluramine, all drugs currently proven to stimulate 
the 5HT2B receptor to induce carcinoid-type changes in valve tissue are ergot 
derivatives68. Pergolide is an ergot-derived dopamine receptor agonist used in 
the treatment of Parkinson's Disease and restless legs syndrome73. Previous 
research has determined that pergolide also interacts with this receptor. 
Histological analysis has shown that valve tissue exposed to pergolide is 
pathologically similar to carcinoid valve disease. Echocardiographs allowing the 
scientist to view regurgitation of the valves have shown that approximately 20% 
of patients taking pergolide have suffered some sort of valvulopathy73. 
Identification of valvular disease in the older generation that is more 
susceptible to Parkinson's disease is difficult. Since degenerative and 
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calcification valvular diseases tend to affect the left heart valves of the elderly, 
the effect of pergolide is better assessed by focusing on the pathology, such as 
regurgitation, of the tricuspid valve. This analysis can be performed on living 
subjects using echocardiography. The reversibility of the effects of Pergolide 
have not been accurately assessed, as the patient and doctor tend to weigh the 
neurological benefits of the drug higher than the cardiac side effects and are 
reluctant to cease drug use73. 
2.3.3. Summary of Relevant Heart and Valve Disease 
Previous studies have indicated that valvular ECM remodels in response 
to changes to the mechanical and chemical environments. Aortic valve response 
to alterations to the mechanical environment due to LVAD support has been well-
characterized, but little research has been done on the mitral valve response. 
The formation of a plaque on the mitral valve stemming from increased serum 
serotonin levels has been documented, but the mechanism of this plaque 
disposition is undefined. This project will look specifically at the effects of LVAD 
treatment and serotonin agonist exposure on the mitral valve. 
2.4. Bioreactors Used in Valve Organ Culture and Tissue 
Engineering 
Bioreactors are useful for their ability to inexpensively reproduce the in 
vivo biochemical and mechanical valve environment74. Bioreactors modeling the 
valvular environment have been used to create tissue engineered semilunar 
heart valves75 (Chapter 3) and to provide invaluable information about mitral 
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valve disease and recovery by characterizing structural remodeling due to 
environmental changes76. Previous models used in heart valve research include 
flow loop77,78, cyclic pressure79,80, and cyclic flexure81"85 systems. 
The mitral valve has not been frequently cultured using a bioreactor; 
however, aortic valve bioreactors have provided some valuable insight into the 
role of mechanical forces on valvular remodeling. In one experiment, aortic valve 
leaflets were exposed to static flow (no movement of media), steady flow, and 
pulsatile flow conditions in a tubular system similar to a flow loop. Leaflets were 
also exposed to shear flow using a parallel plate system. After 48 hours, valve 
leaflets were compared to tissue that had not undergone any incubation. The 
aortic valve that had not undergone any incubation showed low levels of protein, 
GAG, and DNA synthesis, while samples exposed to static flow showed higher 
levels of component production. Additionally, tissue exposed to static flow 
conditions had significantly greater synthesis of DNA and GAGs than all other 
groups of tissue. Tissue in the tubular and parallel plate systems tended to have 
protein assembly levels closer to, although not as low as, the control valves76. 
An alternate system exposed aortic valve tissue to static pressure. These results 
were similar in that collagen synthesis was found to increase with pressure, but 
there was no appreciable change in either GAG or DNA synthesis74. 
With the end goals of repeatability and cost reduction, this project 
proposed to create a "splash" bioreactor, where the medium was moved across 
the mitral valve to mimic the fluid mechanics in the filling left ventricle. The 
forces across the valve were not as high as those in the left heart, but may have 
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more closely mimiced those seen in the right heart. The valve modeled with this 
proposed bioreactor saw more of a physiological force distribution86, as opposed 
to the shear forces in the example above. The compact and inexpensive design 
allowed multiple bioreactors to be made at a low cost; therefore, multiple 
experiments could be conducted simultaneously. 
2.5. Unanswered Questions in Current Research 
The research currently available lacked characterization of the mitral 
valve, especially when compared to the information available on the aortic valve. 
CHF was proven to encourage mitral regurgitation, but the changes to the 
myocardium that influenced this pathology were unclear. A link between LVAD 
treatment and aortic valve commissural fusion was proposed, but few studies 
until this work existed to show any remodeling of the mitral valve tissue due to 
LVAD support. 
Similarly, the exposure of aortic valves to the in vitro conditions of a 
bioreactor has been well documented. Organ culture of the mitral valve in similar 
circumstances, however, had not been performed to the same extent. The 
chordae of the valve created an additional element of tension to the valve; 
therefore the overall motion of the valve leaflets and chordae were an ideal 
subject for a bioreactor model. 
The characteristics of the plaques that form in serotonergic diseases, such 
as fen-phen valvulopathy, have been studied; however, little information was 
available on the mechanism of the disease progression. Elevated blood 
serotonin levels were associated with this family of diseases, but, aside from the 
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presence of 5-HT receptors on the valve tissue, the remodeling process 
remained a mystery. 
This research project was designed to define the remodeling of the mitral 
valve observed due to chemical and mechanical changes in its environment. 
Aortic valve remodeling has been well-characterized, but anatomical differences 
of the mitral valve warrant closer examination. The resulting knowledge of the 
causes and mechanisms of mitral valve disease obtained from this research 
should lead to more effective treatment options in cardiac disease patients. 
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Chapter 3. Age-Related Structural Changes in Cardiac 
Valves: Implications for Tissue-Engineered Repairs1 
3.1. Abstract 
Elderly patients would receive substantial benefits from tissue engineered 
heart valves (TEHVs), but most TEHV research has not focused on applications 
for this growing patient population. There will be numerous technical challenges 
involved in developing TEHVs for the elderly, such as designing tissues to 
accommodate higher blood pressure and larger aortic roots that may be friable or 
calcified. Concomitant medications may also affect the biology of the TEHV. 
Due to the predominantly senescent behavior of cells from older persons, a non-
autologous cell source may be required to develop the TEHV. Decellularized 
heart valve allograft from an elderly donor may not be durable enough to use as 
a scaffold, but several polymer and natural biodegradable scaffolds may provide 
promising alternatives. The selection of cell sources, scaffolds, and 
mechanical/biological conditioning will need to be precisely targeted to meet the 
diverse physiological, medical, and surgical requirements of elderly patients. 
' Previously published in the American Journal of Geriatric Cardiology, Sept-Oct 20061 
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3.2. Motivation for Tissue Engineered Heart Valve 
Development 
Approximately 53,000 people over the age of 65 underwent a valve 
replacement or other type of valve surgery in 2003, an incidence higher than any 
other age group and almost double that of patients age 45-64.87 Valvular heart 
diseases common in the elderly include aortic stenosis (AS), mitral valve 
regurgitation (MR) and aortic valve regurgitation (AR).88 AS has multiple causes 
in younger patients; however, calcific degeneration is the most common cause in 
elderly patients. The standard treatment for AS patients able to tolerate surgery 
is an aortic valve replacement (AVR). MR in the elderly is often caused by 
calcification of the valve annulus, myxomatous degeneration of the tissue, or 
ischemic heart disease. While MR does not worsen over time in the majority of 
elderly patients, it can lead to an increased risk of valvular tissue deterioration. 
Minor cases of MR can be managed by digoxin and diuretics, whereas valve 
reconstruction or replacement surgeries are reserved for more severely ill 
patients. Mild to moderate AR can often be managed with a vasodilator, but AVR 
is often recommended for more severe cases.88 
When replacement is warranted, the standard implant choices are a 
mechanical or a bioprosthetic heart valve. The thrombogenic materials used in 
the mechanical heart valves require lifelong anticoagulation therapy. 
Bioprosthetic heart valve replacements require a significantly shorter course of 
anticoagulation therapy, but tend to calcify over time and must be replaced more 
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frequently. When selecting an appropriate valve replacement, therefore, the 
ability of the patient to tolerate anticoagulation therapy must be balanced with the 
ability to tolerate multiple surgical procedures. Despite the risk of a repeated 
operation, the use of bioprosthetic valves in elderly patients has been 
recommended. A study following elderly artificial heart valve recipients showed 
that the 5-year survival rates of patients receiving either type of valve were 
identical; however, valve-related morbidity events related to the mechanical valve 
occurred more frequently than those related to the bioprosthetic valve, mostly 
due to anticoagulant-related hemorrhage.89 A living, nonthrombogenic tissue 
engineered heart valve replacement (TEHV), which could be created from 
donated or autologous tissues and would only require a single surgical 
procedure, is a possible solution to these current dilemmas presented by artificial 
valves. 
3.3. Feasibility and Technical Challenges for Using TEHVs in 
Elderly Patients 
3.3.1. Alterations to Mechanical Environment 
Aging-related changes in the overall function of the heart, such as 
reductions in left and right diastolic function,90 influence the behavior of the 
connected valves and arteries as well as the remodeling of the cardiac and valve 
tissue microstructure. Aortic compliance decreases with age, increasing the 
resistance to blood flow from the left ventricle.91 This decreased compliance,92 in 
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addition to the calcification of the aortic valve tissue with age, has been 
hypothesized to cause native valve failure.92 Due to the decreased aortic 
compliance, aortic systolic pressure also increases. An aortic TEHV for use in 
elderly patients should be strong enough to withstand these pressure changes. 
Insertion of the valve replacement into an elderly patient's less compliant 
and more friable aortic root may also be an issue. The suture retention strength 
of the TEHV will also be a critical property, as the implant must be able to 
withstand the mechanical forces within its new environment without dislodging 
from the aortic root. Finally, the aortic root itself dilates with age,94 possibly 
requiring that larger TEHVs be designed for implantation into older patients. 
3.3.2. Mechanical Behavior Mismatch 
When creating a TEHV, especially one within a vascular conduit, 
biocompatibility will be improved by matching the material properties of the 
biomaterial and the surrounding native tissue.95 Since this environment changes 
with age, the TEHV specifications should likewise be altered to prevent a 
mismatch between the material properties of the TEHV and the in vivo structure 
to which it will be attached. 
3.3.3. Alterations to Chemical Environment 
The blood chemistry of the elderly patient should also be considered prior 
to the creation of a TEHV for a specific patient. For example, some of these 
patients may be undergoing concomitant treatment for Parkinson's disease with 
the ergot-derived drug pergolide, which may be linked to the formation of plaques 
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on the mitral and aortic valves; other medications commonly taken by older 
patients could also affect the implanted TEHV. 
3.4. Tissue Engineering Principles and Relevance to Aging 
Valves 
The design of any tissue engineered structure generally combines cells, 
scaffold, and exogenous growth factors.95 A self-sustaining engineered tissue 
must contain cells that proliferate within the scaffold structure and secrete 
extracellular matrix (ECM) components. A scaffold is used in the beginning 
stages to provide support but will ideally degrade or become remodeled as these 
cells begin to secrete their own ECM. Finally, growth factors and mechanical 
stimulation are used to stimulate the cells to proliferate and differentiate 
appropriately. 
3.4.1. Ceils 
TEHVs have been developed using cells from a variety of sources, 
including vascular smooth muscle and endothelial cells, stem and progenitor 
cells, and valvular cells.82,96"100 Heart valves are covered with a smooth layer of 
endothelial cells, but are populated internally by valvular interstitial cells (VICs), a 
characteristically heterogeneous set of cells.101"104 Much of the basis for the 
heterogeneity of VICs is unknown, although the regional variability in valve 
microstructure, anatomy, and material behavior may be a factor. 
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VICs are thought to have a phenotype similar to, yet distinct from, any 
other cell type.103 VICs are likely not classical fibroblasts, as they are coupled by 
communicating junctions and respond to vasoactive agents.105 Compared to 
either skin fibroblasts or smooth muscle cells, VICs release 10-fold more 
prostacyclin and exhibit a greater mitotic response when exposed to endothelial 
cell conditioned medium.103 In injury or disease, VICs' expression of smooth 
muscle alpha actin (SMaA) becomes elevated.104 Transgenic growth factor beta 
(TGF-P) can also stimulate VICs to differentiate into myofibroblast-like cells which 
express abundant SMaA, cytokines and ECM components.106 
The effects of advanced aging on valve cells are not well characterized. It 
has been observed that the density of cells (graded 0-4 semiquantitatively) drops 
from grade 3-4 in adolescents to grade 1 after age 60,93 and the remaining cells 
demonstrate irregularities in overall morphology as well as in their intracellular 
composition.107 The low cell density and surgical timing logistics would likely 
preclude the use of autologous VICs to develop TEHVs for elderly patients. 
Moreover, in our laboratory, VICs isolated from older patients grow more slowly 
and senesce earlier in culture than VICs from younger people, which would be a 
disadvantage for growing a TEHV from elderly valve cells. Alternative 
autologous elderly cell sources, such as the saphenous vein, have produced 
ECM of inadequate strength when used in a tissue engineered vascular graft,108 
even after transfection of elderly human cells with telomerase was used to 
improve cell proliferation. Putative mesenchymal stem cells with very high 
proliferative capacity were isolated from the connective tissues of adult rats via 
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dilutional cloning, but this work has not yet been translated to older human 
adults. For these reasons, non-autologous cells may be preferable in developing 
TEHVs for elderly patients. 
3.4.2. Scaffold 
In the preparation of a TEHV, cells are seeded onto a scaffold, which 
serves a support function analogous to the valvular ECM. Various synthetic 
biodegradable polymers, natural decellularized scaffolds, and natural 
biodegradable polymers have been considered as support materials. 
3.4.2.1. Synthetic Biodegradable Polymers 
Many synthetic biodegradable polymers have been explored for use as 
TEHV scaffolds due to their ranges of initial mechanical strength and degradation 
times as well as their nontoxic degradation products.82'96 A TEHV constructed 
from polyglycolic acid (PGA) and seeded with ovine vascular endothelial cells 
and smooth muscle cells was successfully implanted into the pulmonary position 
of a sheep model, but this polymer has a high initial rigidity.98 A pulmonary valve 
conduit consisting of a composite of PGA and polyhydroxyoctanoate (PHO), with 
leaflets made of PHO seeded with ovine cells, was viable in a lamb for 6 
months.98 The PHO did not degrade completely, possibly leading to a foreign 
body response. Alternatively, Sodian et al.97 used polyhydroxyalkanoates 
(PHAs) to create an entire valve. The PHA exhibited mechanical strength and 
elasticity appropriate for a TEHV scaffold.97' 10° Polyvinyl alcohol) (PVA) has 
also been evaluated for use in TEHVs.99 PVA is hydrophilic, preventing adhesion 
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of VICs; the incorporation of poly-L-lactic acid, a hydrophobic polymer, increased 
both hydrophobicity and cell adhesion, but also increased the degradation time of 
the macromer." 
The composition and fabrication of the above polymeric scaffolds can be 
altered to obtain the proper material properties, which will be different for elderly 
patients than for younger patients. At this time, most of these valve structures 
have been tested either in bioreactors or in the pulmonary valve position of an 
animal model, leading to the concern that these implants will not be strong 
enough to withstand the forces imposed upon the aortic or mitral valves. 
Additionally, the required lifespan of the polymer is still an open question. A 
polymer scaffold would ideally degrade as cells secrete structural ECM 
components. This degradation time will likely be different in the elderly than in 
younger adults, but would also depend on the types of cells chosen to populate 
the scaffold. 
3.4.2.2. Decellularized Animal Valve 
A decellularized xenograft or human valve could be seeded with human 
cells or used alone to produce a TEHV. When implanted in the pulmonary 
position of a sheep model, decellularized porcine scaffolds (unseeded) showed 
little degradation or calcification.110 The method of decellularization used in this 
study is known as the SynerGraft™ procedure,111 and it has shown promising 
results in adults.112 Preseeding the decellularized valves with cells (i.e., human 
dermal fibroblasts) prior to implantation has improved the resulting TEHV 
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performance in a bioreactor, resulting in valves that contained more collagen at 4 
weeks than decellularized structures that were unseeded at the start of the 
study.113 
Various enzymatic and detergent-based decellularization treatments have 
been compared, with mixed results. In one study, a combination of the non-ionic 
detergents Triton-X 100® and sodium deoxycholate appeared to completely 
decellularize the matrix while maintaining the underlying structure.114 Other 
studies have shown that the decellularization process itself can weaken the 
scaffold through a loss of ECM components.115 Because collagen present in the 
scaffold could stimulate thrombus formation via a combination of platelet 
activation and coagulation factor XII,116 recent studies have combined the 
decellularised animal scaffold with biodegradable poly(hydroxybutyrate), a 
member of the PHA family, in order to strengthen the scaffold and reduce any 
inherent thrombogenicity.116 
The evidence of numerous age-related changes to the valvular ECM 
indicates that valve allografts from elderly donors would not be durable scaffolds 
for TEHVs. With age, the valves thicken117 and their relative proportion of 
collagen decreases.118 Collagen in the older aortic valve resists digestion with 
collagenase, potentially due to an increase in crosslinking118 which would be 
consistent with their reduced extensibility.119 In normal heart valves, individual 
collagen fibers were found to become thicker and less aligned with age. 
Additionally, lipid accumulation and calcification within normal valves increased 
with aging in a similar manner as valves afflicted with AS.93 
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3.4.2.3. Natural Biodegradable Scaffold 
An assortment of materials are currently under investigation for use as a 
natural biodegradable scaffold. Porcine small intestine submucosa has shown 
some promise in the replacement of mature pulmonary valve leaflets, forming a 
more valve-like structure over time, although some thrombus formation on the 
leaflet surface was observed after implantation in a porcine model.120 Collagen 
sponge101 and fibrin gel121 have also been shown to support valve cell growth. 
Fibrin has certain advantages in that it can be isolated from a patient's blood 
(including from elderly patients) to remove the risk of an immune reaction, and its 
degradation is controllable with aprotinin. Unfortunately, fibrin gels have tended 
to shrink with time and have an initially low mechanical stiffness.121 Crosslinked 
hyaluronan gels have also been investigated as substrates for cell growth, with 
the possibility for use in a final TEHV product.122 While these natural scaffolds 
appear to be useful as a cell support structure, more work must be done to 
develop scaffolds with appropriate degradation, mechanical, and 
nonthrombogenic properties. 
3.4.3. Factors Influencing Cell Growth 
Chemical growth factors and mechanical stimulation have been frequently 
used to control proliferation and differentiation of cells, as well as the mechanical 
properties of the scaffold and resulting TEHV. These tools can likewise be used 
to tailor the final TEHV structure to the physical and chemical environment of the 
elderly patient. The growth factor TGF-(3 has been shown to mediate the 
52 
differentiation of VICs, promoting myofibroblast-like characteristics (SMaA 
expression, contractility), yet inhibiting proliferation and apoptosis.106 Fibroblast 
growth factor-2, which was upregulated six-fold by VICs in a scratch wounding 
experiment,123 is mitogenic and could also mediate the remodeling of nascent 
TEHVs. Mechanical stimulation of the cell/scaffold combination can affect the 
mechanical properties of the polymeric scaffold;82 for example, dynamic flexure 
can fragment PGA fibers or disrupt bonding of poly(hydroxybutyrate) to the 
polymer. Mechanical conditioning has also been shown to improve cell 
distribution throughout the scaffold, ECM development, and the resulting 
mechanical properties of the engineered tissue,82'124 and could therefore 
plausibly be used to control these characteristics so the TEHV will perform 
properly in the altered physiological environment of the elderly patient. 
3.5. Conclusions 
Interest in developing tissue engineered heart valves has grown 
exponentially over the last decade. Frequent reviews of this field have provided 
lively debate and, more importantly, close scrutiny of preclinical and clinical 
results. Although elderly patients have not yet been the focus of TEHV research, 
recent successes implanting TEHVs in adult patients111,112 should spur new 
efforts in developing living valve tissues for patients older than 65 years. The 
selection of cell sources, scaffolds, and mechanical/biological conditioning, 
however, will need to be precisely targeted to meet the physiological, medical, 
and surgical requirements of this diverse, large, and growing population. 
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Chapter 4. Effects of CHF and LVAD Use on the Mitral 
Valve 
Specific Aim 1: Determine how LVAD support, and the resulting decrease in left 
ventricular load, affect the ECM composition of the mitral valve of CHF patients. 
4.1. Background 
Approximately 60,000 people are diagnosed with New York Heart 
Association Class IV congestive heart failure (CHF) each year; the yearly 
mortality rate is 50%46. In the United States, the most common underlying 
pathologies leading to CHF are dilated cardiomyopathy (DCM) and ischemic 
cardiomyopathy (ICM), both resulting in a loss of myocyte function. The body's 
compensatory mechanisms eventually cause the ventricular chamber to dilate, 
leading to heart failure. When a patient does not respond adequately to oral 
medical management therapies such as ACE-inhibitors and beta-blockers, a 
heart transplant is often advised. Unfortunately, only 2,300 donated hearts are 
available every year125, indicating a great need for an alternative treatment. 
The left ventricular assist device (LVAD) has been successful in offloading 
the cardiac muscle, increasing myocyte contraction50 and decreasing myocyte 
diameter51,52, reducing intensity of CHF symptoms. Additionally, collagen 
deposition within the cardiac tissue has been found to decrease after LVAD 
use52'53. Ventricular function, as measured by left ventricular ejection fraction 
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and end-diastolic diameter, was observed to improve after 30-60 days of LVAD 
treatment but declined after 90-120 days52'53. 
Results from the Randomized Evaluation of Mechanical Assistance for the 
Treatment of Congestive Heart Failure (REMATCH) study have shown that the 
LVAD is more successful than oral medical management therapies at treating 
CHF; follow-up studies with new LVAD designs have shown a continued increase 
in long-term survival126,127. The success of the LVAD as a bridge-to-transplant 
device has suggested an alternative use of the device as destination therapy for 
end-stage CHF; certain devices have received FDA approval for this use. 
Unfortunately, it appears that sufficient recovery to permit LVAD explantation 
only takes place in approximately 4-9% of patients53,128, and that a level of 
recovery exists after which further LVAD treatment is not beneficial to the 
patient38,53. 
It was recently shown that the mitral valve tissue of patients with end-
stage CHF contains less water, more cells, and more collagen than normal 
tissue42. These fibrotic changes contribute to the mitral valve regurgitation often 
observed in the failing heart. Although severe mitral valve regurgitation worsens 
CHF prognosis129, this condition functionally improves with LVAD treatment61,62. 
If the LVAD does not reverse the fibrotic remodeling of the valve tissue, however, 
a patient weaned from the device may experience continued valvular 
regurgitation. Additionally, previous studies have indicated cusp fusion and 
thrombus formation on the aortic valve with LVAD treatment27,29; it is unknown 
whether there is a similar effect on the mitral valve. Combined, the possibility of 
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continued mitral valve fibrosis and the known detrimental effect of the LVAD on 
the aortic valve motivate the investigation of mitral valve remodeling in LVAD 
patients. 
The current study examined the effect of LVAD use on mitral valve 
microstructure. It was hypothesized that, while LVAD use promoted recovery of 
the cardiac tissue, restoration of the normal mitral valve extracellular matrix 
(ECM) would not be complete. A possible implication of this result would be 
continued mitral valve dysfunction, such as mitral regurgitation, after device 
explantation. Determination of valve pathologies due to mechanically-induced 
matrix remodeling could lead to recommended clinical workarounds, such as the 
LVAD cycling recommended in some patients to prevent aortic valve fusion. 
4.2. Methods 
The first specific aim compared mechanical, biochemical, and histological 
data from CHF patients who did or did not receive LVAD support prior to 
transplant. The purpose of this study was to determine if alterations in the 
mechanical environment stimulate cell-mediated remodeling of the ECM, 
resulting in changes to the mechanical properties and function of the tissue. 
Data gathered in support of Aim 1 was analyzed both alone and, for 
completeness, in conjunction with data obtained previously at the Cleveland 
Clinic. 
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4.2.1. Tissue Selection 
Human test tissue was obtained from the Cleveland Clinic Foundation 
(CCF, Cleveland, OH), St. Luke's Hospital (Houston, TX), and the Cooperative 
Human Tissue Network (CHTN); IRB approval was obtained as needed at each 
institution. Mitral valves were excised from the diseased hearts after transplant 
and stored in phosphate buffered saline (PBS) at 4°C until dissection. Once 
received, each valve was photographed and visible anomalies, such as 
calcification, were noted. Patient data, such as LVAD use, age, gender, and 
medical therapies, was gathered as available. Control tissue, from patients 
without history of heart disease, was obtained from CCF and Ben Taub Hospital 
(Houston, TX). After autopsy, the tissue was excised and treated in the same 
manner as diseased tissue. 
4.2.2. Mechanical Testing 
4.2.2.1. Machine Setup 
During dissection, 5-10 mm wide radial and/or 5-10 mm wide 
circumferential tissue sections were removed from the anterior and posterior 
leaflets of the valve and set aside for mechanical testing. Additionally, anterior 
basal/marginal and posterior basal/marginal chordae were tested. Tissue could 
be tested up to 5 days after transplant or autopsy, since valve tissues kept at 4°C 
have been shown to retain their matrix-based mechanical properties up to 5 
days130. All mechanical testing was performed using an Instron (Norwood, MA) 
or EnduraTec ELF 3200 machine (EnduraTec, Minnetonka, MN). Text files 
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generated by the mechanical tester were imported into Mathematica® 5.0 
(Wolfram Research, Champaign, IL) programs for analysis. 
Tester 
Figure 4.1: EnduraTec ELF 3200 mechanical testing machine. The grips, clamping a piece 
of mitral valve leaflet, are shown in the inset. 
The machines performed uniaxial tensile testing on small pieces of tissue 
(Figure 4.1). The tips of the grips were rounded to prevent tissue tearing, and 
the grip face was given a sandblasted finish to tightly grip the tissue between the 
two faces without slipping. As an extra precaution against slipping, 600 grit 
wet/dry sandpaper was glued onto the grip faces. A saline chamber was 
available to keep the tissue at 37°C during long-term testing. The Cleveland 
Clinic used a similar bath for all mechanical tests, but a chamber was not 
available during the first mechanical tests at Rice; these early samples were 
therefore not included in data analysis. 
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4.2.2.2. Sample Preparation and Dimensions of Test Strips 
Before testing, the thickness and width of the tissue were measured. The 
strip of tissue was then inserted between the two grips of the machine, and the 
grips were tightened as much as possible to prevent slipping. The distance 
between the two grips was adjusted until the tissue sample was only slightly 
slack, and the gap was measured to give the initial length of the tissue. 
The gauge length was defined as the point at which collagen fibers began 
to uncrimp and support the load imparted upon the tissue (Appendix 1). The 
original method used to calculate gauge length was defined by Carew and 
Vesely131. After comparing the mathematical gauge length obtained by the 
CarewA/esely method to the tissue load-elongation curve, the original algorithm 
was modified to better fit the physical results by Meaghan McNeill, a 2008 NSF 
REU student from Baylor University (Appendix 1). 
To reduce hysteresis, restoring physiological tissue behavior, all tissue 
was pre-conditioned prior to mechanical testing by cycling the sample at least 
three times from zero strain to a strain able to induce elastic behavior. If the 
tissue showed evidence of slip or failure, the sample was discarded. 
4.2.2.3. Load-Elongation 
The tissue was then subjected to load-elongation testing. All tissues were 
cycled at 1 Hz from a state of zero strain to a strain sufficient to induce elastic 
behavior. The first three waveforms of the load-elongation test, as with the 
stress-relaxation and failure tests, were designed to retain the conditioned state 
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of the tissue. Subsequent waveforms were used for data analysis. Samples that 
showed evidence of slipping or failure were discarded. Time, load, and 
displacement were recorded to a text file for analysis in Mathematica. 
4.2.2.4. Stress-Relaxation 
After load-elongation testing, the tissue was subjected to stress-relaxation 
testing. The maximum strain used for load-elongation testing was used for the 
stress-relaxation testing. The tissue was first pulled using 3 triangle waveforms 
at a frequency of 1 Hz to return tissue to its conditioned state. The tissue was 
then returned to the peak displacement and held for 100 seconds, then returned 
to the initial displacement. Time, load, and displacement were recorded to a text 
file for analysis in Mathematica. 
4.2.2.5. Failure 
After stress-relaxation testing, tissue was pulled until failure after exposure 
to three preconditioning waveforms. If failure was not obtained for a specimen 
before reaching the machine's displacement limit, results for load-elongation and 
stress-relaxation testing only were analyzed. Time, load, and displacement were 
recorded to a text file for analysis in Mathematica. 
4.2.2.6. Radius of Curvature 
Radius of curvature is a relatively new phenomenon to be studied in valve 
tissue mechanics. As noted in Chapter 2, the valve tissue is anisotropic; the 
orientation of the collagen fibers in the circumferential direction causes greater 
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stiffness in the circumferential than the radial direction . When viewing a tissue 
stress-strain curve of a circumferential section, the transition region is smaller. If 
a circle were to be fit to this transition region, its radius would be smaller than if a 
circle were fit to the transition region of the stress-strain curve of a radial 
segment. The differences in the radii of curvature between these two tissue 
orientations are due to the mechanisms of collagen uncrimping as the tissue 
begins to bear load. Collagen fibers are preferentially aligned in the 
circumferential direction in the valve leaflet and uncrimp together when tension is 
applied to the tissue. On the other hand, the fibers are less aligned in the radial 
direction and uncrimping occurs in a more heterogeneous manner as fibers 
rotate before bearing load. This new tool to assess mechanical behavior is 
therefore especially novel, as it can be used as a measure of collagen fiber 
orientation within the leaflet. In this manner, a circle was fit to the transition 
region of the strain-strain curve from load-elongation data obtained during testing 
in Section 4.2.2.3. The radius of this circle was measured using Mathematica. 
4.2.2.7. Data Analysis 
All results were analyzed using a one-way analysis of variance (ANOVA) 
between the two test groups of CHF patients with and without LVAD support in 
addition to a group of normal subjects. Results were considered statistically 
significant at p<0.05. A Holm-Sidak, or Dunn's test was then used as appropriate 
to assess differences between subgroups showing a statistically significant 
difference (p<0.05). Independent variables were the tissue regions tested and 
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the tissue displacement (strain) throughout the course of the experiment. The 
dependent variable was the force response (stress) of the tissue sample to the 
displacement. 
4.2.3. Histology and Immunohistochemistry 
4.2.3.1. Sample Preparation 
A 5 mm radial section of the posterior and anterior leaflets of each valve, 
as available, was reserved for histology. Strips extended the entire radial length 
of the valve, from annulus to free edge. When possible, the strips were taken 
from the center of the leaflet. These strips sometimes contained chordae; 
however, chordal diameter is small compared to the width of the tissue sample, 
and the chordae was not present in many tissue sections from the microtome. 
As a result, chordal histological samples were often examined separately. Other 
tissue sections of interest, such as sites of commissural fusion, were taken when 
present. Histological sections were inserted into a tissue cassette and placed in 
HistoChoice™ Tissue Fixative (Amresco, Solon, OH) for at least 24 hours; use of 
HistoChoice™ prevented excessive cross-linking of the tissue. 
Flex™ (Richard-Allen Scientific, Kalamazoo, Ml), a mixture of isopropyl 
alcohol and methanol, was used in place of ethanol. After fixation, the tissue was 
dehydrated in preparation for embedding in paraffin. The sample was placed in 
50% and 70% Flex™ 100 (Richard-Allen Scientific) solutions for 1 hour each. 
The sample was then placed in 80%, 90%, and 95% Flex solutions for 2 hours 
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each and in 100% Flex for 4 hours. Finally, the sample was placed in a 50:50 
Flex:xylene solution and then 100% xylene for 4 hours each. 
Prior to paraffin embedding, the sample was placed in liquid paraffin for 2 
hours. The tissue was then placed in a mold with paraffin, which was allowed to 
set. After embedding, the sample was cut with a microtome into 5 urn sections 
and mounted on a slide. After the slides were dried, they were placed in an oven 
overnight and set aside for staining. 
4.2.3.2. Hematoxylin and Eosin 
Hematoxylin and eosin (H&E) staining (Appendix 2) was used to stain the 
cell nuclei blue (hematoxylin) and the cytoplasmic and ECM proteins pink (eosin) 
so that a change in cell concentration within a sample could easily be detected 
(Figure 4.2). Images of the H&E slides were created at 5X magnification. As 
available, at least three images each of the leaflet free edge, leaflet center, and 
chordae were created. Cell density in each valve layer was measured using 
ImageJ software (NIH, Bethesda, MD). Using the Movat sample (described 
below) as a guide to the locations of the atrialis, spongiosa, and fibrosa, regions 
of interest were defined on each image. The area of the region was measured, 
and the cells counted. Cell density was expressed in number/mm2. 
4.2.3.3. Movat Pentachrome 
Movat staining (Appendix 2) was used to label the different ECM 
components in the sample. In the finished sample, elastin was stained black, 
smooth muscle cells and fibrin red, collagen yellow, glycosaminoglycals (GAGs) 
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and proteoglycans (PGs) blue-green, and cell nuclei a blue to black color (Figure 
4.2). Rather than quantification of any one ECM component, this stain was used 
as a way to qualify any disruption to the layered valve structure. 
Attachment Edge 
Fibrosa ;—-fjlf 
Atrialis 
Spongiosa 
Chordae 
(Collagen Gore) 
Chordae 
(Elastin Sheath) , 
Chordae (near 
Papillary Muscle) 
Figure 4.2: Posterior leaflet mitral valve samples from patient with ICM. H&E staining (left) 
indicates cellular density of tissue, while Movat staining (right) identifies ECM components 
in tissue. 
4.2.3.4. Immunohistochemistry (IHC) 
Samples were stained for the presence of the PGs versican, decorin, 
biglycan, and collagen types I and III to ascertain the extent of ECM remodeling 
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(Appendix 2)1. After capturing images of each sample, the images were blinded 
by another party to remove possible sources of bias. The samples were then 
semi-quantitatively graded for intensity on a scale of 0-4: 0 indicated no stain; 1 
indicated a weak stain in <50% of sample; 2 indicated a weak stain in >50% of 
sample or strong stain in <10% of sample; 3 indicated a strong stain in <50% of 
sample, and 4 indicated a strong stain in >50% of sample. The samples were 
graded twice on two separate days. The difference between the two assigned 
grades was examined; a difference greater than 2 required a re-grade of the 
sample by microscope. 
4.2.3.5. Data Analysis 
Average cellular concentration was analyzed for significance among the 
three subject groups (normal, non-LVAD, and LVAD patients) using a one-way 
ANOVA. For immunohistochemical testing, the average grades for each subject 
group were also analyzed using a one-way ANOVA. Holm-Sidak, Tukey, or 
Dunn's post-hoc testing was used as appropriate, with p<0.05 defined as 
significant. 
4.2.4. Biochemistry 
Biochemical assays were used to quantify content of collagen, DNA, and 
GAGs in the tissue. Since biochemical data for normal tissue has already been 
1
 Immunohistochemical data for PGs within the posterior leaflet of normal patients have been 
previously published133. 
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published by this lab12,42, the current work focused on comparing the differences 
between non-LVAD and LVAD patients. 
4.2.4.1. Proteinase-K Digestion 
Mitral valves excised from diseased and normal hearts were dissected into 
the following seven portions: anterior leaflet free edge (ALF); anterior leaflet 
center (ALC); anterior leaflet basal chordae (BC); anterior leaflet marginal 
chordae (MC); posterior leaflet (PL); posterior leaflet BC; and posterior leaflet 
MC. Any tissue left over after histological and mechanical testing samples were 
removed was set aside for biochemical analysis. The wet weight of each group 
was then recorded, and the tissue was dehydrated overnight. The dry weight of 
the tissue was recorded and percent hydration calculated. 
Each sample was rehydrated with 1 mL 100 mM ammonium acetate (pH 
7.0). More ammonium acetate was added as needed so that the liquid would 
cover the tissue. The tissue was minced, and a 100 uL aliquot of 10 mg/mL 
proteinase-K solution was added. Samples were allowed to digest for 16 hours 
at 60°C. If necessary, another 100 uL of proteinase-K solution was added to 
complete the digestion. The samples were heated for 30 minutes at a 
temperature slightly above 70°C to denature the enzyme. If desired, the samples 
were placed in a speed-vac to concentrate them to a volume less than 1 mL. 
This concentration step was not necessary, as it did not affect the amount of 
protein, collagen, DNA, or GAG in the sample; it just allowed simplified 
calculations using rounded volumes. After concentration, the sample was 
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leveled to 1.0 ml_, 1.25 ml_, or 1.5 ml_ using ammonium acetate. The sample 
was then set aside for use in the biochemical assays described below. 
4.2.4.2. Collagen Determination 
The hydroxyproline assay (Appendix 3), used to quantify collagen levels in 
tissue, works on the premise that heart valve collagen contains 13% 
hydroxyproline134. The tissue was first digested with proteinase-K to break up 
the tissue structure and hydrolyzed with HCI to recover the peptide-bound 
hydroxyproline. The samples were mixed with a sodium A/-chloro-p-toluene 
sulfonamide (Chloramine-T) and propanol solution to oxidize the hydroxyproline. 
After incubation with the Chloramine-T, the samples were incubated with an 
Erlich's reagent (p-dimethylaminobenzaldehyde) and perchloric acid solution to 
form the chromophore. The assay samples were then analyzed using a 
spectrophotometer (Molecular Devices Corp, Sunnyvale, CA) to determine 
hydroxyproline content5. 
4.2.4.3. DNA Assay 
The DNA assay was performed to give a measure of cellular density in the 
tissue135. As for the hydroxyproline assay, an aliquot of tissue with a pre-
estimated quantity of DNA42 was first digested with proteinase-K. Unlike the 
other biochemical assays, where the supernatant was tested, the DNA assay 
tested both the liquid and the residual solid matter, containing cells, from the 
proteinase digestion. The sample was sonicated to break up the individual cells 
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and release the DNA, and the DNA was tagged with a fluorescent dye (Hoechst 
33258) and read using a fluorimeter (Molecular Devices Corp, Sunnyvale, CA). 
4.2.4.4. Carbohydrate Analysis 
Fluorophore-assisted carbohydrate electrophoresis (FACE) is a process 
that uses a 1-D gel to differentiate GAG disaccharides by molecular weight and 
charge136. The tissue of interest was first digested with proteinase-K to break up 
the tissue structure and the PG core protein. Aliquots estimated from previously 
determined concentrations of total GAGs137 were then further digested with a 
chondroitinase to cleave the GAG chains into disaccharides of different sulfated 
amino sugars linked to A/-acetyl-galactosamines or glucosamines. The terminal 
N- acetylgalactosamine groups from the end of the GAG chain were also 
released. Chondroitinase ACII specifically cleaved HA and CS, and 
chondroitinase ABC specifically cleaved HA, CS, and DS138. After digestion, 
samples were fluorotagged using 2-aminoacridone (AMAC) (Molecular Probes, 
Eugene, OR) to replace the hydroxyl group on the disaccharide. After insertion 
into an acrylamide gel, the samples were electrophoresed and the gels viewed 
using a fluorescent light source136'138 (Figure 4.3). 
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Figure 4.3: FACE gel upon viewing with fluorescent light source. GAG disaccharides, as 
separated by charge and molecular weight, are indicated. C/D=Chondroitin/Dermatan 
Sulfate; GAG=glycosaminoglycan; GalNAc=A/-acetyl-galactosamine. 
4.2.4.5. Data Analysis 
Biochemical data has been published for normal valves12; data analysis in 
the present study was performed to assess differences in valve ECM between 
non-LVAD and LVAD patients. A Student's t-test compared the mean values 
between the two patient groups. If an apparent difference was observed 
between short-term (<100 days) and long-term (>100 days) LVAD treatment, a 
one-way ANOVA was then performed between non-LVAD, short-term LVAD, and 
long-term LVAD patients with Tukey, Holm-Sidak, or Dunn's post-hoc testing 
performed as appropriate. In both cases, p<0.05 was considered significant. 
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4.3. Results 
This section first examines deviations from normal mitral valve function 
with CHF and LVAD treatment. After the mechanical testing results have been 
presented, the biochemical and immunohistological data describing changes in 
tissue structure will be examined. Since valve ECM structure and mechanical 
properties are related, these results will give a complete picture of the effects of 
the mechanical environment changes induced by CHF and subsequent LVAD 
treatment. 
The data presented includes all patients examined during the course of 
this study (Table 4.1); however, not all groups are fully represented due to 
limitations on the availability of donated tissue. Additionally, the size of the LVAD 
limits its use in children and smaller women. It was decided, therefore, to define 
a cohort of these patients matched for gender, age, race, and pathology (Table 
4.2). The results from this cohort will be presented as appropriate. 
Due to the use of donated human tissue throughout this aim, obtaining an 
ideal sample size to achieve statistical significance was not always feasible. In 
the results below, if statistical analysis revealed a power value <0.80 (indicating a 
possible Type II error), the power is noted. 
4.3.1. Mechanical Properties 
Before testing, mitral valve tissue was divided into four groups: leaflet 
radial, leaflet circumferential, and the two types of chordae (BC and MC). The 
uniaxial testing of these two different leaflet orientations and of the two different 
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chordae was designed to give a clear picture of the changes in tissue behavior 
due to CHF and LVD treatment. 
Table 4.1: Patient Data. 
Gender 
Race 
Pathology 
n 
Mean Age 
Male 
Female 
African-American 
Caucasian 
Other/Unknown 
ICM 
DCM 
RCM 
LVAD Support (days) 
Control 
24 
48.3±20.5 
14 
10 
8 
13 
3 
non-LVAD 
34 
53.3±9.8 
25 
9 
6 
25 
3 
16 
17 
2 
LVAD 
15 
51.0±13.3 
14 
1 
0 
12 
3 
11 
4 
0 
100.2+72.2 
Data are presented as mean ± standard deviation. 
Note: One patient was diagnosed with DCM and possible ICM. 
CHF=congestive heart failure; DCM=dilated cardiomyopathy; ICM=ischemic cardiomyopathy; 
LVAD=left ventricular assist device; RCM restrictive cardiomyopathy. 
Table 4.2: Patient Data - Caucasian Male Cohort 
n 
Mean Age 
LVAD Support (days) 
Control 
7 
56.0±21.3 
non-LVAD 
9 
53.0+10.3 
LVAD 
10 
57.3±6.2 
111.8±78.5 
Data are presented as mean ± standard deviation. 
CHF=congestive heart failure; LVAD=left ventricular assist device. 
In the extensibility, failure strain, and radius of curvature leaflet data sets, 
data from a single LVAD subject will be presented. Calculations for samples 
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obtained at CCF were originally performed with the older gauge length algorithm. 
When the algorithm for determining gauge length was edited (Appendix 1), the 
gauge lengths resulting from execution of the two programs were very different 
for some samples. Analyses that relied heavily upon gauge length (i.e., 
extensibility, failure strain, and radius of curvature) therefore needed to be 
redone. Unfortunately, some of the original data files from CCF were missing. In 
the cases of stiffness, relaxation, and failure stress, the results of the calculations 
using the two different algorithms were similar enough to be able to confidently 
use CCF results. For the remaining analyses, CCF results were disregarded, 
and significance between control and non-LVAD subjects was assessed using 
the Student's t-test. 
4.3.1.1. Leaflet Radial 
Radial leaflet stiffness (Figure 4.4) was significantly higher in CHF than in 
control patients. This stiffness remained elevated in patients treated with the 
LVAD (p<0.05, control vs. non-LVAD and control vs. LVAD). Conversely, 
extensibility was lower in CHF patients than control (p=0.03). Although only data 
from a single patient was available, this property also did not appear to recover 
with LVAD use. Although leaflet relaxation, a measure of viscous nature, did not 
vary significantly between test groups, it was positively correlated with age in 
non-LVAD patients (r^O.73, p<0.01, data not shown). 
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Figure 4.4: Alterations to the mitral valve mechanical properties due to CHF and LVAD 
treatment. Stiffness (A) appeared to increase globally throughout the valve with CHF. 
Extensibility (B) decreased with CHF but the LVAD appeared to restore extensibility in the 
chordae. Relaxation (C) did not significantly change between any of the groups. While 
radial leaflet failure strain decreased (D) with CHF, circumferential leaflet failure tension 
(E) increased with CHF. Radius of curvature (F) generally decreased with CHF, with 
apparent recovery towards normal values with LVAD use. n=6-12 (control), n=7-18 (non-
LVAD), n=1-6 (LVAD). Lack of error bar indicates n=1. Data represented as mean ± 
standard deviation. *p<0.05 (Dunn's post-hoc testing), tp<0.01 (Holm-Sidak post-hoc 
testing), Jp<0.05 (Student's t-test), Ap<0.01 (Student's t-test), **p=0.03 between groups. 
CHF=congestive heart failure; LVAD=left ventricular assist device. 
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Although failure tension did not show any significant trends, failure strain 
was lower in CHF than control patients (p=0.02). Radius of curvature was also 
significantly lower with CHF (p=0.005), suggesting that the tissue underwent 
fibrotic remodeling radially. Effect of LVAD use on these mechanical properties 
could not be accurately discerned due to the small sample size. 
Data from the matched patient cohort generally followed that of the entire 
population studied. Additionally, leaflet relaxation within the control patient group 
correlated negatively with age (^=0.94, p=0.03). It should also be noted that the 
leaflet thicknesses were not significantly different between the non-LVAD and 
LVAD patient groups (1.37±0.38 mm vs. 1.29±0.23 mm, non-LVAD vs. LVAD). 
4.3.1.2. Leaflet Circumferential 
Failure tension in the circumferential leaflet samples was close to reaching 
statistical significance (p=0.08 between groups, power=0.31). Since the number 
of LVAD patients was low (n=3), an additional comparison was made between 
the control and non-LVAD groups, and failure tension was found to be 
significantly greater in CHF than control patients (p=0.04, Student's t-test). LVAD 
use did not appear to return this tension to normal values. Stiffness, extensibility, 
relaxation, failure strain, and radius of curvature were not significantly different 
between the three subject groups (Figure 4.4). The non-LVAD radius of 
curvature tended to be lower than normal (p=0.08). No further trends were noted 
in the patient cohort, which had behavior consistent with the whole group. 
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4.3.1.3. Chordae 
Chordal extensibility (Figure 4.4) was significantly different between the 
three test groups (BC: p<0.001, MC: p=0.03). Post-hoc testing showed that BC 
extensibility in LVAD patients was significantly greater than that in both control 
(p<0.01) and non-LVAD (p<0.01) patients. Stiffness was significantly greater in 
the MC of non-LVAD patients (p=0.03) and although the number of LVAD 
subjects was too small to confidently analyze (n=2), LVAD use did not appear to 
return stiffness to normal values. 
Radius of curvature in the BC was significantly different between the three 
subject groups (p=0.02), and post-hoc testing showed that radius of curvature 
was greater in the LVAD patient group than the non-LVAD patient group 
(p<0.05). Radius of curvature was also lower in the MC of non-LVAD subjects 
than control subjects (p=0.004); since the number of LVAD patients was small 
(n=2), the effect of LVAD treatment could not be analyzed. Relaxation, failure 
strain, and failure tension were not significantly affected by either CHF or LVAD 
use. 
The patient cohort held a number of interesting observations (data not 
shown). First, BC stiffness was positively correlated with LVAD support duration 
until 200 days, when a sharp drop occurred. MC relaxation in non-LVAD patients 
was significantly lower than that of controls (p=0.05); the number of LVAD 
subjects was too low to assess any impact of the device. Failure tension and 
age in the BC of LVAD patients tended to be positively related (1^=0.86, p=0.07). 
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Radius of curvature in MC tended to be negatively associated with age in the 
non-LVAD patients (r^O.86, p=0.07). 
4.3.2. Structural Properties 
After assessing mechanical behavior of mitral valve tissue with CHF and 
LVAD treatment, the microstructure and the overall matrix composition of the 
valves were examined. These changes to the valve structure illuminated 
possible causes of the observed changes to mechanical properties. 
The different sections of the mitral valve have normal compositions 
relating to their function. The ALF and PL contain a more defined spongiosa, 
where the PGs and GAGs counteract the compression forces imposed upon the 
tissue during coaptation. Conversely, the ALC and chordae have a larger 
collagenous fibrosa layer to support the tension imparted upon the tissue. The 
following section will include a description of the changes to the layered structure 
of the valve and the relationship to the mechanical changes noted above. 
4.3.2.1. Collagen 
When measured biochemically, no change in overall mitral valve collagen 
content was noted between non-LVAD and LVAD patients in the general 
population; in the cohort, ALF collagen was significantly greater in LVAD patients 
than non-LVAD (52.0±18.5% vs. 40.5±6.3%, p=0.05). When compared to non-
LVAD patients, however, short-term LVAD patients (55.0±27.2 days, n=10) 
showed significantly higher levels of collagen while long-term LVAD patients 
(190.6±35.5 days, n=5) showed significantly lower levels (Table 4.3) in the ALF 
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(p=0.03) and the PL (p=0.05). Mean collagen levels in the ALF of short-term 
LVAD patient groups were significantly higher than those of long-term LVAD 
patient groups (p<0.05). Post-hoc testing did not show any further significant 
changes in PL collagen levels between any paired combinations of the three 
subject groups. In the cohort, collagen in LVAD patients was significantly greater 
than that in non-LVAD patients in the ALF and PL. Additionally, collagen content 
in the posterior MC was negatively correlated with LVAD support duration 
(1^=0.64, p=0.02). 
Table 4.3: Percentage collagen in mitral valve. 
Anterior Leaflet Free Edge 
Anterior Leaflet Center 
Posterior Leaflet 
Anterior Chordae 
Posterior Chordae 
Non-LVAD 
46.0±12.2 
(n=28) 
47.2±9.0 
(n=26) 
44.5±10.2 
(n=28) 
50.4±10.4 
(n=54) 
55.2±10.7 
(n=55) 
Short-Term LVAD 
57.1±13.9 
(n=9) 
49.6±7.2 
(n=8) 
54.2±16.0 
(n=10) 
50.9±7.2 
(n=18) 
60.1+11.5 
(n=16) 
Long-Term LVAD 
39.4±10.6* 
(n=5) 
44.2±17.2 
(n=5) 
39.3+11.9 
(n=5) 
50.9±8.1 
(n=10) 
55.1±11.4 
(n=8) 
Data are given as mean ± standard deviation. 
*p=0.03 among groups; +p=0.05 among groups; +.p<0.05 in comparison to short term LVAD 
samples. 
LVAD = Left Ventricular Assist Device 
When Movat slides from all CHF patients were compared to the control 
subjects, collagen and elastin staining in the CHF valves appeared stronger in 
the spongiosa, particularly at the free edge (Figure 4.5). These areas of collagen 
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and elastin deposition within the normally PG-rich spongiosa were deemed 
"mixed spongiosa". Collagen found in the mixed spongiosa was mostly type I 
collagen and was combined with the PGs in a marbled pattern (Figure 4.6). 
Similarly, areas of PG and elastin deposition found within the normally 
collagenous fibrosa layer were called "mixed fibrosa". This mixed fibrosa showed 
greater PG staining in CHF patients. Collagen and PGs were also present within 
the normally elastin-rich atrialis layer of CHF patients; these changes were 
particularly noticeable near the free edge of the PL. When compared to control 
subjects, it was observed that expression of both collagen type I and type III was 
lower in the CHF AL atrialis while collagen I expression was higher in the CHF 
PL atrialis. Type I collagen was slightly greater in LVAD posterior chordae and 
type III collagen was greater in both anterior and posterior LVAD chordae; both 
types of collagen were found outside of the core, where collagen is observed in 
normal valve tissue. 
Examination of Movat-stained mitral valve tissue showed no differences in 
overall amount or localization of total collagen between non-LVAD and LVAD 
patients. Intensity of type I and type III collagen staining also did not show a 
significant difference between the three subject groups. 
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Figure 4.5: Movat stain of anterior leaflet free edge. Compared to tissue from control 
subjects (A), tissue from non-LVAD (B) and LVAD patients (C) displayed greater levels of 
collagen (yellow) and elastin (black) stain in the middle spongiosa layer. Thick black 
arrows indicate collagen and thin white arrow indicates elastin deposition in the normally 
protroglycan-rich spongiosa of the free edge. a=atrial side; LVAD = Left Ventricular Assist 
Device; v=ventricular side. 
Within short-term LVAD support, collagen content in the ALF of ICM 
patients was positively associated with LVAD support duration (Figure 4.7, 
1^=0.52, p=0.05). In the PL, ICM patients older than 60 treated with the LVAD 
showed less staining for collagen I (p<0.001) and collagen III (p=0.04) when 
compared to patients younger than 60. No other trends were noted when patient 
data were analyzed by LVAD support duration or patient age. 
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Figure 4.6: Anterior leaflet free edge of LVAD patient. Spongiosa collagen noted in the 
Movat stain (A), when compared to a negative control (B), contained high levels of 
collagen I (C) and moderate levels of collagen III (D). Thick black arrows indicate collagen 
and thin white arrow indicates elastin deposition in the normally protroglycan-rich 
spongiosa of the free edge. a=atrial side; LVAD = Left Ventricular Assist Device; 
v=ventricular side. 
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Figure 4.7: Change in collagen content in anterior leaflet of ischemic cardiomyopathy 
patients with LVAD support duration. Within the short-term and long-term LVAD support 
groups, collagen levels tended to be positively associated with LVAD support duration. 
Regression line of anterior leaflet free edge in patients undergoing short-term LVAD 
support had an r2 value of 0.52 (p=0.05). LVAD = Left Ventricular Assist Device. 
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4.3.2.2. Hydration 
Hydration was greater in the ALC (p<0.01) of LVAD patients than in non-
LVAD patients (Figure 4.8). Hydration was also significantly elevated in the 
anterior MC (p=0.03). In the ALC, hydration in non-LVAD patients was lower 
than normal, and hydration was closer to normal in the LVAD patient group. In 
the chordae, however, the non-LVAD patient tissue had normal water content 
while LVAD patient tissue was more hydrated than normal. A similar trend was 
noticed in the cohort; additionally, the posterior BC displayed a difference in 
hydration (78.6±3.6% vs. 68.4±17.2%, LVAD vs. non-LVAD, p=0.05). 
Average Hydration 
D non-LVAD 
l LVAD 
Anterior Leaflet Anterior Leaflet Posterior Leaflet Anterior Marginal 
Free Edge Center Chordae 
Figure 4.8: Average hydration of mitral valve in non-LVAD and LVAD patients. Anterior 
leaflet center and anterior marginal chordae show significantly greater hydration with 
LVAD treatment. Mean hydration values for normal valve sections are represented by 
dashed lines12. *p<0.01; tp=0.03. LVAD = Left Ventricular Assist Device. 
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Differences in ALC hydration were statistically significant between the 
three CHF subject groups (p=0.03), and hydration levels were higher in both 
long-term and short-term LVAD groups as compared to the non-LVAD (p<0.05) 
(Table 4.4). A similar result was noted in the grouped anterior (basal and 
marginal) chordae (p=0.003), with significantly greater hydration noted in both the 
short-term and long-term LVAD patient groups as compared to the non-LVAD 
patient group (p<0.05). Hydration level changes were not noted in either the ALF 
or PL, nor were they dependent upon patient age or support duration. 
Table 4.4: Percentage water in mitral valve. 
Anterior Leaflet Free Edge 
Anterior Leaflet Center 
Posterior Leaflet 
Anterior Chordae 
Posterior Chordae 
Non-LVAD 
85.4±3.0 
(n=29) 
77.9+4.5 
(n=27) 
86.0±3.6 
(n=29) 
73.8±10.5 
(n=56) 
73.7±9.4 
(n=58) 
Short-Term LVAD 
84.9±3.8 
(n=9) 
81.2±2.7* 
(n=9) 
85.3±3.4 
(n=10) 
79.5±3.8 * 
(n=18) 
78.1 ±3.4 
(n=17) 
Long-Term LVAD 
87.3±1.7 
(n=5) 
82.3±4.3 * 
(n=5) 
86.2+2.8 
(n=5) 
78.7±12.2 * 
(n=10) 
78.0±1.8 
(n=8)) 
Data are given as mean ± standard deviation. 
*p=0.03 among groups; +p=0.003 among groups; +.p<0.05 in comparison to non-LVAD samples. 
LVAD = Left Ventricular Assist Device 
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4.3.2.3. Cellularity 
Changes in overall DNA concentration between groups, measured 
biochemically, were used to assess changes in overall tissue cellularity. DNA 
concentration of mitral valves from CHF patients did not change with LVAD 
treatment. In ICM patients, DNA content in the ALF was negatively associated 
with the duration of short-term LVAD support (Figure 4.9,1^=0.80, p=0.04). In 
the ALC, DNA content was lower in DCM LVAD patients than in ICM LVAD 
patients (p=0.02). There was no change in DNA concentration of the entire 
population with age; however, non-LVAD patients from the cohort experienced a 
negative association in MC cell concentration with age (anterior MC: 1^=0.73, 
p=0.03; posterior MC: 1^=0.76, p=0.01). 
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Figure 4.9: Change in DNA concentration in anterior leaflet of ischemic cardiomyopathy 
patients with LVAD support duration. (A) Within the short-term and long-term LVAD 
support groups, DNA content tends to be negatively associated with LVAD support 
duration. (B) Regression line of ALF in patients undergoing short-term LVAD support has 
an r2 value of 0.80 (p=0.04). ALC = Anterior Leaflet Center; ALF = Anterior Leaflet Free 
Edge; LVAD = Left Ventricular Assist Device. 
Since the mitral valve is a heterogeneous structure, cells on H&E-stained 
samples were counted to determine if any changes by cell layer existed. In the 
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ALC, cell density was significantly lower in non-LVAD subjects compared to 
controls in the fibrosa (p=0.01 between groups, p<0.05 for control vs. non-LVAD) 
and atrialis (p<0.001 between groups, p<0.05 for control vs. non-LVAD and 
control vs. LVAD). While the cell density in the atrialis of the LVAD group 
appeared to be slightly greater than that of the non-LVAD group, the cell 
numbers in the fibrosa did not appear to recover with LVAD support. While not 
significant, a similar pattern was noted in the mixed-fibrosa and chordal regions 
(Figure 4.10). This trend for the fibrosa held in the patient cohort (p=0.03 
between groups; p<0.05, control vs. LVAD). Cell density in the CHF valves 
tended to be lower than normal in the atrialis, but the control sample size was too 
small (n=2) to suggest significance. Similar patterns were also noted in the 
annular region of the PL (Figure 4.10). Non-LVAD subjects had a lower than 
normal cell density; while LVAD use appeared to reverse this trend in the fibrosa 
and mixed-fibrosa regions, the remaining sections did not recover. 
Cell Concentration-Anterior Leaflet Center v ' Cell Concentration-Annular Posterior Leaflet 
Figure 4.10: Cell density of the anterior leaflet center (A) and the annular region of the 
posterior leaflet (B). The heart failure valves often had lower cell density than control. 
LVAD treatment did not always reverse these trends. Data represented as mean ± standard 
deviation. *p<0.05. LVAD=left ventricular assist device. 
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In the spongiosa of the ALF, non-LVAD cell density was negatively 
correlated with age (1^=0.90, p=0.01). The reverse trend was true for the fibrosa 
of the PL annular region (^=0.98, p=0.001). The mixed-spongiosa region of the 
PL annular region demonstrated lower cell densities with LVAD support duration 
(1^=0.73, p=0.01). These trends in the posterior leaflet were also noted in the 
cohort, where cell density of the anterior chordae also tended to be lower than 
normal in all CHF patients (p=0.066). 
4.3.2.4. Glycosaminoglycans 
Normal heart valve glycosaminoglycan values have been published 
previously12; the current research compares these values with those obtained for 
non-LVAD and LVAD heart valves. As in the report, results were grouped based 
on the type of force resisted by the tissue; tension (Figure 4.11) or compression 
(Figure 4.12). 
In tension-bearing tissues such as the ALC (Figure 4.11), the D4S and 
hyaluronan (HA) GAGs have been found to be the most abundant normally12. 
Hyaluronan (HA) was slightly lower than normal values in all CHF patients 
regardless of treatment. In the ALC of CHF subjects, however, unsulfated 
chondroitin (COS) was significantly greater in LVAD patients compared to non-
LVAD (p=0.01). Conversely, D6S was slightly greater than normal values in all 
CHF patients. The values of all other individual GAGs, as well as the total GAG 
content, did not significantly deviate from normal values in CHF patients, 
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regardless of treatment. In the patient cohort, overall HA content was 
significantly greater in LVAD than non-LVAD patients (p=0.01) 
GAG expression in the chordae tended to follow many of the trends 
observed in the ALC. In the BC, HA content was slightly lower than normal in all 
CHF patients, regardless of therapy, while HA values in the MC remained 
unchanged from normal (Figure 4.11). In both BC and MC, COS remained 
constant in non-LVAD patients but was greater in LVAD patients. C6S content in 
both BC and MC was greater than normal in non-LVAD patients, and while not 
significant, C6S content in LVAD patients tended to be greater than non-LVAD. 
Conversely, BC/MC D6S content in non-LVAD valves was slightly greater than 
normal while reduced in LVAD patients; this difference was significant in the 
posterior MC (p=0.05). C2S was significantly greater in LVAD than non-LVAD 
posterior MC (p=0.05). C4S, D4S, and total GAGs in both the BC and MC were 
not significantly different either between the two CHF groups or from normal 
values. In BC, GAG chain lengths in chondroitinase-ABC digested samples were 
significantly lower in non-LVAD than LVAD patients (54.9±49.7 vs. 95.4±79.3 
disaccharides, p=0.01). In the patient cohort, BC and MC HA content was 
significantly greater in non-LVAD than LVAD patients (BC: p=0.05; MC: p=0.03). 
COS and D4S in the MC were also greater in non-LVAD patients (p=0.05, COS 
and D4S), as was total GAG content (p=0.03). 
In the ALF (Figure 4.12), total GAG content was significantly greater in 
non-LVAD valves than LVAD samples (p=0.01). All CHF samples contained 
slightly less HA than normal tissue. While D4S in the non-LVAD tissue was 
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slightly greater than normal, LVAD tissue contained normal amounts of this GAG. 
In the patient cohort, D4S in the non-LVAD tissue was significantly higher than 
LVAD (p=0.03). No other differences were noted either between normal and 
CHF tissue or between non-LVAD and LVAD tissue. 
For both PL CHF treatment groups, HA and C6S contents were slightly 
elevated from normal values. Although C4S content in the non-LVAD samples 
was equivalent to that of normal tissue, LVAD C4S was significantly greater than 
in non-LVAD tissue; this trend also held for C2S. No other significant differences 
were noted in the remaining GAGs or in total GAG content. 
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Figure 4.11: GAG composition in the tension-bearing regions of the (A) anterior leaflet 
center and (B) chordae. Data presented compare GAGs from non-LVAD and LVAD 
patients. Dotted lines indicate normal GAG composition of the mitral valve12. 
GAG=glycosaminoglycan; LVAD=left ventricular assist device. 
t p * 0.05. 
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Figure 4.12: GAG composition in the compression-bearing regions of the (A) anterior 
leaflet free edge and (B) posterior leaflet. Data presented compare GAGs from non-LVAD 
and LVAD patients. Dotted lines indicate normal GAG composition of the mitral valve12. 
GAG=glycosaminoglycan; LVAD=left ventricular assist device. fp£ 0.05. 
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4.3.2.5. Proteoglycans 
Proteoglycan content was assessed using a semi-quantitative method of 
grading IHC-stained tissue samples for overall intensity. Samples were 
separated into anterior and posterior leaflets. All three patient groups were 
tested and compared in this manner. It should be noted that, while the 
diaminobenzene (DAB) was made from powder for the immunohistochemical 
staining of most of the PG samples (see Methods), the lab eventually switched to 
use of a DAB kit for health and safety reasons. The three controls tissues 
obtained later into the study period, therefore, used a different DAB treatment, 
which may have skewed the control results slightly higher. It is therefore 
possible that the results are more significantly different than indicated below. 
Decorin staining was greater in LVAD anterior leaflet tissue than control or 
non-LVAD tissue samples (p=0.05 among groups) (Figure 4.13). Versican 
staining in LVAD tissue was greater than in control tissue (p<0.01, power=0.072). 
Biglycan staining intensity was not significantly different between any of the 
groups. Similar trends were noted in the posterior leaflet, but there were no 
significant differences between groups (power < 0.151 in PG testing of cohort 
PL). PG staining intensity in both classifications of CHF patients tended to be 
greater in both anterior and posterior chordae, infiltrating the collagen core. In 
general, versican staining was co-localized with elastin while decorin and 
biglycan were co-localized with collagen. 
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Figure 4.13: Proteoglycan content of the anterior leaflet. Versican and decorin staining 
intensities were both greater in the LVAD than normal samples. Negative control intensity 
staining=0.34±0.48 (all groups). * p<0.05 among all patient groups, f p<0.01. LVAD=left 
ventricular assist device. 
No significant differences were observed in PG content with LVAD support 
duration or patient age. When comparing DCM and ICM patients, it is important 
to note that due to the small number of DCM LVAD patients in the study, 
statistical significance could not be reached. In ICM patients, there was a trend 
of lower biglycan staining in LVAD patients (2.4±0.8 vs. 1.8±0.4, non-LVAD vs. 
LVAD, p=0.065). In the anterior leaflet of ICM patients, versican staining 
intensity was greater in short-term LVAD patients (2.7±0.2 vs. 2.0±0.0, short-term 
vs. long-term, p=0.01). Decorin staining in the posterior leaflet was slightly 
greater in long-term LVAD patients, but significance could not be ascertained due 
to a small sample size (n=3). 
91 
4.4. Discussion 
Previous research in this lab showed that the mitral valve underwent 
fibrotic remodeling in CHF patients42; this remodeling was likely due to changes 
in the geometry of the left ventricle and therefore in the forces imparted upon the 
valve during the cardiac cycle. The tissue itself became stiffer and less hydrated 
and contained more collagen and cells. It was unknown whether the unloading 
of the left ventricle due to LVAD treatment encouraged beneficial or continued 
pathological remodeling of the mitral valve tissue. 
Tissue remodeling throughout the valve was varied in nature and did not 
always have the expected compensatory result on the tissue structure. Partial 
summaries of the structural remodeling are located below (leaflet center: Figure 
4.14, chordae: Figure 4.15, leaflet free edge: Figure 4.16). LVAD use did not 
appear to reduce collagen content toward more normal values; however, tissue 
from long-term LVAD patients contained less collagen than short-term LVAD 
patients. The amount of collagen was greater in both the ALC, which was 
normally rich in collagen, and in the PG-rich ALF, which contained disorganized 
collagen and elastin. The greater than normal GAG content of the non-LVAD 
ALF suggested remodeling of the tissue, while the reduced GAGs in LVAD tissue 
showed a possible compensatory mechanism of the tissue. Conversely, GAG 
content was slightly greater in the non-LVAD posterior leaflet with no substantial 
recovery due to LVAD use. Unlike normal ALF and PL tissue, which contains 
more 6S GAGs than 4S GAGs12, the fact that CHF tissues contained similar 
quantities of both types of GAGs indicated that different PGs were involved in the 
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remodeling of the tissue. In particular, the shift from HA to D4S may have been 
related to ALF fibrosis in the non-LVAD patients. Greater versican and decorin 
expression in the LVAD anterior leaflet may have indicated the formation of new 
elastin and collagen, with elastin17 appearing in the short-term and collagen 
appearing with long-term support. The increase in collagen coupled with the 
decrease in DNA concentration with short-term LVAD support also indicated that 
the amount of collagen, and possibly other ECM components, produced per cell 
increased. A cohort of Caucasian males was defined to study trends within a 
matched patient subgroup. The results of this cohort shared many trends with 
the overall patient overall group, lending credence to the testing and analysis 
methods. 
Leaflet Center 
Figure 4.14: Overview of selected biochemistry results for the anterior leaflet center. 
Arrows represent relative magnitude of component content between normal/non-LVAD 
patients and non-LVAD/LVAD patients. Red arrows indicate pathological remodeling, 
while green arrows indicate no change or beneficial remodeling. 
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Chordae 
Figure 4.15: Overview of selected biochemistry results for the chordae. Arrows represent 
relative magnitude of component content between normal/non-LVAD patients and non-
LVAD/LVAD patients. Red arrows indicate pathological remodeling, while green arrows 
indicate no change or beneficial remodeling. 
While the free edge remained fibrotic with LVAD treatment, the 
collagenous ALC and chordae began to recover normal hydration levels. It is 
interesting to note that HA, which is also associated with hydration, was lower in 
these tissues, suggesting that an upregulation of different GAG (i.e., sulfated) 
classes, such as the 6S GAGs found in the hydrated PG versican, was 
responsible for the higher tissue water content, especially in chordae. DNA 
concentration was lower in the ALC, suggesting that overall ECM upregulation, 
rather than greater cell proliferation, was the responsible mechanism. In LVAD 
ALC samples, the relative proportion of 4S and 6S GAGs was similar to that of 
the normal ALC12; remodeling did not tend to alter the basic GAG composition of 
the tissue. 
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Figure 4.16: Overview of selected biochemistry results for the anterior and posterior leaflet 
free edges. Arrows represent relative magnitude of component content between 
normal/non-LVAD patients and non-LVAD/LVAD patients. Red arrows indicate 
pathological remodeling, while green arrows indicate no change or beneficial remodeling. 
Mechanical testing results showed that the ECM remodeling described 
above worsened leaflet behavior while improving chordae behavior to a point 
similar to that observed in normal tissue. In the mitral valve leaflet, collagen 
fibers are normally aligned parallel to the annulus, in the circumferential direction. 
The orientation of the fibers shifts to align in the radial direction at the 
commissures and the strut (large basal) chordae139. This alignment imparts a 
normal greater stiffness and lower extensibility in the circumferential direction 
than in the radial direction. While properties in the circumferential direction did 
not change drastically with either heart failure or LVAD use, radial stiffness was 
greater and extensibility lower in CHF subjects. This result suggested that any 
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new collagen incorporated into the CHF mitral valve structure was less organized 
than in normal valves and tended to be more oriented in the radial direction, a 
result corroborated by the decrease in the radius of curvature of the radial 
section load-elongation curve. The marbled collagen and elastin in the mixed 
spongiosa layer as well as the marbled elastin and PGs in the mixed fibrosa layer 
also indicated that these valve layers were bearing their respective compression 
and tension loads less efficiently than normal. Conversely, LVAD use appeared 
to return chordal mechanical behavior to normal. This result may have been due 
to the general uniaxial motion of the chordae and highly aligned collagen in the 
tissue. 
It is interesting to note that the mitral valve segments that displayed the 
greatest increases in water content with LVAD treatment, the ALC and chordae 
tendinae, were the least hydrated tissues of the normal mitral valve 12. 
Conversely, the ALF and PL, which contained the least collagen in normal valve 
tissue, showed the greatest changes in collagen content with CHF and LVAD 
treatment42. These results were likely due to changes in the types of forces 
imparted on the different valve sections due to the changing geometry of the left 
ventricle in CHF and in LVAD unloading. For example, decreased coaptation of 
the valve free edges in CHF due to a dilated left ventricular annulus apparently 
encouraged valve fibrosis. If the LVAD did not restore this coaptation, and the 
mitral valve instead fluttered during the cardiac cycle, normal valve structure and 
resulting functionality would not be restored. 
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Changes in hydration, collagen content, and cell concentration were often 
noted with longer LVAD support duration. In particular, mean collagen content 
was reduced below normal values after 100 days of LVAD treatment. The 
reduction in mean collagen concentration may also indicate that, with long-term 
LVAD support, cells upregulated production of other ECM components such as 
PGs, possibly leading to the lower proportion of collagen measured in the ALF 
and PL. The time scale of these changes to the valve microstructure were 
interesting when compared to the decline in ventricular function after 90-120 
days of LVAD support previously noted 52,53; it was likely that this decline led to 
dysfunctional remodeling after long-term LVAD support. 
The two measures of change in cellularity, DNA concentration and cell 
density, had very different outcomes. These apparently contradictory results can 
be clarified by understanding what exactly was measured. The Hoescht assay 
resulted in DNA concentration in the entire tissue sample. Unfortunately, the 
digestion of the tissue required for the assay removed the ability to examine any 
layer-specific cellularity changes. Tissue dehydration in preparation for digestion 
also negated the water-retention property of the spongiosa GAGs and PGs, 
leading to a lower initial tissue volume against which cellularity was normalized. 
In order to consider the effect of the layered valve structure, cell density in H&E-
stained samples was measured by counting cell nuclei in each layer. The 
downfall of this cellularity measurement was its dependence on the point at 
which the tissue was mounted upon the slide. The two measures of cellularity 
combined gave a more complete assessment of changes in cell proliferation with 
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CHF and LVAD use. In the ALC, DNA concentration in CHF patients was greater 
than control42, and did not appear to recover with LVAD use. Cell density in the 
fibrosa and atrialis, on the other hand, was lower in both CHF and LVAD patients 
when compared to control. These results suggested that cell number increased 
with CHF as well as increased ECM secretion, particularly elastin and collagen, 
per cell. This increased ECM per cell was also noted in the ALF, where DNA 
concentration decreased and collagen concentration increased with short-term 
LVAD support duration. 
Remodeling of the valve tissue, while appearing to restore the biochemical 
tissue composition, did not improve leaflet mechanical behavior. Hydration and 
PG content both were greater in the LVAD leaflets. These results suggest that 
the valve tissue was undergoing remodeling towards a less fibrotic state, possibly 
to compensate for the lack of mobility in the radial direction. Additionally, overall 
collagen content appeared to have been negatively associated with prolonged 
LVAD use, but immunohistochemical staining of the normally PG-rich ALF 
indicated presence of disorganized type I. It was possible that the lower overall 
collagen was due to PG abundance rather than a decrease in collagen. 
Reduction of overall GAG content in the ALF further suggests that the tissue 
remodeling did not improve radial mechanical behavior of the tissue. Instead of 
the compartmentalized three-layer structure found in the normal valve, the non-
LVAD and LVAD patient valves had a more amorphous composition. This 
disruption of the normal structure may explain the continued suboptimal 
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performance of the mitral valve tissue, particularly in the radial direction, with 
LVAD use. 
One major limitation of this project was the small number of LVAD 
subjects available for analysis. A larger patient group would corroborate some of 
the trends reported while improving characterization of the LVAD effects on 
women and minorities. A more varied patient group could also allow the efficacy 
of different LVAD designs to be compared. An additional limitation was the 
inability to compare tissue effects of heart failure with LVAD treatment in the 
same patient. All tissue samples were obtained at transplant; therefore, the 
tissue properties at a final CHF state, but not multiple timepoints, could be 
studied. In the future, an interesting subject group would be patients weaned 
from the LVAD, as the use of tissue from transplant patients assumes a failed 
heart. 
Overall, collagen was upregulated in the CHF tissue, resulting in a 
disorganized structure compared to the normal layered mitral valve and reduced 
radial motion of the leaflet. The LVAD induced further remodeling of the tissue, 
but in such a way that the normal tension-bearing ALC and chordae become 
more hydrated and the normal compression-bearing ALF and PL remained 
fibrotic, with the disorganized collagen dominating the tissue mechanical 
behavior. PG content was greater with LVAD treatment; this compensatory 
mechanism for radial movement could not overcome the disruption of the layered 
structure. 
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4.5. Conclusion 
CHF induces fibrotic remodeling of the mitral valve; the tissue is stiffer, 
less hydrated, more collagenous, and more cellular. This remodeling is due to 
dilation of the left ventricle and resulting changes in the mechanical conditioning 
of the valve tissue. The LVAD unloads the left ventricle, allowing sufficient 
recovery of the tissue to bridge the patient to transplant. The LVAD has been 
successful as a bridge-to-transplant device, and an additional use has been 
proposed for the LVAD as a destination therapy. In order for the device to be 
successfully explanted after completion of treatment, normal function of the entire 
heart should be restored. 
The current research has shown that the mitral valve did undergo 
continued remodeling as a result of the altered load imparted by the LVAD. This 
remodeling apparently benefitted the chordae. The tissue retained its usual 
hydration, and the normal mechanical properties were restored. Unfortunately, it 
does not appear that this remodeling restored the normal leaflet structure; the 
disrupted layered structure remained, especially in the normally PG-rich free 
edge. This altered leaflet structure translated to a continued suboptimal 
mechanical performance of the radial leaflet tissue. Before the LVAD can be 
widely used as a destination therapy, more work should be done to ensure that 
the mitral valve function can be restored prior to weaning the patient from the 
device to prevent further complications. 
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Chapter 5. Design and Validation of a Splashing 
Bioreactor 
Specific Aim 2: Develop an inexpensive, efficient bioreactor to maintain 
mechanical stimulation to the mitral valve while modeling normal and altered 
chemical environments of the tissue. 
5.1. Background 
Although animal models have been used with great success in studying 
many forms of cardiovascular disease, the invasive nature of valve surgery 
creates an obstacle in studying the early stages of valve disease. Additionally, a 
large number of animals would be required to study multiple early timepoints. 
Alternatives to surgical methods, such as molecular imaging, have been 
explored140. Cell studies are another less expensive alternative; current 
experimental research of valvular biology and remodeling generally employs 
cultures of valvular cells maintained in a monolayer106'141,142. This widely 
accepted protocol, however, does not allow investigators to determine any 
changes to the layered valve structure. Additionally, a monolayer culture 
imposes a drastic change in environmental stimuli for the cells, and thus may not 
accurately elicit the in vivo response. To compensate for these shortcomings, 
this aim focused on organ cultures, which maintain the valvular cells within the 
native physical structure of the tissue. Ideally, the organ cultures are grown in 
conditions engineered to mimic the native environment. Organ cultures have 
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successfully been established for a variety of tissues, including vascular 
intima143, canine leptomeninges144, mouse gallbladder epithelium145, brain 
hippocampal slices146, and human lacrimal gland tissue147. In human and 
mammalian heart valve tissues, short-term (6 day) organ cultures have been 
used to investigate wound healing responses148"150. 
Heart valve tissues are particularly appropriate for organ culture research 
because the cells within adult valves are nourished primarily through diffusive 
transport of oxygen and nutrients (as opposed to through vascularization151). 
Therefore, it was believed that designing a valvular organ culture system might 
be much simpler than for more complicated fully vascularized tissues. Previous 
work in our laboratory used a simple system for organ culture (based on work by 
Lester et al.148"150) to demonstrate that the cells within the cultured valve tissues 
remained alive during culture periods up to 7 weeks152. 
The aforementioned work has also suggested, however, that static heart 
valve organ culture techniques did not maintain cell location. Fewer endothelial 
cells were noted on the cultured tissue. Although interstitial cells were still 
present and viable after seven weeks, fewer cells were located deep within the 
tissue, suggesting cell death or migration of these cells to the periphery to obtain 
nutrients152. Results from a histological study performed by Anna Sophia 
McKenney, an undergraduate intern (manuscript in progress) indicated that with 
increased culture time, the layers of the valve became less defined. That work 
was performed on porcine tricuspid valves, which have a layered structure similar 
to that of the mitral valve. Expression of prolyl-4-hydroxylase (P4H), an indicator 
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of collagen formation, was consistently upregulated over a culture period of five 
weeks (Figure 5.1). Proteoglycan (PG) content in the spongiosa decreased 
dramatically as collagen content increased, creating a spongiosa layer more 
similar in structure to the fibrosa (Figure 5.2). Elastin, generally noted in the 
atrialis, also became more diffusely distributed within the tissue. A successful 
bioreactor design would limit this fibrotic remodeling. 
Figure 5.1: Collagen synthesis mediator upregulation in porcine tricuspid valve organ 
cultures at 0 ,1 , 3, and 5 weeks (magnification^ OX). The rightmost figures 
(magnification=40X) illustrate the accumulation of surface cells in damaged regions and 
crevices of the tissue blocks. (A) P4H, with negative control (B) beneath, (C) Movat 
pentachrome stained sections corresponding to the P4H images, suggesting that cells 
have migrated from the densely collagenous regions, but then begin to synthesize 
collagen (in yellow). P4H= prolyl-4-hydroxylase. Images courtesy of Jane Grande-Allen 
and Sophia McKenney. 
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(A) Collagen (Yellow) (B) PG& GAG (Blue) (C) Elastin (Black) 
Figure 5.2: Movat pentachrome stained sections of porcine organ cultured valve tissue 
blocks (magnification 10X). The ventricular surfaces are on the right and the atrial 
surfaces are on the left. (A) Collagen content (yellow) clearly dispersed from the normal 
structure and began to dominate the valves, usually becoming the only remaining matrix 
protein by the conclusion of culture. (B) PG and GAG content (blue-green) gradually 
disappeared, becoming just a diffuse haze in the mixture. (C) Elastin (black) became less 
localized and occasionally dominated the cross section, often together with collagen. 
Arrow indicates increased culture duration. GAG-glycosaminoglycan; PG=proteoglycan. 
Images courtesy of Jane Grande-Allen and Sophia McKenney. 
5.2. Methods 
5.2.1. Bioreactor Design Evolution 
The design of the basic bioreactor was intended to be a subphysiological 
representation of a mitral valve environment; the emphasis was to be placed on 
creating a simple and easily reproducible model. The bioreactor design was 
motivated by the in vivo movement of the fluid past the valve providing both 
perfusion and gentle stretch to the tissue. The valve was to be positioned such 
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that it would "open" and "close" at regular intervals, although less frequently than 
observed clinically. The tissue would be attached slightly slack to prevent excess 
tension along the chordae during organ culture. 
The original design of the bioreactor included a chamber made of 
transparent plexiglass (Figure 5.3A). This chamber would be sealed at the top 
with a 0.2 urn filter screw cap to allow air exchange while ensuring sterility. A 
valve, submerged in fluid, was to be mounted using sterile 4-0 polypropylene 
sutures (Ethicon, Somerville, NJ) onto customized ledges in the chamber. A 
silicone membrane attached to the bottom of the bioreactor would be jostled 
regularly to model blood flow over the mitral valve surface. The bottom of the 
membrane rested against a piston that moved up and down courtesy of a rocker 
plate. When the piston attached to the membrane was pushed up (Figure 5.3B), 
fluid would flow upward in the chamber, past a mitral valve leaflet segment and 
chordae. When the piston was pulled down (Figure 5.3C), the fluid would flow in 
the opposite direction. This action of the fluid would perfuse and exert gentle 
forces on the leaflet face and pull the chordae. 
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Figure 5.3: Original bioreactor design. The original chamber design (A) consisted of a 
hollow tube into which a mitral valve segment would be sutured, from annulus to chordae. 
The bottom of the tube would be covered with a silicone membrane, which rested atop a 
piston. The piston would cyclically move down (B) and up (C), forcing culture media inside 
to splash across the valve surface. Image courtesy of Jane Grande-Allen. 
Construction and use of the proposed design, however, proved to be 
difficult and impractical. Suturing the valve segment into the long, thin tube was 
awkward. Additionally, the piston was moved by a rocker plate, and the motion 
was not easily reproducible between cycles. Additionally, most membrane 
materials tested failed within days. The final design combined user convenience 
with reproducible motion. 
The original solid chamber design was first divided into multiple segments 
(Appendix 4 - ELSIE Version 1). The chamber was then filled with fluid (Figure 
5.4) and allowed to sit for one week with no piston motion. When the chamber 
design proved to be leak-proof, a dynamic test was designed (Figure 5.5), where 
the goal was to expose the chamber to cyclic piston-driven fluid motion for a 
period of two weeks. The small diameter of the inner chamber required a thin, 
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flexible membrane that could deform to the extent necessary to force the culture 
media to move up into the chamber. Different membrane materials, including 
latex and nitrile, as well as a variety of membrane shapes were tested. 
Unfortunately, the nature of the long-term experiment required a more robust 
material, and no material or membrane shape was found that satisfied all these 
requirements. 
Figure 5.4: Static leak test. The segmented ELSIE design was allowed to sit for one week 
with fluid inside to determine water-tightness. 
At this time, it was decided to focus on the use of the chamber as an 
organ culture environment. The solid chamber top was replaced by a threaded 
top (Appendix 4 - Version 2) onto which a filtered cap from a tissue culture flask 
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could be placed. This cap design allowed for easy replacement of the culture 
media as well as air exchange. A nitrile membrane was attached to the base of a 
number of different ELSIE segments, with the intent of replacing membrane 
segments during media changes to circumvent the short lifespan of the 
membrane (Figure 5.6A, Appendix 4 - Version 3). This design was eventually 
discarded due to a concern of damaging the organ cultures with repeated 
dismantling of the chamber. 
Figure 5.5: Leak test with dynamic motion. The ELSIE bioreactor was set up with the 
piston moving up (A) and down (B). After 3 days (C), the membrane began to show signs 
of wear (black arrow). Rupture occurred after 5 days (D, black arrow). 
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Throughout these design changes, the movement of a single plunger was 
powered by a simple 14V DC motor (Barber-Coleman, Rockford, IL) connected 
to a power source. In order to determine how well this motion translated to 
multiple chambers, the chambers were lined up in series (Figure 5.6B). The 
motion was weaker in chambers further from the motor, and membrane leakage 
was still a major issue. After the motion test, a lab rotator was found that could 
move the chambers 360°; the resulting fluid motion was similar to that applied by 
the piston and had the advantage of being replicable (Figure 5.6C). The 
membrane was therefore replaced by a solid piece in the final design, resolving 
the leakage issue. 
Figure 5.6: Improving mechanical motion constancy and removing leak sources. (A) Using 
replaceable membrane segment to work around material fatigue issue. (B) Ascertaining 
reproducibility of motion between several chambers. (C) Replacing the piston with a lab 
rotator fixed both issues of material fatigue and motion reproducibility. 
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5.2.2. Final Design 
The final bioreactor chamber design (Appendix 5) consisted of 3 
polycarbonate segments (McMaster-Carr, Chicago, IL), each 2" in diameter 
(Figure 5.7). The segments were clamped together via four 4" long, %"-28 
partially threaded screws and nuts spaced 90° around the circumference of the 
bioreactor. The two ends of each segment each had 3 1/16" neoprene washers 
(McMaster-Carr, Robbinsville, NJ) mounted using Loctite® glue. The washers 
were wrapped with Teflon tape upon chamber construction to prevent leaks. 
The main body of segment "A" was 1.5" tall and had a !4" hole in the 
center to accommodate fluid flow. The top of "A" was 1" tall and threaded to fit 
the vented filter cap from a 25 cm2 tissue culture treated flask (BD Biosciences, 
San Jose, CA) in order to allow gas exchange in the bioreactor. Segment "B" 
was 5/8" tall and had a 14" hole in the center. Polyester mesh squares (Sefar 
America Inc, Depew, NY) approximately 0.5x1 mm were glued between the 
neoprene washers to provide a mounting location for the mitral valve. Segment 
"C" was 1.25" tall, and a 1/2" hole was cut through the top 1" for fluid flow. The 
bottom %" of the segment was solid. 
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Figure 5.7: Splashing bioreactor chamber. The chamber was comprised of three hollow 
segments ("A", "B", and "C") into which the valve segment was mounted. The media 
(represented here by the green fluid) provided nutrients to the tissue. Valve attachment 
sites (inside chamber) are also indicated by ANN=annulus and CH=chordae. 
Fluid motion was provided by a Labnet Mini LabRoller ™ (ISC Bioexpress, 
Kaysville, UT). This rotator fit two bioreactors on a pallet, secured with two 3/16" 
cable ties (Figure 5.8). The rotator moved a full 360° at an approximate speed of 
0.33 revolutions/second. This rotation caused the media to splash across both 
valve surfaces, imparting a combination of normal and shear force to the valve. 
Turbulent flow in the physiological system generally indicates an abnormality, 
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such as valve regurgitation or stenosis153. Media in the bioreactor tended to flow 
along the inner volume of the chamber; the result was a mostly laminar flow with 
turbulence at the chamber top and bottom, far from the tissue sample. The use 
of the rotator ensured that the motion was repeatable. A final volume of 4.5 mL 
was selected; while the media only partially bathed the tissue, this smaller 
volume (as opposed to completely filling the chamber with fluid) allowed greater 
forces to be imparted onto the valve surface. The presence of any bubbles in the 
media from the splashing motion improved oxygen pressure in the system. 
Figure 5.8: Bioreactor on rotator. The pallet moved a full 360 degrees, forcing media over 
the valve surfaces. 
Sterility testing of the bioreactor was performed by allowing media to 
remain in the chamber for one week. Initial tests were performed without valve 
tissue, and later tests included a mitral valve segment mounted in the bioreactor 
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chamber. When the media was changed, a sample of the old media was placed 
into a 6-well plate and returned to the incubator. A sample of the fluid was also 
applied to an agar plate and allowed to incubate for 3 days. Additionally, media 
was spot-checked for contamination during the design validation studies (Section 
5.2.3) by drawing media samples and incubating in a 6-well plate for 2-3 days. 
5.2.3. Design Validation 
Porcine mitral valves from animals approximately six months in age were 
used to validate the bioreactor design. Valves were extracted from the heart 
within 6-10 hours after sacrifice and rinsed in sterile PBS containing 5% 
antibiotic/antimycotic solution (Mediatech Inc, Herndon, VA) to remove bacteria. 
Two 5 mm wide radial sections (one surrounding each strut chordate, Figure 
5.9A) were then removed from the anterior leaflets (n=19). The first section from 
each valve was cultured, under either static or dynamic conditions, for two 
weeks. Static cultures (negative control, n=10) were placed in a T-25 tissue 
culture flask, while dynamic cultures (n=9) were mounted in the bioreactor 
(Figure 5.9B.C). In both test cases, the tissue was bathed in organ culture media 
containing 5% antibiotic/antimycotic solution for the first 24 hours after dissection, 
after which it was replaced by media with 1% antibiotic/antimycotic solution. The 
second section from each valve was designated a baseline control sample. All 
tissues were fixed in Histochoice™ after two weeks (cultured samples) or 
immediately after dissection (baseline control samples). After fixation, all tissue 
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samples were dehydrated to xylene, paraffin embedded, sectioned into 5 urn 
slices, and mounted on slides (Section 4.2.3.1). 
(A) 
5 mm 
(B) (C) 
ANN 
CH 
-ANN 
\ : 
Figure 5.9: Valve insertion. (A) A 5 mm radial valve section was removed from the AL. (B) 
The section was then mounted at the ANN and CH. The free edge was unattached. (C) Top 
view of valve in bioreactor. AL=anterior leaflet, ANN=annulus, CH=chordae, PL=posterior 
leaflet. 
All samples were stained with H&E and Movat pentachrome (Appendix 2) 
to visualize the cells and extracellular matrix (ECM) components within the tissue 
layers. The PGs versican (VC), decorin (DCN), and biglycan (BGL), as well as 
collagen types 1 and 3 (COLLI/COLL3), were localized within the valve 
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microstructure through immunohistochemical staining (Appendix 2). In addition 
to these ECM components, localization of the ECM precursors P4H, lysyl 
oxidase (LOX), and heat shock protein 47 (HSP47) was performed. P4H and 
HSP47 are associated with different stages of collagen synthesis, while LOX is 
involved in collagen and elastin cross-linking. Use of antibodies against matrix 
metalloproteinase-1 (MMP1), MMP2, MMP9, and MMP13 identified sites of 
enzymatic matrix degradation. An antibody against the tissue inhibitor of matrix 
metalloproteinase 1 (TIMP1) stain was also employed. An antibody sensitive to 
proliferating cell nuclear antigen (PCNA) determined the location of proliferating 
cells within the tissue to assess cell viability. 
All sample slides were blinded and then graded for staining intensity on a 
scale of 0 (no stain) to 4 (heavy stain), as done in Section 4.2.3.4. In order to 
determine the effect of the mechanical stimulation throughout the tissue, intensity 
was assessed in all three valve leaflet layers: the elastin-rich atrialis, located at 
the atrial surface; the middle spongiosa layer, comprised of PGs and 
glycosaminoglycans (GAGs); and the collagenous fibrosa, located near the 
ventricular surface. Staining intensity was also measured in the chordae 
tendinae. Localization of the different ECM components and turnover mediators 
within the valve layers was performed via comparison of the 
immunohistochemically stained samples to the Movat samples. 
The Movat samples were also used to determine sample thickness. Five 
sections along the radial sample were selected: ALC near valve annulus, middle 
ALC, strut chordae insertion (generally the midpoint of the valve, where the ALC 
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and ALF are separated), middle ALF, and ALF tip. Each section was measured 
at five different points to account for variability in thickness. 
5.2.4. Statistical Analysis 
Since each anterior valve leaflet has two strut chordae (Figure 5.9A), each 
valve yielded two sections for testing. For each valve obtained during the 
validation study, one section was treated as a baseline control, and the second 
section was cultured for two weeks in either the no mechanical stimulation or 
cyclic mechanical stimulation condition; therefore, each test sample had its own 
matched control. In each valve, staining intensity of each ECM component and 
turnover mediator of the cultured section was normalized to that of the baseline 
control section. A normalized staining intensity of 1.0±0.2 (100±20%) defined 
maintenance of the component over the treatment period. Normalized staining 
intensity of the dynamic organ culture was compared to that of the negative static 
control using a Student's t-test, with statistical significance defined as p<0.05. 
Valve thickness was normalized to the baseline control in the same manner, and 
normalized static and dynamic sample thicknesses were compared using a 
Student's t-test. 
5.3. Results 
After the bioreactor was designed and built, it was tested to verify that the 
mechanical stimulation would indeed maintain ECM structure and cell viability. 
Short-term sterility tests showed that the environment within the bioreactor 
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remained free from contamination during the test period (data not shown) both 
with and without tissue in the chamber. 
In samples without mechanical stimulation, PCNA immunostaining 
indicated that fewer proliferating cells were located deep within the tissue, 
although proliferating cells were found near the tissue surface (Figure 5.10). 
H&E staining (not shown) displayed the same trend. After two weeks of static 
culture, the layered structure of the valve was also compromised. Although the 
Movat image showed maintenance of the atrialis, the fibrosa and spongiosa 
became less defined, with an increase in collagen content in the normally PG-
rich free edge spongiosa. These results corroborated the earlier work performed 
in our lab. 
The bioreactor appeared to counteract these static culture trends; after 
two weeks of culture, cell localization in the middle and periphery of the 
dynamically cultured samples were comparable to that in control tissue, as 
indicated by both H&E and PCNA staining. Positive PCNA immunostaining 
(Figure 5.11) also suggested that these cells remained viable during the culture 
period. Additionally, tissue samples cultured in the bioreactor displayed a similar 
ECM structure to that of the control samples; the collagenous fibrosa and PG-rich 
spongiosa layers were clearly delineated in the Movat images. 
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Figure 5.10: Comparison of a mitral valve free edge before (A, C) and after (B, D) two 
weeks of static organ culture (matched samples). When compared to the control (A), 
Movat staining showed an increase in collagen stain (in yellow, arrows) after two weeks of 
culture (B). PCNA stain in the control (C) identified proliferating cells (in brown) 
throughout the tissue. After two weeks (D), fewer cells were found deep within the tissue, 
although many cells were observed at the tissue periphery (arrow). V - Ventricular surface. 
Magnification = SX. 
The use of baseline controls for both the static and dynamic culture 
groups allowed the normalization of staining intensities of the ECM components 
and the turnover mediators for comparison of differences after two weeks of 
culture (Figure 5.12). A normalized value of 1 indicated that there was no 
change in the component after culture, while value <1 indicated reduced 
expression and value>1 indicated greater expression. The splashing bioreactor 
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was successful at maintaining most tested ECM components and turnover 
mediators; factors not maintained to within 20% (normalized staining intensity of 
1.0±0.2) are presented in Table 5.1. The most compelling results are noted 
below. 
Figure 5.11: Comparison of a mitral valve free edge before (A, C) and after (B, D) two 
weeks of dynamic organ culture (matched samples). When compared to the uncultured 
fresh control (A), Movat staining indicated maintenance of tissue structure after two weeks 
of culture (B). PCNA stain in the fresh control (C) and the cultured (D) tissues displayed 
proliferating cells (in brown) throughout the tissue. The thick arrows identify the 
spongiosa layer, while the thin arrows identify the fibrosa. V - Ventricular surface. 
Magnification = 5X. 
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In the atrialis (Figure 5.12), normalized COLLI expression was maintained 
with dynamic culture and reduced in static culture (p=0.03). Normalized COLL3 
expression tended to be greater with dynamic culture than static culture (p=0.06). 
PG expression remained constant compared to baseline with both static and 
dynamic culture, as did MMP1, MMP2, MMP9, and LOX content. TIMP1 
expression was too varied between samples to draw a conclusion. MMP13 
normalized expression was slightly greater in the dynamic samples, while HSP47 
was reduced (Table 5.1). 
Normalized spongiosa MMP9 (p=0.01) and TIMP1 (p=0.04) content 
(Figure 5.12) were both greater and closer to 1.0 with dynamic than static culture. 
Normalized MMP1 content, on the other hand, tended to be reduced in the 
dynamic culture samples compared to static culture samples (p=0.07). DCN and 
VC contents were comparable to the baseline control with both static and 
dynamic loading conditions, while BGL and COLL1/3 remained lower than the 
control (Table 5.1). MMP2, MMP9, and HSP47 expression was constant 
between the dynamic culture samples and baseline controls. Their resulting 
normalized stain intensity, which was approximately 1.0, was greater than and an 
improvement over that of the static samples. Normalized staining intensity was 
approximately 1.0 for MMP13, P4H, and LOX in both static and dynamic 
samples. 
Normalized fibrosa MMP2 expression (Figure 5.12) was greatly elevated 
with dynamic culture compared to the baseline control (Table 5.1) as well as in 
comparison to the static culture (p<0.001, dynamic vs. static). In the fibrosa, 
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BGL and COLLI expression remained constant between the baseline control, 
static culture, and dynamic culture samples. Normalized DCN expression in 
dynamic culture samples was slightly elevated compared to static culture, while 
VC content was lower (Table 5.1). Although not significantly different, 
normalized COLL3 expression (Table 5.1) in the fibrosa of dynamic culture 
samples was slightly lower than the elevated value found in static culture 
samples. P4H content was similar between the three sample groups, while 
expression of MMP1, MMP9, LOX, and HSP47 was increased toward baseline in 
dynamic samples. Dynamic MMP2 and MMP13 expression was elevated above 
baseline, while TIMP1 was reduced. 
Normalized expression of LOX (Table 5.1) and BGL in the chordae (Figure 
5.12) was greater in dynamic culture compared to both the baseline control and 
the static culture condition (p=0.02, LOX and p=0.02, BGL); however, COLLI 
content was upregulated in the dynamic culture samples compared to static 
culture samples (p<0.01). COLL3 expression was similar to baseline in the 
dynamic culture samples, as was VC and DCN content. Content of HSP47, 
MMP1, MMP2, MMP9, MMP13, and TIMP1 in the dynamic culture and baseline 
control samples was approximately equal. Normalized P4H (Table 5.1) 
expression in the dynamic samples was greater than in static samples. 
Although it was desired to show how the mechanical stimulation provided 
by the bioreactor improved cell viability and ECM structure compared to static 
culture conditions, it was also important to show that the bioreactor design would 
be a successful culture environment. Since a normalized value of 1 for stain 
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intensity indicated that there was no change in the expression of the specific 
component from baseline, the normalized expression for all components was 
tracked. The components that were not maintained with dynamic culture are 
listed in Table 1. Except for atrialis HSP47, which showed a slight improvement 
with dynamic over static culture, these components showed similar component 
expression with both static and dynamic culture. In general, however, the 
bioreactor was effective at maintaining ECM structure of the valve. 
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Figure 5.12: Staining intensity, normalized to paired baseline control, of selected ECM 
components and turnover mediators in the (A) atrialis, (B) spongiosa, (C) fibrosa, and (D) 
chordae. Data shown as mean ± standard deviation. For all data sets shown, the difference 
between the static and dynamic groups was significant (p<0.05). 
122 
Table 5.1: ECM components and turnover indicators not maintained by bioreactor 
Tissue Layer 
Atrialis 
Spongiosa 
Fibrosa 
Chordae 
Components (normalized stain intensity) 
HSP47 (0.77±0.26), MMP13 (1 6±0.57) 
BGL (0.79±0.28), COLLI (0.71 ±0.28), COLL3 (0.53+0.27), MMP1 (0.54±0.57) 
VC (0.70±0.25), COLL3 (1.32±0.41), MMP2 (2.6+0.89) 
P4H (1.25±0.42), LOX (1.29±0.46) 
Data represented as mean + standard deviation. 
BGL=biglycan, COLL=collagen, HSP47=heat shock protein 47, LOX=lysyl oxidase, MMP=matrix 
metalloproteinase, P4H=prolyl-4-hydroxylase, VC=versican. 
Normalized valve thickness was greater near the annulus for static than 
dynamic organ culture samples (1.66±0.71mm vs. 0.93±0.33 mm, static vs. 
dynamic, p=0.01). At the valve tip, valve thicknesses for both culture groups 
were greater than for the baseline control (2.08±1.77 mm, normalized static and 
1.65±0.94 mm, normalized dynamic); however, the difference between the two 
normalized values was not statistically significant. The normalized valve 
thicknesses at the middle ALC, chordal insertion, and middle ALF were 
approximately 1.0, and the static and dynamic normalized values were not 
significantly different from each other. 
5.4. Discussion 
Previous work in our lab has revealed that valve tissue cultured without 
mechanical stimulation did not maintain tissue structure. Proliferating cells deep 
within the tissue were depleted, and the layered structure definitive of the normal 
valve became less defined with increased culture time. The splashing bioreactor 
designed in this aim provided perfusion and gentle tension to the tissue. This 
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cyclic fluid motion was verified as sufficient to maintain valve structure for the 
two-week period of interest by assessing stain intensity of PGs, collagen, and 
ECM turnover mediators before and after culture. Fluid movement against tissue 
surfaces initiated by rotation of the bioreactor chamber provided the mechanical 
stimulation needed to maintain these aspects of tissue integrity. This novel 
bioreactor, though simple in design and construction, could become a powerful 
tool for studying initial valvulopathy mechanisms. 
A comparison of Movat stains of the mitral valve before and after static 
culture indicated fibrotic remodeling similar to that observed in previous organ 
cultures of the tricuspid valve (Figure 5.2). Additionally, fewer proliferating cells 
were present in the deep layers of the tissue after two weeks of static culture 
compared to fresh tissue, although cells were noted at the tissue periphery. This 
result corroborates the previous work of Allison et al.152, and may be attributed 
either to cell death or to a migration of cells for the purpose of reaching nutrients. 
After two weeks of mechanical stimulation provided by the splashing bioreactor, 
the layered structure of the valve remained intact. Proliferating cells were found 
throughout both the fresh and cultured tissue, indicating that the bioreactor was 
also successful in maintaining cell viability within the valve layers. These results 
show that the light stretching and tissue perfusion provided by the splashing 
bioreactor were sufficient to maintain the valve layered structure and cell viability 
that were lost with static organ culture methods. 
Taken together, the role of MMP13 in collagen degradation and that of 
HSP47 in collagen production, in addition to the increase in normalized COLLI 
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and C0LL3 expression, imply that the mechanical stimulation upregulated 
collagen production in the atrialis, and that the tissue was attempting to maintain 
collagen content via the appropriate turnover mediators. The greater normalized 
COLL3 expression lent further weight to the remodeling theory. It is interesting to 
note that although MMP13 is responsible for cleaving COLLI21,154, there was no 
significant decrease in COLLI staining intensity corresponding to an increase in 
MMP13 staining intensity in the fibrosa; as opposed to the behavior noted in the 
atrialis, this result suggests that collagen remodeling in the fibrosa of dynamic 
culture samples was limited after two weeks. Since MMP13 is associated with 
collagen turnover21, this may have been an attempt to limit the excess collagen 
deposition noted in the earlier study. TIMP1 is an inhibitor of most MMPs21,154; 
its decrease in the fibrosa was likely linked to the increase in MMP expression. 
Expression of COLLI, BGL, LOX, and P4H indicated additional collagen 
remodeling within the chordae. In the chordae, BGL, LOX, and COLLI 
normalized staining intensity in the dynamic samples was significantly greater 
than in the static samples. P4H normalized stain intensity was also slightly 
greater in dynamic than static samples. Since BGL, P4H, and LOX are 
associated with collagen formation, these results indicated that turnover of the 
matrix was occurring. Overall collagen content did not change; COLLI 
normalized staining intensity was approximately 1.0, indicating that dynamic 
culture and baseline COLLI expression were almost equal. This remodeling 
process therefore acted to maintain composition in this highly collagenous tissue. 
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Although the mechanical stimulation appeared to alter PG and collagen 
expression in the atrialis, fibrosa, and chordae, the contents of these ECM 
components remained unchanged in the spongiosa. Lack of improvement in 
BGL and collagen content in the spongiosa was likely due to the lack of 
coaptation in the leaflet free edge; while the bioreactor supplied mechanical 
stimulation from fluid flow, the tissue did not make contact with the opposing 
posterior leaflet as occurs in the heart. Elevated TIMP1 expression indicated the 
possibility that remodeling of the tissue might transpire with increased culture 
time. 
Although the mitral valve tissue in the validation study demonstrated less 
COLLI staining than baseline after two weeks of static culture, the tissue from 
previous studies in our lab showed more total collagen staining with increased 
culture time, as evidenced by the Movat safran stain (Figure 5.2). One possible 
explanation is that tricuspid valve tissue was used in the previous study. The two 
valves may have had different responses to the culture environment. The longer 
culture time in the earlier study may also have led to the greater collagen 
accumulation. As mentioned above, the use of the Movat stain also limited the 
results of the earlier study to a combination of all collagen types present in the 
valve. The validation study in the current research project measured both COLLI 
and COLL3 in the tissue and suggested that an increase in collagen may have 
been due to COLL3 upregulation. COLL3 has been shown previously to be 
greater than normal in patients with myxomatous2 and rheumatic155 heart valves 
and has been presumed to indicate valve remodeling due to pathology; the 
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increase in C0LL3 noted in the current study may have signaled a repair process 
of the tissue. 
In general, valve thickness was maintained in both static and dynamic 
cultured samples when compared to the baseline control. At the annulus, the 
static samples did exhibit some thickening that was not noted in the dynamic 
organ cultures. Both treatments exhibited thickening at the tissue tip; however 
the variability between the measurements made this result less reliable. The 
main limitation in this method of measuring valve thickness was the variability of 
the valve thickness, both along the radial section and in the circumferential. A 
radial valve section taken at another point along the valve might show 
dramatically different results. 
The novelty of this bioreactor design validation method, compared to 
those used to validate previous heart valve tissue engineering bioreactor 
designs76, was in the longer time course of the study as well as the tissue 
analysis methods. Previous heart valve tissue engineering bioreactor studies 
usually focused on deposition of a collagen matrix or its precursors after 48 
hours. Evidence of collagen formation in these earlier studies was a sign of 
improved strength of the engineered leaflet. Conversely, the current study used 
a longer time course to model an existing valvulopathy; this longer study duration 
has not been used as frequently in the heart valve literature. The heart valve 
tissue engineering bioreactor studies often used biochemical methods to assess 
ECM deposition. The research in Aim 2 is one of few bioreactor studies that 
examined changes to the layered valve structure. While the results from this 
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current study cannot be directly compared to those of the previous bioreactor 
studies, when the results are combined, a complete picture of valvular 
remodeling can be drawn. 
Limitations of this project included the subjectivity of the semi-quantitative 
immunohistochemical analysis. An attempt was made to remove all bias through 
blinding of the samples. Repeatability was assessed by a second analysis of the 
tissues, and variability using this method has been previously documented as 
<15%133. It was also possible that cell migration noted in the static culture 
studies was due to a wound response as opposed to nutrient access. This 
possible issue was mitigated by taking samples for staining deep within the 
tissue when mounting slides, away from the original cut. Time limitations 
prevented the use of multiple study durations in this aim. A longer study duration 
could follow the consequences of ECM turnover mediators that were not 
preserved, such as fibrosa MMP2. It is possible that the tissue would 
compensate for the abnormal expression, or that the ECM itself may remodel 
due to the effects of these mediators. 
Organ culture can be a powerful tool to study physiological systems in 
vitro that would otherwise be nearly impossible to observe. In the current study, 
maintenance of both ECM structure and cell concentration within the different 
layers of the tissue indicated successful organ culture. While valve tissue 
cultured without mechanical stimulation displayed both cellular loss deep within 
the tissue and an increase in collagen content, cell localization and ECM 
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structure of tissue cultured for two weeks in the bioreactor remained similar to 
that of fresh tissue. 
5.5. Conclusion 
Previous work in our lab has shown that valve tissue cultured without 
mechanical stimulation lost the normal layered structure; tissue became more 
collagenous with a reduction in PG content. Additionally, cell density deep within 
the tissue decreased. A splashing bioreactor was therefore designed with the 
intent of lightly stretching and perfusing the mitral valve tissue to maintain tissue 
structure. In general, mitral valve sections cultured in the bioreactor, when 
compared with tissue cultured in tissue culture flasks, maintained cell density 
within the layers as well as ECM structure. With this successful design, the 
splashing bioreactor was able to be used to study the early mechanisms of 
valvular heart disease in Specific Aim 3. 
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Chapter 6. Mechanisms of Serotonergic Valve Disease 
Specific Aim 3: Determine receptor effects and early mitral valve ECM 
composition changes due to the introduction of two serotonin receptor agonists, 
serotonin and norfenfluramine. 
6.1. Background 
Carcinoid valve disease, caused by metastatic tumors within the 
gastrointestinal system and pancreas, is characterized by a superficial growth or 
"plaque" on the surface of the right heart valves, with the underlying leaflet 
structure remaining intact. The development of these plaques, which display 
cellular proliferation in addition to increased collagen, proteoglycan and elastin 
production,64,156'157 is associated with serotonin released by the carcinoid 
tumors,. Fenfluramine-phentermine (fen-phen) valvulopathy, the valve disease 
named for the anorectic drug cocktail removed from the market in 1997, is 
defined by the presence of plaques on the left heart valves similar in structure to 
those observed in carcinoid valve syndrome28'70,158. The Parkinson's disease 
drug pergolide was recently removed from the market in the United States due to 
a similar valve pathology73,159, and the club drug "Ecstasy" has also been 
implicated in serotonergic valve disease68. 
The final disease state of serotonergic valve diseases such as carcinoid 
valve syndrome and fen-phen valvulopathy is clear; histological analysis of the 
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valve after surgical resection reveals the presence of a superficial plaque 
impeding proper valve function. Definition of the early disease mechanism, 
however, would be useful in the identification of similar drugs that may stimulate 
or, conversely, prevent plaque formation. Clarification of the disease genesis 
may also increase early treatment options, avoiding the need for valve surgery. 
At present, very little is known about the early mechanism for serotonergic 
valve disease. Studies on ovine aortic valve interstitial cells have indicated that 
the activity of the 5HT2A receptor and consequent G-protein signal transduction 
led to transforming growth factor (TGF)-(31 upregulation and possibly to the 
valvulopathy63. Further studies by this group have also suggested that an 
additional mechanism, possibly via another member of the 5HT2B receptor family, 
may have activated the extracellular signal-regulated kinase 1/2 (ERK 1/2) 
pathway and encouraged cell proliferation65. More recent work using human 
embryonic kidney cells has highlighted 5HT2B as the likely receptor activated in 
serotonergic valve disease68. A schema published by Roth in 200769 has 
suggested that 5HT2B activation leads to dissociation of the G-protein, whose 
Gctq subunit activates the ERK 1/2 pathway leading to cell proliferation, which 
would then increase the overall amount of matrix produced by the cells. It is also 
possible that the GPy subunit causes Src phosphorylation to create Src-P, which 
separately mediates TGF-P receptor activity to further cell proliferation. Recent 
studies have further indicated a role of TGF-0 in the upregulation of sulfated 
GAGs63'160,161. Further details regarding the early disease mechanism are under 
investigation. It is also unknown why these drugs appear to have a preference 
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for the right or left heart valves, or how the plaques form on the valve surface. 
The literature does not agree on a link of serotonergic valve disease with length 
or amount of drug exposure, or whether cessation of drug use reverses the 
effects162. 
The goal of the third aim was to introduce an in vitro method of studying 
serotonergic valve disease. To that end, mitral valve tissue in the splashing 
bioreactor from Aim 2 was exposed to the serotonin receptor agonists serotonin 
(5-hydroxytryptamine, 5HT) and norfenfluramine (NF, a metabolite of 
fenfluramine). These drugs were studied alone and in combination with a 5HT2B 
receptor antagonist to determine the role of the specific receptor in valve 
disease. It was believed that samples treated with the serotonergic drugs would 
have upregulated production of extracellular matrix within the tissue, especially 
glycosaminoglycan (GAG) content, while samples exposed to the receptor 
antagonist would show little remodeling. Additionally, it was hypothesized that 
the mitral valve used in the experiment would show greater NF-induced 
remodeling compared to 5HT, suggesting that an inherent difference between the 
right and left heart valves could be a reason for the differences in drug activity 
noted clinically. 
6.2. Methods 
Porcine mitral valve segments were exposed to the serotonin receptor 
agonists 5HT, NF, and pergolide in order to simulate the early mechanisms of 
serotonergic valve disease. Combinations of the receptor agonists and a 5HT2B 
132 
receptor antagonist were used to confirm the role of this receptor in valve 
remodeling. The first phase of the project involved optimizing the drug 
concentration. The bioreactor created during Aim 2 was then used to provide 
consistent mechanical stimulation during a two-week culture period. 
6.2.1. Drug Dosage Optimization 
Since the available research pertained to cell culture studies, the drug 
concentration to be used in Aim 3 needed to be optimized for organ culture. A 
review of the literature indicated that 5HT67,163-166 and pergolide68,167 
concentrations used in cell culture ranged from 0.01 uM to 10 uM, while NF163, 
164,166
 concentrations used in cell culture ranged from 0.1 uM to 100 uM. 
To allow comparison of multiple valves treated with multiple 
concentrations of each drug, the optimization was performed under static culture 
conditions. The setup of the optimization experiment used 6-well plates instead 
of tissue culture flasks (as with the static culture condition of Aim 2); within each 
plate, sections from three different valves were exposed to two different drug 
concentrations. For each optimization experiment, two plates were used for each 
drug, allowing three valves to each be exposed to four different drug 
concentrations. 
Mitral valve tissue was excised from porcine hearts (Fisher Ham and 
Meat, Spring, TX) within 10 hours of sacrifice. The anterior leaflet was sectioned 
into four (5 mm) radial strips. After dissection, all strips were partially submerged 
in 1.5 ml_ cell culture media containing 5% antibiotic/antimycotic solution. After 
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24 hours incubation (Figure 6.1) at 37°C, the media was replaced by plain or 
serotonin receptor agonist culture media containing 1% antibiotic/antimycotic 
solution. 
(A) 
Began incubation in media 
(1 % antibiotic, with drugs) 
incubation in 
media (5% 
antibiotic) 
Round 1 
Organ culture Cells counted (PO). 
ended seeded on slides 
Organ culture moved 
to new plate 
11 14 
Day 
Immunocytoohemistry 
19 21,22 
(B) 
Began Incubation in media 
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o 1 
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ended 
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determine 
proliferation (P1) 
11 14 16 
Day 
Figure 6.1: Timeline of cell studies. Round 1 (A) determined cell type and Rounds 2/3 (B) 
assessed cell proliferation. 
The first optimization study (Round 1) compared four (0.01 uM, 0.1 uM, 
1.0 uM, 10 uM) concentrations of 5HT hydrochloride (Sigma Aldrich, St. Louis, 
MO; n=3) and four (0.1 uM, 1.0 uM, 10 uM, 100 uM) concentrations of NF 
hydrochloride (Sigma Aldrich, n=3). Tissue samples were partially submerged in 
1.5 ml_ of media, which was changed every 2-3 days. Since 5HT oxidizes in 
solution media, the solution was made fresh prior to each media change. After 
11 days of culture, adherent cells were observed on the bottom of the plate; 
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culture and immunocytochemical analysis methods to identify these cells are 
described in Section 6.2.2 and Appendix 2. 
The next round of drug optimization (Round 2) used the same 
concentrations of NF (n=3) as before and the same concentrations of pergolide 
methanesulfonate salt (Sigma Aldrich, n=3) as for 5HT. Unlike the previous 
round, the valve segments were completely submerged in 3.0 ml_ of media. 
Control samples, submerged within 1.5 ml_ (n=6) and 3.0 ml_ (n=6) of plain 
media for comparison against both partially and completely submerged tissues, 
were also cultured. Pergolide is insoluble in water but soluble in dimethyl 
sulfoxide (DMSO) (5.2 mg/mL) and ethanol (2.0 mg/mL); therefore, the solid was 
alternately dissolved in media solutions containing 0.08% DMSO and 0.42% 
ethanol167. The amount of DMSO/ethanol in the media was optimized to the 
minimum volume of liquid required to dissolve the desired mass of pergolide 
powder. Since pergolide settled immediately from the DMSO solution, the 
experiment was continued using pergolide in ethanol solution, and the pergolide 
control used tissues cultured within 1.5 mL (n=6) and 3.0 mL (n=6) media 
containing 0.42% ethanol. The third and final round of drug optimization (Round 
3) cultured valve segments submerged in 3.0 mL 5HT (n=6), NF (n=3), and 
pergolide (n=3). 
Optimization of the 5HT2B/2C receptor antagonist (SB-206553 
hydrochloride hydrate, Sigma Aldrich; later SB-206553 hydrochloride, Tocris 
Biosciences, Ellisville, MO) was performed in the same manner as for the drugs 
(n=3). Since 5HT2C receptors are not expressed in heart valve cells168, SB-
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206553 was considered a 5HT2B receptor antagonist for the purposes of this 
study. A literature review showed that a concentration of 1 uM was frequently 
used in cell studies65,68,169, and further optimization was performed for this study 
to account for possible differences in the chemical effect on cell and organ 
culture. Concentrations of the antagonist tested were 10 uM, 1 uM, and 0 uM 
(control); all valve sections were cultured in 10 uM NF media. 
After 14 days of organ culture, all tissue samples were fixed in 
Histochoice™. After fixation, all tissue samples were dehydrated to xylene, 
paraffin embedded, sectioned into 5 urn slices, and mounted on slides as 
described in Section 4.2.3.1. Samples were stained with H&E and via 
immunohistochemistry (Appendix 2) for proliferating cell nuclear antigen (PCNA) 
to assess cell localization within the tissue layers. Tissue samples were also 
stained with Movat pentachrome to identify layers and review global changes in 
extracellular matrix (ECM) content. All samples were then viewed to visually 
determine the drug concentration causing the most change to the tissue 
structure. 
6.2.2. Cell Studies 
When adherent cells were observed on the tissue culture plates, it was 
desired to determine the cell type. On day 11 (Figure 6.1), organ cultures were 
removed from the 6-well plates. Before counting on day 19, the three wells 
containing cells from the three valve segments exposed to the same drug 
concentration were combined. Aliquots containing 5 X 105 cells (from 1 uM NF, 
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0.1 uM NF, 0.1 pM 5HT, and 0.01 |JM 5HT organ cultures) were seeded to four 
slides coated with fibronectin. After 2-3 days culture in plain media, cells were 
stained (Appendix 2) with acetylated low density lipoprotein (Dil-AC-LDL, one 
sample each NF and 5HT) to identify valvular endothelial cells (VECs) and an 
antibody against smooth muscle a-actin (SMaA, one sample each NF and 5HT) 
to identify valvular interstitial cells (VICs). 
The remaining two cell studies were performed to assess differences in 
cell proliferation due to drug exposure. Cells from Rounds 2 and 3 were 
confluent on day 11 (Figure 6.1), and cells from all valve samples were counted 
and re-seeded to T-25 culture flasks at 8000 cells/mm2 (the highest 
concentration possible for the flask with the smallest number of cells). Culture 
continued with the appropriate concentration of drugged media. On day 16 
(Figure 6.1), cells were counted again to assess proliferation. To compare 
concentration, the proliferation cell counts were compared across groups using a 
one-way ANOVA with p<0.05 considered significant. Holm-Sidak post-hoc 
testing was used as appropriate to identify significant differences between 
individual concentrations and the control. 
6.2.3. Dynamic Valve Culture 
Based on observation of the Movat- and PCNA-stained samples, the 
results of the optimization experiments described in section 6.2.1 showed that a 
concentration of 10 uM for NF and 5HT elicited the most dramatic tissue 
remodeling (Figure 6.2). After fibrotic remodeling due to use of the static culture 
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method (explained in greater detail in Chapter 5) was taken into account, Movat 
stains of the 10 uM NF and 5HT organ cultures appeared to have deposits of 
proteoglycans (PGs)/GAGs on the valve surface and within the normally 
collagenous fibrosa. Localized clusters of proliferating cells were evident in 
samples immunostained with an antibody against PCNA. The receptor 
antagonist concentration of 10 uM also appeared to be the most effective at 
blocking the drug effects (data not shown). At this time, it was noted that the 
bovine growth serum used contains baseline levels of 5HT (>10pM), which might 
have affected the results of the drug-free media "control" case. The additional 
difficulties in keeping pergolide in solution, as well as a desire to explore more 
thoroughly the role of the 5HT2B receptor, led to a replacement of the pergolide 
test condition with an alternative test condition, that of the 5HT2B receptor 
antagonist only. 
Organ culture in the splashing bioreactor was performed in the same 
manner as in Aim 2 (see section 5.2.3). The following four test cases were 
studied: NF only (n=7), NF + receptor antagonist (NF+BLK, n=8), 5HT only (n=6), 
and 5HT + receptor antagonist (5HT+BLK, n=6). In the NF+BLK and 5HT+BLK 
test cases, media containing only the antagonist (no drug) was added to the 
organ culture 30 minutes before adding the drug+BLK media at every media 
change169 to encourage receptor saturation with the antagonist before 
introduction of the receptor agonist. 
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Figure 6.2: Movat (A) and PCNA (B) stains comparing effects of varying concentrations of 
norfenfluramine on the mitral valve anterior leaflet center. The sample exposed to 10 uM 
norfenfluramine had greater PG/GAG and cell content in the tissue interior compared to 
control, which tended to be mostly collagenous with fewer cells. In all images, the atrialis 
is at the top right and the ventricularis is at the bottom left. Magnification = 5X. 
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Two control groups were prepared. The dynamic stimulation samples 
from Aim 2 (n=9) were used as the first control in this study. A small number of 
tissue samples (n=4) were cultured with the receptor antagonist only (BLK) in 
order to determine any effects of the 5HT inherent to the culture media. 
After two weeks of culture, samples were fixed, stained for ECM 
components and turnover mediators, and graded as described in section 4.2.3. 
Immunohistochemical staining for MMP1 and MMP2 was replaced by staining for 
elastin in these samples, as the Movat stain indicated a possible upregulation of 
elastin in the NF-treated tissue (Appendix 2). In some instances, a foreign 
growth-like object was noted on the valve surface. In these cases, tissue 
samples were also stained for the presence of von Willebrand's Factor (vWF), 
SMaA, and fibrinogen (FB) to determine the possibility of an inflammatory 
response. A Masson's trichrome stain, which identifies nuclei, cytoplasm, 
erythrocytes, myelin and collagen, (Appendix 2) was also performed on these 
samples. 
Prior to performing the organ culture studies, a power analysis was 
performed; the results of this analysis indicated that a subject size of 6 would be 
sufficient to attain statistical significance. Mean staining intensity was compared 
between each drug treatment and the associated agonist + antagonist group 
using the Student's t-test. A Bonferroni adjustment was made to account for the 
use of the three drug treatments in the study; therefore, significance was defined 
at p=0.017. Since the drug treatments were applied independently, however, 
differences with p<0.05 were considered strong trends and p<0.08 were 
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considered slight trends. The mean staining intensities of the three different drug 
groups and the three different agonist + antagonist groups were compared using 
a one-way ANOVA with Dunn's or Holm-Sidak post-hoc testing performed as 
appropriate; the results of post-hoc analysis are shown below when significant. 
These comparisons were designed to assess the possibility that 5HT/NF 
exposure affected a secondary receptor to the 5HT2B receptor. 
6.3. Results 
6.3.1. Explant Culture Cell Proliferation 
Cell number varied in a dose-dependent manner for 5HT, NF, and 
pergolide (Figure 6.3). Cell proliferation was lower than control for all 5HT drug 
concentrations except 1 uM. Cells exposed to 0.1 uM and 0.01 uM pergolide 
also had lower cell proliferation than control. For NF, maximum cell proliferation 
occurred at the 0.1 uM (10"7M) concentration; proliferation appeared to decrease 
as NF concentration increased (Figure 6.4). In the cell proliferation studies 
(section 6.2.2), six valve sections were cultured in plain media and in media 
containing each tested concentration of the three drugs: serotonin, 
norfenfluramine, and pergolide. Prior to cell counting, cells cultured from three of 
the valve sections were combined. The first of these proliferation studies were 
pilot experiments, and it was decided to only compare one set of three valves 
exposed to each drug and to plain media, where the seeding densities and 
animal age were the most consistent between samples. A larger sample size 
would be needed to corroborate the trends shown here. 
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Cell type was identified via ICC stain with SMaA (VICs) and Dil-Ac-LDL 
(VECs). Cells stained strongly for SMaA (Figure 6.5), indicating that the cells 
were mostly VICs. Cell staining for Dil-AC-LDL was not distinguishable from the 
background (data not shown). 
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Figure 6.3: Effects of varying concentrations of serotonergic drugs on cell number. Data 
represented as mean. *: concentration not tested. 
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Figure 6.4: Adherent cells from organ culture exposed to (A) 100 uM and (B) 1 uM 
norfenfluramine. Cells photographed on day 13. Magnification^ OX. 
Figure 6.5: (A) Smooth muscle a-actin and (B) negative control (no primary antibody) 
stains of cells cultured in 0.1 uM norfenfluramine. Cells stained on day 22. 
Magnification^ OX. 
6.3.2. Organ Culture 
The Movat stain of valves cultured with NF showed a strong upregulation 
of elastin in the leaflet free edge after two weeks of dynamic culture (Figure 
6.6C). Staining with the PCNA antibody indicated a greater number of 
proliferating cells than the tissue cultured with plain media (Figure 6.6A) or with 
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the NF+BLK media. No other test group displayed a prominent difference in 
ECM composition or cell proliferation compared to the baseline control. 
Movat PCNA Negative Control 
Figure 6.6: Comparison of anterior leaflet free edge of mitral valve leaflet exposed to (A) 
plain media, (B) media with the 5HT2B receptor antagonist, (C) norfenfluramine, (D) 
norfenfluramine + antagonist, (E) serotonin, and (F) serotonin + antagonist. Of all the test 
conditions, norfenfluramine exposure appeared to induce the most pronounced changes 
to the tissue structure, as noted by greater elastin upregulation (black stain) and cell 
proliferation (black arrows). 
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Of all tested ECM components and turnover mediators, PG expression 
(Figure 6.7) was most pronounced in the test groups. Biglycan (BGL) appeared 
to be elevated in the control and NF groups, while decorin (DCN) and versican 
(VC) appeared to be greatest in the two 5HT groups. BGL expression was 
greater in the control group compared to BLK for the fibrosa (p=0.001) and 
tended to be greater in the atrialis (p=0.04) and chordae (p=0.027). Expression 
in NF samples compared to the corresponding antagonist group was stronger in 
the atrialis (p=0.009), spongiosa (p=0.01), and chordae (p=0.002) with a strong 
trend noted in the fibrosa (p=0.03). A trend was also noted in BGL expression in 
the control (p=0.06) and 5HT (p=0.055) treatment groups in comparison with 
their respective antagonist groups. Within the drug only samples, 5HT BGL stain 
intensity in the fibrosa was lower than control (p<0.05). Chordae BGL stain 
intensity tended to be lower in 5HT samples than both control and NF (p=0.01 
between groups). 
5HT DCN expression in the atrialis tended to be greater than control in 
both the agonist (p=0.055 between groups) and the agonist + antagonist 
(p=0.055 between groups) treatment groups. In the spongiosa, DCN staining in 
the control samples tended to be greater than in the BLK group (p=0.02). 
VC expression in the atrialis (p=0.047 between groups, agonist treatments) and 
spongiosa (p=0.065 between groups, agonist and antagonist + antagonist 
treatments) tended to be greater in 5HT than NF. In the spongiosa, control VC 
staining also tended to be greater than control +BLK staining (p=0.04). Stain 
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intensity of DCN and VC in both fibrosa and chordae was not significantly 
different between groups. 
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Figure 6.7: Proteoglycan expression in tissue samples exposed to combinations of 
serotonin receptor agonists and antagonists. Staining intensity was assessed separately 
in the (A) atrialis, (B) spongiosa, (C) fibrosa, and (D) chordae. Values represented as mean 
stain intensity ± standard deviation. Bars sharing the same letter are significantly different. 
The letter indicates level of significance, a-d: p<0.017 (t-test), e-i: p<0.05 (t-test), j : p<0.05 
(ANOVA post-hoc), k-l: p<0.05 (ANOVA), m-n: p=0.06 (t-test), o-r: p<0.065 (ANOVA). 
5HT=serotonin; BGL=biglycan; BLK=serotonin receptor antagonist; DCN=decorin; 
NF=norfenfluramine; VC=versican. 
Staining intensities of collagen and elastin (Figure 6.8) were comparable 
in magnitude to those of PGs. Elevations in component expression, if present, 
were most apparent in the NF treatment groups. In the spongiosa (p=0.04) and 
chordae (p=0.056), collagen type III (COLL3) stain intensity in control tended to 
be greater than in BLK. When looking spongiosa COLL3 staining in all drug 
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treatment groups, there was a significant difference (p=0.007 between groups), 
with a further difference noted between control and NF (p<0.05). In the fibrosa, 
BLK exposure tended to reduce collagen type I (COLLI) expression in the 
control (p=0.02) and NF (p=0.08) cases. Differences in atrialis elastin expression 
showed a trend of a decrease in NF+BLK compared to NF (p=0.04). Expression 
of COLL3 in the atrialis and fibrosa, COLLI in the atrialis, spongiosa, and 
chordae and elastin in the spongiosa, fibrosa, and chordae was not different 
between groups. 
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Figure 6.8: Collagen and elastin expression in tissue samples exposed to combinations of 
serotonin receptor agonists and antagonists. Staining intensity was assessed separately 
in the (A) atrialis, (B) spongiosa, (C) fibrosa, and (D) chordae. Values represented as mean 
stain intensity ± standard deviation. Bars sharing the same letter are significantly different. 
The letter indicates level of significance, a-c: p<0.05 (t-test), d: p<0.05 (ANOVA post-hoc), 
e: p<0.05 (ANOVA), f-g: p<0.08 (t-test). 5HT=serotonin; BLK=serotonin receptor antagonist; 
COLL=collagen; NF=norfenfluramine. 
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Staining intensity of the collagen and elastin synthesis mediators (Figure 
6.9) was weaker than for the ECM components. Interestingly, the intensities in 
the two 5HT groups were often lower than control. Atrialis heat shock protein 47 
(HSP47) staining intensity was greater in control than 5HT samples (p<0.05) and 
BLK samples (p<0.001). In the spongiosa, HSP47 expression was significantly 
different between all drug treatment groups (p=0.012), and post-hoc testing 
showed that stain intensity in 5HT was lower than control samples. Additionally, 
expression was greater in control than BLK (p=0.008). HSP47 staining in the 
fibrosa was greater in the control group than in BLK (p=0.009). Expression with 
drug treatment was also different between groups (p=0.003), with significant 
difference between the control and 5HT groups (p<0.05). Chordae HSP47 
expression tended to be greater in control than BLK samples (p=0.07). Prolyl-4-
hydroxylase (P4H) expression in the fibrosa was greater in control than BLK 
samples (p=0.016). In the atrialis, P4H expression in NF tended to be greater 
than in NF+BLK (p=0.047), and expression in 5HT tended to be greater than in 
5HT+BLK in the chordae (p=0.025). LOX expression throughout the valve in 
addition to P4H expression in the spongisa was not significantly different 
between groups. 
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Figure 6.9: Expression of extracellular matrix synthesis mediators in tissue samples 
exposed to combinations of serotonin receptor agonists and antagonists. Staining 
intensity was assessed separately in the (A) atrialis, (B) spongiosa, (C) fibrosa, and (D) 
chordae. Values represented as mean stain intensity ± standard deviation. Bars sharing 
the same letter are significantly different. The letter indicates level of significance, a-d: 
p<0.017 (t-test), e-f: p<0.05 (t-test), g-i: p<0.05 (ANOVA post-hoc), j-k: p<0.05 (ANOVA), I: 
p=0.07 (t-test). 5HT=serotonin; BLK=serotonin receptor antaonist; HSP47=heat shock 
protein 47; LOX=lysyl oxidase; NF=norfenfluramine; P4H=prolyl-4-hydroxylase. 
Expression of the matrix metalloproteinases (MMPs) and the inhibitor 
(TIMP1) was weaker than the other ECM components and turnover mediators 
(Figure 6.10). Although not always significant, the combinations of serotonin 
receptor agonists and antagonist led to reduced expression when compared to 
control but greater expression compared to the BLK group. While MMP9 
expression in the atrialis tended to be greater in control than BLK samples 
(p=0.06), it also tended to be lower in 5HT than 5HT+BLK (p=0.03). Stain 
intensity between the three drug treatment groups was significantly different 
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(p=0.009), especially between control and 5HT (p<0.05). MMP9 expression in 
the fibrosa tended to be greater in the control than the BLK (p=0.055) but lower in 
the NF than NF+BLK (p=0.028) samples. ANOVA testing also showed an 
apparent difference between MMP9 expression in the three drug groups 
(p=0.029), but no further differences were noted with post-hoc testing. In the 
chordae, MMP9 staining intensity tended to be lower in NF than in NF+BLK 
(p=0.02). Atrialis MMP13 staining intensity was greater in control than in 5HT 
(p<0.05), NF (p<0.05), or BLK (p<0.001) samples. Likewise, MMP13 expression 
in the fibrosa and chordae was greater in control than in BLK (p<0.001, fibrosa 
and chordae), 5HT (p<0.05, fibrosa chordae), or NF (p<0.05, fibrosa and 
chordae). MMP13 expression was greater in control than BLK (p=0.007). TIMP1 
expression in control tended to be greater than BLK in the atrialis (p=0.02) and 
spongiosa (p=0.03). TIMP1 stain intensity also tended to be greater in NF than 
NF+BLK (p=0.055). Stain intensity of spongiosa MMP9, fibrosa TIMP1, and 
chordae TIMP1 was not significantly different between treatment groups. 
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Figure 6.10: Expression of extracellular matrix turnover mediator in tissue samples 
exposed to combinations of serotonin receptor agonists and antagonists. Staining 
intensity was assessed separately in the (A) atrialis, (B) spongiosa, (C) fibrosa, and (D) 
chordae. Values represented as mean stain intensity ± standard deviation. Bars sharing 
the same letter are significantly different. The letter indicates level of significance, a-d: 
p<0.017 (t-test), e-i: p<0.05 (t-test), j-p: p<0.05 (ANOVA post-hoc), q: p<0.05 (ANOVA), r-t: 
p<0.06 (t-test). 5HT=serotonin; BLK=serotonin receptor antaonist; MMP=matrix 
metalloproteinase; NF=norfenfluramine; TIMP=tissue inhibitor of matrix metalloproteinase. 
Foreign growth-like objects (plaques) were noted in two of the organ 
cultures treated with NF and one treated with NF and receptor antagonist (Figure 
6.11). Throughout the culture period, pieces of the plaque would appear in the 
culture media, and a larger growth would be found affixed to the ventricular 
surface of the valve at the end of the culture period. A Movat stain of the plaque 
revealed elastin and PGs/GAGs (black and blue stain), while a Masson's stain 
showed the presence of collagen and possible smooth muscle (green and red 
stain). The objects stained strongly for BGL (NF only), DCN, LOX, COLLI, 
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C0LL3, FB, vWF, and HSP47 (NF only), indicating that this was more likely a 
tissue than a fungal growth (Figure 6.12). Whenever a plaque was noted, an 
additional organ culture run was performed; however, presence of the foreign 
object did not appear to influence staining intensity for any ECM component 
except elastin (elastin data analysis therefore excluded these samples). No such 
objects were noted in the control, BLK, 5HT, or 5HT+BLK treatment conditions. 
Figure 6.11: Plaque removed from bioreactor. Organ culture was exposed to 
norfenfluramine, and object was stuck onto valve surface. The appearance of the foreign 
object was similar to a thin layer of mitral valve tissue. 
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Figure 6.12: Characterization of plaque from bioreactor. Portions of the foreign object were 
obtained from a norfenfluramine-treated valve organ culture and stained with (A) Movat 
pentachrome (black=elastin, blue=proteoglycans/glycosaminoglycans, red=fibrin/smooth 
muscle), (B) negative control (anti-goat secondary, no primary antibody), (C) fibrinogen, 
(D) negative control (anti-rabbit secondary, no primary antibody), (E) lysyl oxidase, (F) 
von Willebrand Factor, (G) decorin, (H) type I collagen, and (I) type III collagen. 
6.4. Discussion 
Explant cultures and organ cultures were exposed to 5HT and NF for two 
weeks to determine the effect of these serotonin receptor agonists on cell 
proliferation and tissue structure. Both drugs appear to have had an effect on the 
mitral valve, but the two different drugs had very different impacts on the tissue. 
Tissues exposed to NF experienced an upregulation of BGL and collagen 
compared to control. On the other hand, tissues exposed to 5HT had greater 
DCN and VC expression and lower collagen and elastin content than in control 
tissue. The ECM components studied were regulated differently by the 
interaction between these agents and the 5HT2B receptor, indicating the 
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possibility that another mechanism was involved in the valve microstructural 
remodeling. 
In the cell studies, NF tended to increase proliferation. As drug 
concentration increased, however, cell proliferation decreased. Cells exposed to 
5HT exposure showed a similar trend of lower cell number with greater drug 
concentration. These results tended to corroborate those of Hafizi et al.165, who 
proposed the possibility of receptor desensitization at higher drug concentrations. 
Since the cell studies in the current research were preliminary in nature, more 
samples should be included before reaching a final conclusion of the impact of 
drug concentration on cell proliferation. When determining the effects of these 
drugs on cells within the tissue structure, PCNA immunostaining showed that 
tissue cultured with NF contained a greater number of proliferating cells than 
either the control or the other test conditions. This greater number of proliferating 
cells increased the likelihood of ECM turnover within the valve. 
Results of the Movat stain suggested that NF upregulated elastin 
production in the anterior leaflet free edge. It is interesting to note, however, that 
the atrialis and spongiosa of all treatment groups strongly expressed elastin with 
immunostaining methods. The antibody used is known to recognize tropoelastin 
and a-elastin, in addition to insoluble elastin; it is possible that a baseline quantity 
of tropoelastin exists in the normal spongiosa, and that NF exposure induced 
formation of the cross-linked elastin fiber. This explanation is supported by the 
presence of elastin within the plaques observed in serotonergic valve disease28, 
70, 158 
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BGL was also upregulated with NF exposure when compared to the BLK 
sample; the reduced expression in the NF+BLK sample showed that this was 
mediated by the 5HT2B receptor. This result, when compared to a recent study 
that suggested a role of TGF-(3 in BGL expression170, lent strength to the effect of 
the ERK 1/2 pathway and Src phosphorylation on cell proliferation63,69. In the 
spongiosa, DCN expression was slightly greater than control while VC 
expression was lower than the BLK case. In neither case did the NF+BLK case 
differ from the NF case, indicating that a mechanism separate from 5HT2B 
activation may have influenced DCN expression. The fact that DCN was 
upregulated with 5HT exposure also suggested involvement of a separate 
receptor (likely another family of 5HT receptors) or an alternate signaling method; 
these conclusions were also suggested by Xu et al.65. As DCN is known to 
regulate collagen fibrillogenesis, and since 5HT exposure has been associated 
with increased collagen production in valve cells169, it was also possible that the 
DCN upregulation observed in this study could have been due to an increase in 
valve collagen that would have been apparent with a longer culture time. Since 
the plaques involved with serotonergic valve disease have been observed to 
contain PGs, studying differences in the PG composition of plaques induced by 
exposure to different serotonergic drugs might also help to describe the early 
mechanism of the valve disease. 
Spongiosa COLL3 expression was also greater in the NF samples 
compared to control and 5HT, and comparison of the NF and NF+BLK cases 
suggested the involvement of the 5HT2B receptor. Although LOX and P4H 
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expression did not differ significantly from control, the use of the receptor 
antagonist with NF decreased P4H content in the atrialis. HSP47 in the NF 
samples, however, tended to be greater than in the 5HT samples. Expression of 
MMP9 and MMP13 did not show much difference between NF and 5HT or NF 
and BLK, but was often lower in NF than control. Another interesting finding was 
the greater expression of MMP9 in the NF+BLK case than NF in the fibrosa and 
chordae; it appeared that NF exposure combined with inhibition of the 5HT2B 
receptor encouraged elastin turnover. A longer culture time might result in a 
change in elastin content in these valve layers. 
5HT exposure had a considerably different effect on the valve tissue than 
NF exposure. When 5HT was added to the culture media, BGL content tended 
to be reduced compared to the control case, but approximately the same as the 
BLK case. This result was also noted with COLLI, elastin, and P4H expression 
in the fibrosa as well as HSP47 expression throughout all valve layers. The 
decreased content of these components with increased 5HT content indicated 
that there was a possible desensitization of the 5HT2B receptor noted by Hafizi et 
al.165 and in the cell proliferation studies performed during the drug optimization 
studies at the beginning of this aim, leading to a reduced impact of the receptor 
agonist. 5HT exposure, with or without the combined use of the receptor 
antagonist, tended to increase content of atrialis DCN, atrialis VC, and spongiosa 
VC. LOX expression also appeared to decrease in both 5HT treatments as 
compared to both control treatments, although this result was not significant. 
This PG upregulation was consistent with the structure of the superficial plaques 
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indicative of carcinoid valve disease; the lack of difference in PG expression 
between the 5HT and 5HT+BLK groups suggested that an additional mechanism 
may have been responsible for this valve disease. The change in LOX 
expression was also intriguing; since LOX catalyzes cross-links in collagen and 
elastin fibers, its reduced expression may explain the reduced collagen and 
elastin content. 
The BLK test case was introduced to give an indication of the cultured 
state of the mitral valve without activation of the 5HT2B receptor, and the 
comparison of these two control cases indicated that the use of the receptor 
antagonist in this experiment was effective in blocking activity of the receptor. 
Exposure of the tissue to the receptor antagonist, when compared to plain media, 
decreased BGL expression in all valve layers. There was little effect in DCN or 
VC production, except for a slight decrease in the spongiosa. COLLI in the 
fibrosa decreased with BLK exposure and COLL3 decreased in the chordae. 
Although no change in LOX or P4H was noted with BLK use, except for fibrosa 
P4H, the decrease in HSP47 expression throughout the valve layers with plain 
media and BLK application indicated baseline activation of the 5HT2B receptor. 
The same results were found with MMP9 expression in the atrialis and fibrosa, 
MMP13 in all layers, and TIMP1 in the atrialis and spongiosa. The layer-specific 
response of the receptor antagonist showed both that the culture media was 
sufficiently perfusing even the deeper spongiosa layer and that the different valve 
layers can have very different responses to the drugs. It also showed that the 
introduction of the small quantity of 5HT in the tissue culture media was sufficient 
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to upregulate different ECM components and turnover mediator, particularly 
those associated with collagen production. These results corroborated those of 
Mekontso-Dessap et al.169, who noted an increase in [3H]proline incorporation (a 
measurement of collagen production) in human aortic and mitral VICs and VECs 
with 5HT exposure. Interestingly, their study also found no decrease in 
[3H]proline incorporation with exposure to either 5HT2A or 5HT2B/2C receptor 
antagonists, indicating that activation of these receptors was not responsible for 
collagen upregulation. 
The plaques found in the bioreactor chambers during organ culture with 
the NF and NF+BLK cases were also very interesting. At the start, the objects 
were assumed to be fungal growth or something similar; however, they stained 
positive for many of the same components as the NF and NF+BLK samples 
including COLLI, COLL3, DCN, and LOX. This result suggested that the foreign 
object was actually a type of excess tissue, similar to the plaques noted in 
patients with serotonergic valve disease. When the organ culture was removed 
from the bioreactor, the object appeared to be affixed to the ventricular side of 
the valve, as effort was required to remove it. The location of the growth on the 
ventricular side of the valve was consistent with clinical cases of fen-phen 
valvulopathy affecting the ventricular surface and chordae64,70,171; the 
preferential location of the plaques may have been due to a structural difference 
in the ventricular and atrial surfaces of the valve. The proliferation of VICs noted 
in the preliminary cell studies as well as the presence of myofibroblasts in 
plaques removed from patients with serotonergic valve disease suggest that the 
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plaques removed from the bioreactor were generated due to excessive 
proliferation of VICs. 
A limitation of this project was the discontinuation of the original antibody 
used against the MMP13 antigen, which required switching to an antibody 
supplied by a different manufacturer. In all valve layers, MMP13 expression was 
much greater in the control than in the other test cases. It was possible that the 
different antibody used affected the results; however, a comparison of samples of 
fresh valve tissue stained with the old (used in control) and new MMP13 
antibodies showed that there was little to no difference in stain intensity. 
This research has multiple exciting applications to the study of 
serotonergic valve disease. First, it showed that, although the histology of the 
plaques indicative of the disease has shown that the compositions are similar 
between the drugs, the early disease mechanisms due to NF and 5HT exposure 
were very different. This finding further disputed the original serotonin 
hypothesis72 and strongly suggested that the mitral valve responds differently to 
5HT and NF. The difference in the mitral valve response between the two drugs 
could explain why fen-phen valvulopathy preferentially affects the left heart 
valves. A repeat of this study using the tricuspid valve would give further 
evidence for this proposed explanation. 
This study also suggested that, while activation of the 5HT2B receptor was 
involved in the upregulation of the different ECM components and turnover 
mediators, it was not the only mechanism. Another 5HT receptor family or an 
alternate signaling pathway may have been involved. The cell culture and organ 
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culture results also further confirmed that a maximum drug concentration existed, 
above which effects to the tissue would be reduced due to desensitization of the 
5HT2B receptor. 
This research has shown that it was possible use the splashing bioreactor 
from Aim 2 to model the in vivo chemical environment of the mitral valve leading 
to serotonergic valve disease. The results from this study not only displayed 
upregulation of the ECM components and turnover indicators from baseline 
values, they showed a difference between NF and 5HT effects on the mitral 
valve. These results also suggested that activation of the 5HT2B receptor may 
not have been the only mechanism for these valve tissue changes. 
6.5. Conclusion 
The goal of Aim 3 was to use the bioreactor designed in Aim 2 to model 
the effects of the serotonergic drugs norfenfluramine and serotonin on the mitral 
valve. The results of this study suggested that, not only did the two drugs 
instigate very different types of matrix remodeling, but that the activation of the 
5HT2B receptor may not have been the only mechanism by which these drugs 
acted. Although this research did describe the genesis of serotonergic valve 
disease, the results led to other interesting questions that could lead to further 
work with this in vitro system. 
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Chapter 7. Conclusion 
The purpose of this project was to study the effects on the mitral valve 
extracellular matrix (ECM) of alterations to the normal mechanical and chemical 
stimuli provided by the heart and circulatory systems. The mitral valve is not 
merely a simple flap that randomly opens and closes to allow blood to pass. It is 
a complex living tissue that can remodel in a pathological manner preventing 
normal operation; this possibility has often been overlooked in medical 
treatments, with potentially dire consequences. Although much of the previous 
research on valve pathology and remodeling has focused on the aortic valve, the 
position of the mitral valve in the left heart between the two chambers, as well as 
the clinical emphasis on valve repair rather than replacement, make the mitral 
valve an intriguing research subject. 
The first specific aim studied the effects of heart failure and the left 
ventricular assist device (LVAD) treatment on the mitral valve tissue. The results 
of this study are important to consider prior to widespread use of the LVAD as a 
destination therapy in addition to its original application as a bridge-to-transplant. 
The effects of the LVAD on the cardiac muscle and on the aortic valve have been 
well-characterized in the literature while the mitral valve has been less studied. 
Earlier research in our lab has shown that the mitral valve tends to undergo 
fibrotic remodeling in response to the change in ventricular shape and resulting 
change in mechanical forces imparted upon the tissue42. If destination therapy is 
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to be successful, LVAD use should act to reverse this tissue state; therefore, the 
question studied was whether the LVAD induces further positive or negative 
remodeling of the mitral valve tissue. The results of this aim showed that the 
mitral valve does indeed remodel in response to the LVAD use. This remodeling 
improved some aspects of the valve function in the short-term while worsening 
others; however, it also resulted in a disruption to the normal layered tissue 
structure that would likely lead to malfunctioning of the valve in the long-term. 
Results from the first specific aim showed that alterations to the normal 
mechanical environment of the mitral valve would lead to remodeling of the valve 
structure and altered function. An in vitro system to study the influence of 
chemical stimuli to the mitral valve would therefore require a design maintaining 
the in vivo mechanical environment. Previous work in our lab has shown that 
tissue cultured without mechanical stimulation underwent fibrotic remodeling. In 
this vein, the second specific aim entailed the design and verification of a 
splashing bioreactor for the mitral valve. The goal for this project was to create 
an inexpensive, easily replicable bioreactor that would lightly stretch and perfuse 
a valve segment, maintaining tissue structure over the test period. A period of 
two weeks was selected for this test because early tissue remodeling 
mechanisms were of greatest interest. The expression of multiple ECM 
components and turnover mediators was compared between fresh valve tissue, 
tissue cultured with no mechanical stimulation, and tissue cultured in the 
splashing bioreactor. When compared to the fresh tissue, the tissue cultured in 
the bioreactor showed fewer signs of remodeling over the two-week period. The 
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results of this aim produced a viable system for studying the effects of alterations 
to chemical stimuli in the third and final aim. 
The activities of serotonin (5HT) and norfenfluramine were chosen to 
model in the third aim due to the upregulation of ECM components noted in 
histological analysis of patients with serotonergic valve disease. These two 
serotonin receptor agonists were used with and without a 5HT2B receptor 
antagonist in order to isolate the mechanism involved in the plaque formation 
associated with this disease. Results of this aim showed that, while the two 
drugs were similar in composition, their respective impact on mitral valve tissue 
was very different. While NF exposure led to an upregulation of biglycan that 
was apparently due to activation of the 5HT2B receptor, increased decorin 
expression observed with 5HT exposure was not impacted by inhibition of the 
5HT2B receptor. These results were particularly exciting due to the preferential 
impact of serotonin on the right heart valves and of norfenfluramine on right heart 
valves. The use of the receptor antagonist indicated that although activation of 
the 5HT2B receptor was the likely mechanism for some aspects of plaque 
formation, an additional process was probably partly responsible as well. 
This final chapter will summarize the work done for this research project. 
The novelty of these approaches and results will be examined as well as the role 
of the work in the current state of the literature. Although the questions posed in 
earlier chapters were answered, the results led to additional questions which will 
be presented here as possible future directions for this project. It is the hope of 
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the author that this work will not end here, but that it will serve as an inspiration 
for future scientists. 
7.1. Effects of Mechanical and Chemical Stimuli on Valve 
Remodeling: Addressing Unanswered Questions in the Field 
The current research literature pertaining to the success of the LVAD as a 
bridge-to-transplant focuses on cardiac tissue recovery44,47'50"54. With heart 
failure, the left ventricle dilates, and the left heart valves remodel to compensate. 
The mitral valve in particular becomes more collagenous and less hydrated42, 
which can lead to imperfect valve coaptation. Functionally, the LVAD offloads 
the ventricle, and the myocardial tissue recovers its original geometry and 
function. The aortic valve has unfortunately been shown to fuse at the 
commissures27,29 with device use, and it has been recommended to replace the 
valve or alter the LVAD cycle to force bloodflow through the valve periodically. 
The current research was novel because of the emphasis on the mitral valve as 
opposed to the cardiac tissue or the aortic valve. Although commissural fusion is 
not a primary concern with the mitral valve, this study has shown that the 
disruption to the tissue that occurs with heart failure is not always reversed with 
LVAD use. Before a patient is weaned from the LVAD for destination therapy, 
the mitral valve should be functional to prevent further problems for the patient. 
The benefit of this approach was the study of the interaction between the 
structure and function of the mitral valve; the faulty function of the remodeled 
valve was likely due, ironically, to the valve's compensatory remodeling. 
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As mechanical loading is apparently necessary in the successful in vitro 
model, multiple bioreactor designs have been described in the literature74"76, 
many intended for use in the tissue engineering of a heart valve. The novelty of 
the current project lies in the simplicity of the design; the system is small, easily 
replicable with the intention of performing multiple organ cultures simultaneously. 
Many of the bioreactors in the literature focus on the culture of the semilunar 
valves, or the aortic and pulmonary valves. The splashing bioreactor is one of 
the few that are designed specifically for organ culture of the atrioventricular, or 
the mitral and tricuspid, valves. Finally, the analysis of the individual layers in the 
verification steps not only showed that the perfusion was effective in the deep as 
well as shallow tissue layers, it indicated that any drug therapies modeled would 
have an effect throughout the entire valve. 
Although valve tissue from patients with serotonergic valve disease has 
been extensively characterized28, little is currently known about the initial 
mechanisms behind these pathologies. The current research focuses on cell 
proliferation studies, exposing valve cells to serotonin receptor agonists and 
antagonists164,166 and assessing the uptake of markers indicating upregulation of 
ECM components. The use of an organ culture in the current research 
introduces a new level of complexity to this body of research. While the earlier 
works of Setola and Rothman focus on the response of the cells, the organ 
culture approach also studied cell proliferation and ECM regulation within the 
different valve layers. This work also looked at multiple ECM components and 
turnover mediators to give a more complete picture of the initiation of 
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serotonergic valve disease. Although the current work examined some 
outstanding questions regarding the mechanisms of the different effects of 
serotonin and norfenfluramine on the mitral valve, a whole new set of questions 
has risen, and these will be addressed in a later section. 
7.2. Advancing the Understanding of Valve Remodeling 
The results of Aim 1 extended our lab's previous work quantifying 
structural and functional remodeling of the mitral valve as a result of congestive 
heart failure. Additionally, it compared the structure and function of the valve in 
patients treated with the LVAD in order to ascertain whether the valve would 
revert to its normal state. While the remodeling of the valve did lead to improved 
chordal function, the structure and function of the leaflet was still suboptimal. 
This work augments that of Connelly and Rose, who have noted pathological 
remodeling of the aortic valve27,29, and indicates that the function of the valves 
should be among the factors considered in determining use of the LVAD as a 
destination therapy. Furthermore, functional remodeling of the mitral valve may 
actually be an indicator of a successful candidate for destination therapy. 
Aim 2 designed a splashing bioreactor to maintain mitral valve structure 
over a period of two weeks, and the design success was verified by a 
comparison of tissue cultured in the bioreactor with fresh tissue and tissue 
cultured without mechanical stimulation. This splashing bioreactor design 
provided the mechanical stimulation necessary to maintain tissue structure over 
two weeks. This research introduced a viable alternative in vitro method to the 
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flow loops ' , cyclic pressure • , and cyclic flexure systems currently 
available for organ culture and tissue engineering applications. Validation of 
these earlier bioreactor designs often involved biochemical analysis of whole 
valve tissues or qualitative immunohistochemical analysis of the overall valve 
structure to verify success of the bioreactor. The current body of work used a 
semi-quantitative analysis method to compare immunohistochemical staining 
intensities within the individual valve layers, which is important due to their 
different structure and function. A final point of interest is that, while the 
bioreactor tissue engineering studies ideally encouraged collagen deposition to 
strengthen the valve construct, success of the splashing bioreactor was 
assessed by a lack of fibrotic remodeling previously noted in static cultures. 
Aim 3 results showed that norfenfluramine and serotonin could initiate 
remodeling of mitral valve tissue in as little as two weeks. The drug optimization 
studies added evidence to Hafizi's theory165 that the effects of these two drugs 
were dose-dependent, and that a concentration existed above which the affected 
receptor is saturated and no further remodeling would be initiated. In organ-
cultured samples, NF exposure led to an upregulation of biglycan that was 
inhibited by use of the 5HT2B receptor antagonist. On the other hand, 5HT 
exposure led to an upregulation of decorin that was unaffected by the receptor 
antagonist treatment. The varied effects of the two drugs on the mitral valve 
tissue, although they have a similar structure, laid groundwork for further studies 
regarding preferential remodeling of the right heart valves by serotonin and of the 
left heart valves by norfenfluramine. This result also provided further evidence 
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against the "serotonin hypothesis" previously used to explain the difference in 
right and left heart valve remodeling72. The incomplete blocking of this 
remodeling with exposure of the tissue to the 5HT2B receptor antagonist has both 
confirmed the role of this receptor in serotonergic valve disease and introduced 
the idea of an additional involved mechanism, including activation of a separate 
receptor65. This combined body of work has corroborated the work of others in 
the valve biology field while further defining the effects on the mitral valve 
structure and function of alterations to the mechanical and chemical environment. 
7.3. Future Directions 
The Discussion and Conclusions section of the earlier chapters in this 
body of research have noted where holes still exist in the knowledge base or 
where the current research has led to further questions. Additional ideas for 
future directions to this work have been collected during discussions and 
presentations of this data at public forums. Possible future directions of this work 
will be listed below according to the aim that inspired the idea. 
Aim 1 was unfortunately limited by the availability of donor tissue. If the 
patient pool could be expanded, an interesting study would be the effect of the 
different LVAD types (i.e., continuous versus pulsatile flow). In discussions with 
other colleagues, the idea was presented to look at the pressure differences over 
the MV and AV to determine if there is any coupling involved in the valve 
remodeling. Another colleague suggested the use of proliferating cell nuclear 
antigen to augment the results of the biochemical (Hoescht) and histological 
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(H&E) analysis of cellular concentration in CHF and LVAD patients. The factors 
influencing the success of destination therapy should also be further examined; 
the extent of recovery of the left heart valves could identify patients who would 
benefit from this practice. 
A slight change to the design of the splashing bioreactor could make it 
another system available for use in the tissue engineering of a heart valve with 
the introduction of a treated scaffold material and donor cells1 (Chapter 3). The 
entire system could also be scaled up to accommodate an entire valve to better 
model the coaptation of the leaflet free edges. 
The splashing bioreactor can be used in the future to replicate the 
conditions for the foreign object formation observed with norfenfluramine 
exposure. The system might also be used to isolate alternate mechanisms of 
serotonergic heart disease. Further assessment of the activation of the ERK1/2 
pathways in these samples might provide more evidence on the early disease 
mechanism69. A simple test to study preference of drug effects on the different 
valves would be the replacement of the mitral valve with a tricuspid valve section 
in the Aim 3 tests; the modular design of the bioreactor would easily 
accommodate the longer leaflet. 
This study of the serotonergic drug effects on the right and left heart 
valves should be expanded to include the aortic and pulmonary valves. A cell 
proliferation or organ culture study comparing norfenfluramine and serotonin 
exposure on all four heart valves might highlight any inherent differences in the 
valves that would account for the preferential drug effects. Since the plaques in 
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fen-phen valvulopathy tend to occur on the ventricular surface, another cell 
proliferation study could be designed modeling exposure of the exposure of 
norfenfluramine and serotonin on endothelial cells from the atrial and ventricular 
surfaces. The lack of knowledge on the effects of fen-phen duration or drug 
cessation suggests another couple of studies to further define the effects of the 
drug. First, a cell proliferation or organ culture study could be designed to 
assess remodeling of the mitral valve after varying durations of drug exposure. 
Next, drug administration should be ceased at intervals while continuing the 
study to determine if the valve remodeling reverses or if it continues. Since 
pergolide use in this study was thwarted by the low solubility of the chemical, 
development of a reliable method of dissolving pergolide in culture media would 
give an additional type of serotonin receptor agonist to study. These additional 
studies would give a more complete picture of the effects of serotonergic drug 
exposure to the mitral valve, ideally limiting further episodes of serotonergic valve 
disease among the general public. 
7.4. Conclusion 
Taken together, the three specific aims give a complementary picture of 
mitral valve remodeling due to alterations to the normal mechanical and chemical 
environments. The first aim affirmed that LVAD treatment did not completely 
reverse the fibrotic remodeling of the mitral valve observed with heart failure. 
This result is less of a concern with bridge-to-transplant use than it is with 
destination therapy, where the patient should be left with a functional valve to 
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prevent ongoing cardiac health issues after weaning from the device. This 
impact of the change in left ventricular shape further emphasized the importance 
of maintaining the mechanical environment in an in vitro organ culture system, 
such as the one designed for the second aim. The splashing bioreactor was 
successful at maintaining the valve structure for the two weeks desired to 
examine the early mechanism of serotonergic valve disease. After two weeks, 
the serotonin and norfenfluramine caused remodeling of the mitral valve tissue, 
but the effects of the two drugs on the mitral valve were dramatically different, 
consistent with clinical observations that carcinoid valve disease (caused by 
excess serum serotonin) targets the right heart valves while fen-phen 
valvulopathy targets the left heart valves. 
The normal chemical and mechanical environments of the mitral valve 
play an important role in maintaining tissue structure and therefore function. 
When the valve surroundings are altered, the tissue remodels to compensate. 
This ability of the tissue to remodel is the basis behind a number of valve 
pathologies and should be considered when exposing a patient to drug or 
medical device therapies that could modify the valve structure and function. 
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Appendix A1. Mechanical Testing Data Analysis 
A1.1. Determination of Gauge Length - Original Assessment 
In tensile mechanical testing data analysis, the length at which the sample 
began to resist load was used as a reference point to allow comparison of 
mechanical properties between samples. This reference point, the gauge length 
(£g), has been difficult to define in the soft tissue of the mitral valve in an 
objective and easily repeatable manner. Carew and Vesely have defined £g as 
the transition from compression to tension (Figure A1.1) as the sample was 
stretched from a partially wrinkled starting point (^o)131- Since testing was 
initiated with the tissue in compression (slack), £g was always greater than £o. 
The resulting load-elongation curve was first fitted to the cubic line of best 
fit 
F(£) = a£3+b£2+c£ + d 
where F was load, £ was specimen length, and a, b, c, and d were the 
parameters of fit. The correlation coefficient (r2) was then calculated to 
determine the quality of fit. 
£g was estimated to be the stationary (inflection) point on the slope of the loading 
curve, or the value of £ that satisfied 
F(£) = 0 
The estimation of gauge length was therefore 
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£ = ~by 2>a 
In the case that the initial test region did not give the best fit (maximum r2) 
or the best estimate of £
 g, the test region was systematically reduced by 
dropping points in the direction of decreasing length until £o was greater than £g. 
At this point, data points were returned in the direction of increasing length. 
Once the maximum local r2 was identified, the corresponding gauge length was 
returned131. These calculations were performed using Mathematica (Wolfram 
Research, Champaign, IL). 
Specimen length (mm) 
Figure A1.1: Determination of gauge length (A), defined by the point at which the second 
derivative of the cubic line of best fit was equal to 0 (vertical line). Location of gauge 
length with respect to entire data set is indicted in (B)131. 
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A1.2. Determination of Gauge Length - Final Algorithm 
Unfortunately, the results obtained from these programs did not always 
make physical sense; the value obtained through hand calculations for properties 
such as stiffness did not match the values obtained by the Mathematica program. 
The Carew/Vesely algorithm was therefore edited by summer student Meaghan 
McNeill. The new program first determined the last datapoint in the set where 
the load was less than an earlier measured load ("negpoint") in order to negate 
the effects of any noise in the toe region. The load therefore increased 
monotonically after "negpoint." A test region of the data set was selected relative 
to negpoint, beginning at a point in the file 7% before negpoint and ending 70% 
after negpoint. The £g was defined as the minimum, as opposed to the inflection 
point, of the cubic function fit to this test region. Repeated testing verified that 
the algorithm gave a more reasonable approximation of £g. As with the 
Carew/Vesely method, the test region was then adjusted to optimize r2. 
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Appendix A2. Histology and Immunohistochemistry 
The details of the familiar histology stains H&E, Movat pentachrome, and 
Masson's trichrome are presented in greater detail here for the reader. The 
immunohistochemical methods performed and a primary antibody chart are also 
included. This appendix ends with a brief treatment of the immunocytochemistry 
methods used in the cell characterization during the explant cell culture protocol 
in Aim 3. 
A2.1. Hematoxylin and Eosin (H&E) 
H&E was used to identify cell nuclei (purple-hematoxylin) and cytoplasmic 
or extracellular matrix (ECM) proteins (eosin-pink). The samples were first 
rehydrated and deparaffinized by washing in xylene three times for three minutes 
each, then in Flex three times for one minute each. The slides were then placed 
in a 95% Flex solution for one minute and rinsed briefly in first tap water, then 
ultrapure water. The slides were placed in filtered hematoxylin for five minutes 
and rinsed in tap water to remove the excess stain. The slides were placed in 
clarifier for 30 seconds and rinsed in running tap water for 30 seconds, then 
placed in bluing reagent for one minute and rinsed in running tap water for one 
minute. They were rinsed in 95% Flex and placed in eosin for one minute. 
Finally, the samples were dehydrated by washing in the 100% Flex three times 
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for one minute each and in xylene three times for one minute each. After 
removal from xylene, the slides were coverslipped. 
A2.2. Movat Pentachrome 
Movat pentachrome stain was used to identify the ECM components 
within the layers of the valve tissue. The elastin (atrialis and chordae sheath) 
was stained black, and collagen (fibrosa and chordae core) was stained yellow. 
Proteoglycans and glycosaminoglycans (PGs/GAGs) in the spongiosa were a 
blue-green color. Any fibrin or smooth muscle present in the tissue was stained 
red, and cells were black. 
Samples to be stained were deparaffinized in the same manner as above. 
The first stain used was alcian blue (1% alcian blue powder, 3% acetic acid in 
distilled water) to identify PGs/GAGs; the samples were stained for five minutes 
and washed in running tap water for five minutes. The slides were rinsed briefly 
in distilled water and incubated in alkaline alcohol (10% ammonium hydroxide in 
95% ethanol) at 80°C for two minutes to solidify the alcian blue. After incubation, 
the slides were washed in running tap water for 20 minutes to completely remove 
the alkaline alcohol. 
After briefly rinsing the samples in distilled water, they were placed in 
Verhoeff s hematoxylin solution (50% hematoxylin solution, 25% iodine solution, 
25% aqueous ferric chloride solution) for 30-60 minutes (depending upon 
freshness of solution) to stain the elastin and cells black. The hematoxylin 
solution contained 5% hematoxylin in absolute ethanol, the iodine solution 
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contained 2% iodine and 4% potassium iodide in distilled water, and the aqueous 
ferric chloride solution contained 10% aqueous ferric chloride in distilled water. 
After rinsing in distilled water, the samples were differentiated with a 2% aqueous 
ferric chloride solution until individual elastic fibers were visible and then rinsed in 
distilled water to prevent over-differentiation. 
The slides were then incubated in 5% aqueous sodium thiosulfate for one 
minute, washed in tap water for five minutes, and rinsed in distilled water. To 
stain fibrin and smooth muscle, the samples were stained with crocein scarlet -
acid fuschin for 1-4 minutes, depending on the age of the solution. The stain was 
made of two stock solutions: 80% stock solution containing 0.1% Crocein Scarlet 
in 0.5% acetic acid and 20% stock solution containing 0.1% Acid Fuschin in 0.5% 
acetic acid. After staining, the slides were dipped twice in distilled water, 
agitating 1-2 seconds. The slides were then dipped twice in 0.5% acetic acid, 
agitating 1-2 seconds. 
The samples were incubated in 5% phosphotungstenic acid for five 
minutes and dipped in 0.5% acetic acid twice, agitating 1-2 seconds. The 
samples were then dehydrated with three changes of absolute alcohol, 5-6 dips 
for each change. The slides were then placed in Safran (6% Safran du Gratinais 
in absolute ethanol) for five minutes or in a premade Safran solution (Poly 
Scientific, Bay Shore, NY) for 10 minutes to stain collagen. After staining, the 
samples were dehydrated again with absolute alcohol, with 5-6 dips for each 
change. Finally, the samples were cleared with three changes of 100% xylene 
and coverslipped. 
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A2.3. Masson's Trichrome 
The Masson's trichrome stain was used to obtain more information on the 
ECM structure of the foreign objects noted in Aim 3. The protocol would stain 
collagen blue-green and mucus a lighter green. Erythrocytes and myelin would 
stain scarlet, while cytoplasm would stain pink, red, or brown. Cell nuclei would 
stain black. 
Clearing and hydration of the slide were performed in the same manner as 
for Movat (Section A2.2). After rinsing in distilled water for one minute, the tissue 
was exposed for three minutes to Wigart's Fe hematoxylin, which was a 
combination of equal parts hematoxylin (5 g hematoxylin in 500 ml_ EtOH) and 
FeCI (5.8 g FeCI3-6H20 in 495 ml_ H20 and 5 ml_ HCI) solutions. Excess stain 
was then washing away in running tap water for one minute. 
Next, the samples were stained with 1% biebrich scarlet (5 g biebrich 
scarlet in 495 ml_ H2O and 5 mL glacial acetic acid) for four minutes. After a brief 
rinse in running tap water to remove excess stain, tissue samples were 
immersed in PMA-PTA solution (5 g phosphomolybdic acid and 5 g 
phosphotungstenic acid in 200 mL H20). After one minute, samples were 
removed from solution and viewed under a microscope to ensure removal of red 
dye from collagen fibers. Differentiation in PMA-PTA was continued until 
collagen was free of red stain. The slides were then exposed to 2.5% fast green 
FCF (5 g fast green FCF in 195 mL H20 and 5 mL glacial acetic acid) for four 
minutes. 
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After staining, slides were immersed in two changes of acidified water (5 
ml_ glacial acetic acid for every 1 L H20) for 30 s each. Slides were then 
dehydrated, cleared, and coverslipped as in Section A2.2. 
A2.4. Immunohistochemistry (IHC) 
IHC allowed the localization of specific ECM components and synthesis 
indicators within the valve tissue. The following protocol has been generalized to 
include all antibodies used in immunohistochemical staining. The antibody 
concentration, pretreatment method, and secondary antibody used for each 
primary antibody are listed in Table A2.1. 
All samples were first deparaffinized with three changes of xylene and 
placed in two different washes of 100% Flex for one minute each. If the antigen 
decloaker or chymotrypsin pretreatments were not to be used, endogenous 
peroxidase was quenched by placing the slides in 0.7% H2O2 in 100% MeOH for 
20-30 minutes and rinsed in 100% Flex for five minutes. All samples were then 
hydrated to 50% Flex over a span of 10 minutes. 
One of three pretreatments was available for use, depending on the 
antigen of interest (Table 2A.1). Most antibodies required that the tissue be 
incubated in an antigen decloaker solution (Biocare Medical, Concord, CA) for 30 
minutes in an 80°C water bath. The slides were then washed in tap water for five 
minutes and in PBS for one minute. Samples were exposed to a 3% hydrogen 
peroxide solution for five minutes and rinsed in two washes of phosphate-buffer 
saline (PBS) for two minutes apiece. PG samples were incubated in 
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Chondroitinase ABC (Seikagaku, Tokyo, Japan) to expose the binding site for the 
antibody. First, slides were washed in tris-buffered saline (TBS) for 10 minutes. 
The enzyme solution (1% Chondroitinase ABC, 2% BSA, 20% Tris solution in 
water) was then applied to the samples, which were then incubated at 37°C for 
one hour. TBS provided the appropriate pH for the enzyme activity, and its use 
was continued through many of the subsequent steps for PG staining. After 
deparaffination and rinsing in both 100% Flex and water, tissue samples to be 
treated with the elastin antibody were warmed and exposed to a chymotrypsin 
solution (0.4 g chymotrypsin and 0.4 g CaCb in 400 mL water) for 10 minutes. 
This treatment was followed by a rinse in cold tap water. 
In the following steps, use of the general term "buffer" indicates that TBS 
was used for PG samples while PBS was used for all other samples. After the 
applicable antigen retrieval step, wells were drawn around the individual tissue 
samples using a hydrophobic marker. In order to block nonspecific binding of the 
secondary antibody, a 10% goat serum buffer solution (rabbit serum was used 
for fibrinogen) was applied to the samples and allowed to incubate for one hour, 
then removed from the test samples. Negative staining controls were created by 
leaving the serum solution on a sample in lieu of application of a primary 
antibody. The primary antibody (in buffer and 0.1% bovine serum albumin) was 
then added to the wells of the test samples. The antibody then incubated 
overnight at 4°C (Aim 1) or at 37°C for one hour (Aims 2 and 3). 
After incubation, the slides were rinsed and washed in two washes of 
buffer, for five minutes each. The appropriate biotinylated secondary antibody 
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(Jackson ImmnoResearch, West Grove, PA) was then added to all samples and 
allowed to incubate for one hour at room temperature. After incubation with the 
secondary antibody, the slides were rinsed and washed twice in PBS, for five 
minutes each. Samples were then incubated for 30 minutes at room temperature 
with an avidin-biotin complex, made from a Vectastain kit (Vector Laboratories, 
Burlingame, CA). The slides were rinsed and washed twice in PBS, for five 
minutes each. 
The final step, tagging the antibody complex with diaminobenzene (DAB) 
solution, allowed visualization of the antibody binding sites. At the beginning of 
Aim 1, the DAB solution was made from a powder. Samples were washed in 
TBS for five minutes, then in tris buffer (0.05 M, pH 7.6) for 10 minutes at 37°C. 
All samples were then incubated with the DAB solution (100 mg DAB, 100 uL 
30% H202, 0.08 g NiCI2) 200 ml_ tris buffer) for 10 minutes at 37°C. After 
incubation, the samples were returned to the tris buffer and then rinsed in water. 
A DAB kit (Vector Laboratories) that required less physical contact with and 
disposal of the carcinogen was eventually purchased. Since many of the PG 
samples had already been stained, the powdered DAB solution was used to color 
all of these slides to reduce sources of batch variation. All collagen samples 
from Aim 1 were stained with the DAB kit. Use of the DAB kit was extended to 
Aims 2 and 3. All samples were finally counterstained with hematoxylin before 
coverslipping. 
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A2.5. Fluorescent Cell Markers and Immunocytochemistry 
Cell staining methods were used briefly during Aim 3 to characterize the 
cells obtained from the explant cell culture as either valvular endothelial cells 
(VECs) or interstitial cells (VICs). Cells from culture were first cultured for 2-3 
days on slides treated with fibronectin. Cells were washed with PBS and cells 
were exposed to DMEM containing 10 ug/mL acetylated low density lipoprotein 
(Dil-AC-LDL) to identify VECs. The cells were incubated at 37°C for four hours 
then washed with PBS to remove free Dil-AC-LDL. Cells were then fixed with 5% 
formalin in PBS for 10 minutes, washed in PBS, and mounted using Vectashield 
with DAPI (4',6 diamidino-2-phenylindole, Vector Labs), a nuclear marker that 
fluoresced blue. When viewed using a rhodamine filter, cells staining positive for 
Dil-AC-LDL appeared red. 
VICs were identified using immunocytochemistry with an antibody against 
smooth muscle a-actin (SMaA). Cells were fixed with two PBS rinses followed 
by two 10 minute acetone treatments. As with IHC, cells were incubated at room 
temperature for one hour each in 10% goat serum in PBS and in a 1 MOO dilution 
of the SMaA antibody in PBS containing 1% BSA. To create a negative control, 
cells were incubated for one hour in a 1:100 dilution of IgG in PBS containing 1 % 
BSA. After incubation in the primary antibody, cells were washed in three 
washes of PBS for five minutes each. In order to create a permanent slide, cells 
were incubated at room temperature in a 1:1000 dilution of biotinylated goat-anti-
mouse secondary antibody (as opposed to a fluorescein isothiocyanate, or FITC, 
182 
conjugated antibody) in PBS with 1% BSA for one hour. After rinsing the slide 
with three changes of PBS, the IHC protocol described in Section A2.4 was 
followed, beginning with application of the avidin-biotin complex. The stain could 
be viewed with a light microscope, and the slides could be stored indefinitely. 
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Table A2.1: Antbodies used in immunohistochemical staining 
Primary 
Antibody 
BGL 
BGL 
COLLI 
COLL3 
DCN 
DCN 
Elastin 
FB 
HSP47 
LOX 
MMP1 
MMP2 
MMP9 
MMP13 
MMP13 
Dilution 
1:2000 
1:500 
1:1000 
1:500 
1:800 
1:500 
1:150 
1:1600 
1:1000 
1:250 
1:200 
1:100 
1:100 
1:200 
1:50 
Vendor 
Location 
(Cat. Number) 
Larry Fisher, Ph.D. 
NIH 
(LF-51) 
Larry Fisher, Ph.D. 
NIH 
(LF-104) 
Larry Fisher, Ph.D. 
NIH 
(LF-41) 
Larry Fisher, Ph.D. 
NIH 
(LF-69) 
Larry Fisher, Ph.D. 
NIH 
(LF-136) 
Larry Fisher, Ph.D. 
NIH 
(LF-122) 
Abeam 
Cambridge, MA 
(AB9519) 
Abeam 
Cambridge, MA 
(ab6666) 
Abeam 
Cambridge, MA 
(Ab13510) 
Imgenex 
San Diego, CA 
(IMX-5121) 
Assay Designs 
Ann Arbor, Ml 
(905-472) 
Assay Designs 
Ann Arbor, Ml 
(905-482) 
Assay Designs 
Ann Arbor, Ml 
(905-486) 
Chemicon 
Billerica, MA 
(MAB3321 (Discon.)) 
R&D Systems 
Minneapolis, MN 
(MAB511) 
Pretreat 
Method 
cABC 
cABC 
None 
None 
cABC 
cABC 
Chymo 
None 
AgR 
AgR 
AgR 
AgR 
AgR 
None 
AgR 
Secondary 
Antibody 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Mouse 
Rabbit anti-
Goat 
(Abeam) 
Goat anti-
Mouse 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Rabbit 
Goat anti-
Mouse 
Goat anti-
Mouse 
Aim 
1 
2,3 
1,2,3 
1,2,3 
1 
2,3 
2,3 
3 
2,3 
2,3 
2 
2 
2,3 
2 
3 
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Table A2.1 (cont): Antbodies used in immunohistochemical staining 
Primary 
Antibody 
P4H 
TIMP1 
VC 
vWF 
Dilution 
1:200 
1:100 
1:5000 
(Aim1) 
1:500 
(Aim2,3) 
1:100 
Vendor 
Location 
(Cat. Number) 
Chemicon 
Billerica, MA 
(MAB2701) 
Assay Designs 
Ann Arbor, Ml 
(905-484) 
Seikagaku 
Tokyo, Japan 
(270428) 
Sigma 
St. Louis, MO 
F3520 
Pretreat 
Method 
AgR 
AgR 
cABC 
None 
Secondary 
Antibody 
Goat anti-
Mouse 
Goat anti-
Rabbit 
Goat anti-
Mouse 
Goat anti-
Rabbit 
Aim 
2,3 
2,3 
1,2,3 
3 
AgR=antigen decloaker treatment; BGL=biglycan; cABC=chondroitinase ABC enzyme treatment; 
Chymo=chymotrypsin treatment; COLL=collagen; DCN=decorin; FB=fibrinogen; HSP47=heat 
shock protein 47; LOX=lysyl oxidase; MMP=matrix metalloproteinase; P4H=prolyl-4-hydroxylase; 
TIMP=tissue inhibitor of MMP; VC=versican; vWF=von Willebrand Factor. 
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Appendix A3. Biochemical Methods 
A3.1 . Collagen Quantification 
A3.1.1. Hydroxyproline Assay Protocol 
The general purpose of the hydroxyproline assay was to quantify collagen 
content in the valve tissue by measuring the hydroxyproline prevalent in primary 
structure of the collagen protein. After digestion with proteinase-K, the samples 
were centrifuged to form a pellet of undigested tissue (elastin residues, cells, and 
calcium) at the bottom of the tube. An aliquot was taken based on the presumed 
amount of collagen in the tissue sample in order to have the experiment results 
fall within the range of a standard curve. This aliquot was placed into each of two 
2 mL closed glass vials with a large enough amount of 6N HCI to hydrolyze the 
collagen (approximately 250 uL HCI for a 20-25 uL sample aliquot). The 
samples were hydrolyzed for 4 hours at 115°C. The vial cap was removed, and 
the vials were returned to the 115°C heating block to allow the HCI to boil away. 
The residue was then dissolved in enough ultrapure water to bring the 
concentration of hydroxyproline in the sample below 300 ug/mL. 
The sample in each glass vial was assayed in two separate test tubes, so 
that each original tissue sample would be assayed using a total of four test tubes. 
The following assay steps were also performed on an aliquot of each of seven 
known concentrations of hydroxyproline (0,10, 25, 50,100, 150, and 300 ug/mL) 
used to form the standard curve. 500 uL dH20 was measured into each test 
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tube, and a 20 uL of sample or standard was then added. 250 uL of chloramine-t 
reagent (44.06 mg chloramine-t, 0.625 ml_ dH20, 0.625 ml_ n-propanol, 5 ml_ 
hydroxyproline buffer) was added to each tube. The tubes were then vortexed 
and allowed to sit for 20 minutes at room temperature. 250 uL of 
aldehyde/perchloric acid was added to all tubes, which were then vortexed and 
incubated at 60°C for 15 minutes (0.5 g Erlich's reagent, 2 mL n-propanol, 0.867 
ml_ 70% perchloric acid). The tubes were vortexed again, and two 250 uL 
aliquots from each tube were placed in a 96-well plate. The absorbance of each 
well was read at 558 nm. The absorbances of the 7 standards were graphed 
against the known quantity of hydroxyproline, and the coefficients of the linear fit 
were used to calculate the amount of hydroxyproline in each sample. The 
amount of hydroxyproline in the original sample was then back-calculated using 
the amount found in the sample and the known level of dilution. The amount of 
collagen was calculated using the amount of hydroxyproline found. 
A3.1.2. Estimation of Collagen in Tissue 
The measurement of hydroxyproline in collagen begins by hydrolyzing the 
sample in HCI then evaporating away the HCI. Before dissolving the hydrolyzate 
in dh^O, it is important to have an idea of the amount of collagen in the original 
tissue sample. In order to obtain meaningful results, the concentration of 
hydroxyproline in the sample, after assay preparation, must fall within the limits of 
the standard curve (<300 ug/mL). 
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Before the tissue is hydrolyzed, the dry weight is measured. This value is 
multiplied by the known percentage of collagen for the particular tissue type to 
estimate the total amount of collagen in the tissue. Chordae and leaflets are 
assumed to contain approximately 80% and 60% collagen, respectively. Heart 
valve collagen is assumed to be approximately 13% hydroxyproline2. This 
proportion is based on the known mass percentage of the amino acid 
hydroxyproline among all amino acids in collagen, in addition to collagen 
composition of the normal mitral valve (74% type I, 24% type III, and 2% type V 
collagen)2. The total amount of collagen is therefore multiplied by 0.13 to give 
the total amount of hydroxyproline in the tissue. 
The final step is to determine the amount of hydroxyproline in the aliquot 
taken for the hydroxyproline assay. The amount of collagen in the aliquot taken 
is determined, then the amount of water required to bring the concentration 
below 300 ug/mL is calculated. 
Example: 
ALF sample dry weight: 0.0293 g 
Final volume of proteinase-digested tissue: 1.5 mL 
Total collagen = 0.0293 g * 60% = 0.0176 g 
Total hydroxyproline = 0.01758 g * 13% = 0.00229 g 
Hydroxyproline in 50 uL aliquot: 0.00229 g * 50 uL /1500 uL = 7.62 X 10"5 g = 
76.2 ug 
Minimum final volume = 76.2 ug / 300 ug/mL = 0.254 mL = 254 pL 
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At least 254 |jL dH20 must be added to bring the concentration of hydroxyproline 
in the sample below 300 ug/mL for a meaningful result when compared against 
the standard curve. 
A3.2. DNA (Hoescht) Assay Protocol 
Samples were tested for DNA content as a measure of tissue cellularity. 
An aliquot of sample was determined based on presumed amount of DNA in the 
sample. This process was trial-and-error, as the aliquot was chosen so that the 
sample fit within the limits of the standard curve. This aliquot and an appropriate 
volume phosphate (Pi) buffer (50 mM Na2HP04, 2 mM EDTA, 0.02% NaN3, pH 
7.4) were placed in a 1.5 ml_ centrifuge tube. Two different dilutions per sample 
were tested for repeatability. Samples were then sonicated for 3 minutes to 
rupture the cell membrane and release DNA into the solution. 
Standards were made from calf thymus double-stranded DNA. The 100 
ug/mL stock solution was diluted 10:1 in ultrapure water to make 1 mL of 10 
ug/mL DNA solution. The DNA solution was then mixed with Pi buffer to create 
100 ng/mL, 200 ng/mL, 500 ng/mL, 750 ng/mL, 1000 ng/mL, and 2000 ng/mL 
standards. 
The dye stock solution was made using 0.2 mg Bisbenzimide (Hoechst 
33258) in 1 mL ultrapure water. This stock was then diluted 1:100 in NaCI/Pi 
buffer (4M NaCI, 50 mM Na2HP04, 2 mM EDTA, 0.02% NaN3, pH 7.4). This dye 
was added to the samples and standards, and the tubes were vortexed. The 
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tubes were then protected from light and allowed to sit at room temperature for 
15-30 minutes. 
The standards and samples were aliquoted into black 96-well plates in 
duplicate 270 uL volumes. The plates were then read by a fluorocolorimeter with 
excitation set to 356 nm and emission set to 458 nm. The data obtained was 
imported into Excel (Microsoft Corp., Redmond, WA) for analysis. 
A3.3. Glycosaminoglycan (GAG) Quantification 
A3.3.1. Fluorophore-Assisted Carbohydrate Electrophoresis (FACE) 
The purpose of the FACE assay was to first cleave the GAG 
dissacharides from the proteoglycan (PG) core protein, then to measure the 
measure content of individual GAGs via electrophoresis. After the samples had 
been digested with the proteinase-K solution, they were centrifuged to form a 
pellet of undigested tissue at the bottom of the tube. The samples were then 
digested using either chondroitinase ACM alone (to cleave HA and CS) or a 
combination of chondroitinase ACM and chondroitinase ABC (to cleave HA, CS, 
and DS). One aliquot of sample, estimated from previously determined 
concentrations of total GAGs. was used for each type of digest. The sample 
was mixed with dH20,1 M ammonium acetate (pH 7.0), and 3 uL of 10 mU/uL 
chondroitinase ACM. Samples undergoing chondroitinase ACM/ABC digestion 
had an additional 3 uL of 10 mU/uL chondroitinase ABC added. The tubes were 
then allowed to incubate in a 37°C water bath for 3 hours, frozen, and placed in a 
speed-vac until dry. Emphasis was placed on maintaining pH<7.0 throughout the 
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process for complete digestion of the hyaluronan and unsulfated chondroitin by 
the chondroitinases. The unsaturated disaccharides that were the product of the 
enzymes were also unstable at a basic pH. Phenol red, which was present in the 
sample to verify that the pH of the samples was no greater than 7.0136, was 
reduced to a colorless compound with cyanoborohydride to prevent detection in 
the FACE gel. 
The next step was to label the GAG disaccharides with the fluorescent tag 
AMAC. A 0.0125 M AMAC solution in 3:17 v/v acetic acid/dimethylsulfoxide 
(DMSO) was prepared, and 40 uL of this solution was added to each tube. The 
samples were allowed to incubate at room temperature for 10-15 minutes. 40 uL 
of 1.25M sodium cyanoborohydride (NaCNBhU) was then added, and the 
samples were incubated 15-16 hours at 37°C. The samples were then cooled to 
room temperature, and 20 uL glycerol were added. 
Prior to inserting samples into the FACE gel, the samples were diluted 1:4. 
A 2 uL aliquot of sample was mixed with 2 uL maltotriose standard and 4 uL 
AMAC buffer (34% by volume DMSO, 6% glacial acetic acid, 40% 1.2M 
NaCNBhU, 20% glycerol). The maltotriose standard was available in 
concentrations of 200,100, 50 and 25 (concentrations in 4X of pmol/5 uL), and a 
different maltotriose standard was added to each sample in order to allow create 
a fluorescent standard curve. 
Gels appropriate for running FACE analysis were not readily available, 
and were therefore made in the lab (Section A3.3.3.). To perform FACE, the gel 
box was placed in the center of a basin (Figure A3.1). Ice was added to the 
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basin to surround the gel box, and cold water was added to a level approximately 
one-third that of the ice. 1 L 4°C TBE buffer (100 mM Tris, 90 mM Boric Acid, 1 
mM ethylenediaminetetraacetic acid, pH 8.3) was added to the gel box, and a stir 
bar was added to the gel box to maintain temperature equilibrium. The comb 
was removed from the gels. The gel glass and wells were then rinsed out with 
the TBE buffer. One gel was placed in each side of the FACE apparatus with the 
lower side facing inward. The gels were secured in the apparatus, and the 
apparatus was placed in the FACE box. 100 ml_ buffer was added to the top of 
the apparatus to fully cover the gel wells. 
Figure A3.1: FACE experimental setup. The gel was secured within the FACE apparatus, 
buffer was added to the FACE box, and an electrical current was run through the gel to 
separate the GAG classes by molecular weight and charge. 
A power source was programmed to provide a current of 500 V, 100 W 
and 400 mA to the apparatus. The gels were pre-run to verify that the actual 
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current was approximately 40-60 mA for 2 gels. A higher current indicated a 
shorter run time for the gel. A multipipetter was then used to add 5 uL of each 
sample to each well. The power source was turned on, and the gels were 
allowed to run for 30 min - 1.5 hours, depending on the pre-test current. 
The gels were immediately imaged after removal from the FACE 
apparatus. First, a gel was rinsed with tap water and dried. The gel was then 
exposed to a UV transilluminator. Images were captured using a Kodak Gel 
Logic System (Eastman-Kodak, Rochester, NY) with a charge-coupled device 
(CCD) camera and Kodak 1D 3.6 software. Three exposures were taken: one 
low, one medium, and one high. Generally, the low exposure was selected such 
that none of the bands were saturated. The medium exposure was made at a 
time double that of the low exposure, and the high exposure was made at a time 
double that of the medium exposure, so that less abundant bands could be 
visualized. Band integrated optical density (IOD) was then measured using Gel-
Pro software version 3.1 (Media Cybernetics). 
A3.3.2. Estimation of Uronic Acid 
Preparation for the FACE assay begins by digesting an aliquot of 
proteinase-K digested tissue with a GAG enzyme (Chondroitinase ACM and/or 
Chondroitinase ABC) to cleave the GAG chains into the disaccharides. As with 
collagen, GAG content in tissue should be estimated prior to taking an aliquot 
from the proteinase-K digested tissue in order to ensure that the results will fall 
within the confines of a standard curve. First, the wet weight of the sample is 
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determined. The wet weight for a leaflet is multiplied by 1200, or the wet weight 
for chordae is multiplied by 700, to give the amount of uronic acid, in ug, in 1 ml_ 
of sample. 
The total amount of uronic acid is divided into 1000 uL to get the volume 
(in uL) of 1 ug uronic acid. This volume is multiplied by 5 to get the volume of 5 
ug uronic acid. If the final volume is less than 30 uL, it is rounded to the next 
whole number, and reduced by 5. If the final volume is less than 210 uL, it is 
rounded to the next whole number, and reduced by 10. If the final volume is less 
than 1 mL, it is converted to 200 uL; otherwise, the volume is converted to 250 
uL This algorithm has been noted to work well as the 5 ug uronic acid is an 
ideal amount of substrate for the 3 uL of GAG enzyme used in the FACE 
preparation, based on the unit activity of the enzyme and a stock enzyme 
concentration of 10 mU/uL). 
Example: 
ALF sample wet weight: 0.1925 g 
Concentration uronic acid = 0.1925 g * 1200 = 231 pg/mL 
Volume of 1 ug uronic acid = 1000 / 231 pg/mL = 4.33
 u|_ 
Volume of 5 |jg uronic acid = 5 * 4.33 uL = 21.64 uL 
Round volume up to next whole number: 22 uL 
Final volume = 22 pL - 5 pL = 17 pL 
An aliquot of 17 pL should be used to obtain results that are meaningful within 
the standard curve produced in FACE. 
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A3.3.3. Preparation of FACE Gels 
Gels appropriate for running FACE analysis were not readily available, 
and were therefore made in the lab. Two glass panes, one square and one with 
two pegs at the top (Figure A3.2A), were cleaned with alcohol. A thin layer of 
petroleum jelly was applied to both sides of two plastic spacers, and a spacer 
was placed on each side of the pegged pane (Figure A3.2B). The square pane 
was carefully placed on top of the pegged pane so that the spacers were 
between the two panes of glass. One side of the cassette was clamped and the 
other sealed with 3M™ Plastic Tape. The taped side was then clamped, and the 
other side was sealed with tape and re-clamped. The bottom of the cassette was 
wrapped with Parafilm® (SPI Supplies, West Chester, PA) to prevent 
unpolymerized gel from leaking. The cassette was then undamped and placed 
in a Bio-Rad (Bio-Rad Laboratories, Hercules, CA) apparatus (Figure A3.2C). 
A resolving gel was made of 5.0 ml_ 40% Acrylamide/bis-acrylamide 
(Acryl/bis, 37.5:1), 500 uL 50% glycerol, 1120 uL 400 mM Tris Acetate (pH 7.0), 
3.38 ml_ dH20, 70 uL 10% ammonium persulfate and 15.0 uL Temed. The 
resolving gel was poured into the glass cassette to a height of 1.5 cm below the 
top of the pegged plate. After polymerization of the resolving gel, a stacking gel 
was made of 1.0 ml_ 40% Acryl/bis (37.5:1), 250 uL 50% glycerol, 560 uL 400 
mM Tris Acetate (pH 7.0), 440 uL 50% w/v polyethylene glycol (PEG), 2.75 ml_ 
dhfeO, 28 uL 10% ammonium persulfate and 7.5 uL Temed. The resolving gel 
was poured to the top of the pegged plate, and an 8-well comb was placed 
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between the two plates. After polymerization, the gel cassette was wrapped in 
plastic wrap and stored at 4°C until use (Figure A3.2D). 
Figure A3.2: Creation of FACE gel. (A) Pegged pane of glass. (B) Glass with two spacers. 
(C) Taped gel in Bio-Rad apparatus- (D) Completed FACE gel. 
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Appendix A4. ELSIE Chamber Design Evolution 
A4.1. Version 1: Initial Test of Piston/Crank Mechanism 
Figure A4.1: Initial bioreactor design with motor and power supply. Arrows represent 
rotation of the motor causing lateral movement of the piston. The individual chamber 
components are labeled on the next page. 
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Figure A4.2: Close-up view of the chamber. A membrane was mounted to the top of 
section "D*" and affixed to the top of the piston. Fluid (represented in green) filled the 
chamber and the membrane, and the lateral movement of the piston forced the fluid to 
move up and down within the chamber. Design schematics of the lettered segments are 
depicted on the following pages. Note that the modular design of the chamber allowed 
flexibility of testing parameters (i.e., distance between tissue mounting locations) and as 
such, not all chamber pieces are represented in the photographs. 
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A4.2. Version 2: Introduction of Filtered Cap 
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Figure A4.3: Bioreactor design with filtered cap closure. A membrane was mounted to the 
top of section "A*" and affixed to the top of the piston using magnets (one each glued to 
the membrane and piston) to allow easy removal of the chamber from the piston/crank 
assembly. The designs of the lettered segments are depicted with the "Version 1 " 
sketches; segment "C" was replaced with segment "C*" pictured below. As with the 
"Version 1 " photo, not ail chamber pieces are represented in the image. 
/^7zs";z;::::::$z: 
/ -€k X
 k < \„.....L*.. 
-*€>- r j -K£KJ-—c* 
v "::::::::z::::::::*z: 
\ -@r....y/ 
^ ^ J*/ \v' 
: 
T 
> 
1/2" 
; 
< 
i 
> 
1/2" ; 
< >{ 
u-
1 1 
1 
1 r 
c*-c* 
Bottom View 
(symmetrical) 
202 
C * - C * 
Side View 
(symmetrical) 
Thread top (see bottle) 
A4.3. Version 3: Final Version Using Piston / Crank Assembly 
Figure A4.4: Front (top) and side (bottom) views of final bioreactor design using piston 
and silicone membrane assembly. After testing of this design, the crank/piston assembly 
was abandoned, and the number of segments used in the chamber was reduced to 
discourage contamination during assembly and media changes. The new segment 
schematics are presented on the following pages. 
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Appendix A5. Final ELSIE Chamber Design 
Figure A5.1: Finished bioreactor chamber design. The chamber was comprised of three 
hollow segments ("A", "B", and "C") into which the valve segment was mounted. The 
media (represented here by the green fluid) provided nutrients to the tissue. Valve 
attachment sites (inside chamber) are indicated by ANN=annulus and CH=chordae. Design 
schematics for the individual segments are presented on the following pages. 
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